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Summary 
In the 90s, Ghent University Hospital was one of the pioneers in successful implementation of 
IMRT in several tumour sites. Subsequently, the need for an efficient and fast technique to 
irradiate large concave targets lead to the introduction of rotational intensity modulated RT: 
intensity modulated arc therapy (IMAT). Introducing IMAT in the multimodality treatment of 
pelvic gynaecologic tumours was a logical consequence. In the first place, the use of box (or 
other conventional) techniques in cervical and endometrial cancer is synonymous to 
irradiation of large parts of Organs At Risk (OARs) lying within the concavity of the 
horseshoe-shaped target volume. Secondly, dose limits to kidneys and liver and adequate 
irradiation of the whole peritoneal cavity in case of ovarian cancer are incompatible using 
conventional techniques. Reducing toxicity by implementing IMAT in the radiotherapeutic 
treatment of gynaecological cancer was however not the only aim of this thesis. Triggered off 
by the high local recurrence rates in locally advanced cervical cancer (LACC) and the poor 
prospects of women with chemotherapy-resistant ovarian cancer we dared to think out of the 
box and to challenge some dogmas. Could we challenge the gold standard chemoradiation + 
brachytherapy by re-introducing surgery in the treatment of LACC and if so, how could we 
overcome the scepticism of the treating physicians towards surgical toxicity?  Does the dogma 
that a whole abdominopelvic RT for advanced ovarian cancer is infeasible and too toxic still 
stand in this era of modern RT? After all: “Convention is the enemy of progress” (Trevor 
Bayliss). 
Early-stage cervical carcinoma and endometrial carcinoma patients are initially treated 
with a hysterectomy and lymph node dissection. If findings in the surgical specimen suggest a 
high-risk of pelvic (and/or systemic) recurrence, post-operative (chemo) radiation therapy 
(RT) is recommended. Two-field or box irradiation of the pelvis encompasses large parts of 
OARs. This is even more pronounced in the postoperative setting where small bowel tends to 
fall into the vacated space in the true pelvis. Not surprisingly, substantial severe acute and late 
complication rates are unavoidable using conventional techniques.  The entrance of modern 
RT-techniques such as IMRT and IMAT allows better sparing of those OARs. Whether this 
reflects in lower toxicity rates (acute and late) in the postoperative treatment of endometrial 
and early stage cervical cancer, as described in publication 1. 
Definitive chemoradiation (CRT) is standard of care in locally advanced cervical 
cancer (LACC) and consists of a combination of external beam radiotherapy (with 
concomitant administration of cisplatin) and brachytherapy. Unfortunately, despite the advent 
of image-guided dose-intensified brachytherapy, local control remains the major cause of 
treatment failure. Removing chemo- and radioresistant foci by performing a post-CRT 
hysterectomy seems therefore a valid treatment option and has been used successfully in the 
past. However, since 1 randomized trial failed to prove survival benefit and due to the fear of 
excessive toxicity, this treatment option has sunk into oblivion. We hypothesized that the 
chance of surgery-related toxicity using IMAT would be reduced in a twofold way. At first, 
the use of IMAT leads to less irradiation of surrounding tissues and should therefore result in 
less toxicity. Secondly, substituting the brachytherapeutic boost by a simultaneously 
integrated boost (SIB) using IMAT should allow reducing the dose distribution uncertainties 
inherent to two treatment modalities which are difficult to add up. A SIB, by delivering a 
higher dose to the tumour or affected lymph nodes without changing the amount of treatment 
fractions and thus delivering a higher dose per fraction, theoretically results in a double 
control benefit. Indeed, in cervical cancer the positive relationship between higher doses, 
shorter overall treatment time and tumour control is well established. In publication 2, we 
concluded that the implementation of a SIB in the treatment of LACC using IMAT was 
feasible without compromising the dose to the elective lymph node areas or the OARs. The 
observation that using IMAT with a SIB is associated with low toxicity rates, allows a safe 
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post-CRT hysterectomy and leads to promising local control and survival rates is discussed in 
publication 3. The decision about extrafascial hysterectomy is made multidisciplinary and 
depends on local response diagnosed clinically, by Magnetic Resonance Imaging (MRI) and 
18FDG PET-CT. Reports concerning the value of MRI and 18FDG PET-CT in predicting 
radical resectability of locally advanced cervical cancer after neo-adjuvant CRT are sparse, 
our results are presented in publication 4. 
 The evolution in chemotherapeutic and targeted therapies for advanced stages ovarian 
cancer in the last decades has been impressive. Unfortunately, this did not translate into a 
corresponding evolution in survival benefit. Over 70% of women presenting with advanced 
stage ovarian carcinoma will relapse eventually, of whom 85% solely within the abdominal 
cavity. For patients with progressive disease after second- or third-line chemotherapy, 
therapeutic options are limited and often restricted to best supportive care. However, ovarian 
cancer is known to be radio-sensitive and RT has been used successfully for curative whole 
abdomino-pelvic treatment and localized palliative care in the past. Excessive treatment 
morbidity and mortality and the entrance of chemotherapeutic agents have finished the role of 
RT in the treatment of ovarian cancer. Introducing IMAT for whole-abdominal pelvic 
radiotherapy (WAPRT) has proven to be feasible and is an important palliative treatment for 
patients with peritoneal carcinomatosis. The use of WAPRT in the palliative treatment of 
chemotherapy-resistant patients is discussed in publication 5 and updated in the discussion 
section. 
IMAT allows a challenging combination of reducing dose at the surrounding tissues while 
intensifying the radiation dose to the tumour at the same time. Consequently both in the 
endometrial and early stage (FIGO I and IIA, non bulky) cervical cancer as well as in the 
primary treatment of LACC toxicity rates are low and tumour control high. IMAT allows a 
safe adjuvant hysterectomy in LACC. Finally, in ovarian cancer, WAPRT revived in the 
palliative setting with important symptom palliation and response rates. 
Several hypotheses described in this thesis remain to be tested. The hardest challenge 
however, lies in convincing the radiotherapeutic and gynaecologic community to embrace the 
opportunities created by new radiation techniques and to rethink the existing dogmas. 
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Samenvatting 
 
Het universitair ziekenhuis Gent was in de jaren ’90 één van de pioniers die succesvol 
intensiteitsgemoduleerde radiotherapie (IMRT) voor multipele tumorlokalisaties 
implementeerde. Een blijvende vraag naar een efficiënte en snelle radiotherapietechniek die 
de bestraling van grote concave doelvolumes mogelijk maakte, leidde tot de ontwikkeling van 
een intensiteitsgemoduleerde radiotherapietechniek die in boogvorm wordt uitgevoerd: 
intensiteitsgemoduleerde boogtherapie (IMAT). De intrede van IMAT in de algemene aanpak 
van pelviene gynaecologische tumoren was een logische stap. Het gebruik van conventionele 
radiotherapie zoals een 2-velden (voorachterwaartse of APPA) of 4-velden (box) techniek in 
de behandeling van baarmoeder- of baarmoederhalstumoren staat gelijk met behandeling van 
grote volumes risico-organen tot een hoge dosis, gezien het doelvolume een hoefijzervorm 
aanneemt dat grote volumes gezonde weefsels (=risico-organen) omvat. Daarenboven is voor 
gevorderde ovariumtumoren een homogene behandeling van de volledige peritoneale holte tot 
een adequate dosis met conventionele technieken niet mogelijk; bij deze dosis wordt de 
tolerantiedosis van nieren en lever immers overschreden. Afname van toxiciteit door middel 
van de integratie van IMAT in de behandeling van pelviene gynaecologische tumoren was 
echter niet het enige doel van dit onderzoek. Geïnspireerd door het grote risico op lokaal 
herval bij patienten met lokaal gevorderde baarmoederhalstumoren en door het gebrek aan 
behandelopties bij platinum-resistente ovariumtumoren stelden we enkele vastgeroeste 
dogma’s in vraag. Is het mogelijk om de gouden standaard (chemoradiotherapie + 
brachytherapy) in de behandeling van lokaal gevorderde baarmoederhalstumoren aan te 
vullen met heelkunde? Zo ja, hoe kunnen we het scepticisme van de behandelende artsen 
betreffende de postoperatieve morbiditeit doen afnemen? En houdt de stelling dat pan-
abdominopelviene RT bij patienten met platinum-resistente ovariumcarcinoom te moeilijk en 
te toxisch is, eigenlijk wel nog steek na de intrede van moderne RT?  Immers: “convention is 
the enemy of progress”(Trevor Bayliss). 
Baarmoedertumoren en lokaal beperkte baarmoederhalstumoren worden in eerste instantie 
heelkundig benaderd. Indien welbepaalde microscopische bevindingen een hoog risico op 
locoregionaal (en/of metastatisch) herval voorspellen, wordt adjuvante (chemo)radiotherapie 
voorgesteld. Twee-velden of box bestraling van het desbetreffend doelvolume omhelst echter 
ook de bestraling van grote hoeveelheden gezond weefsel. In deze postoperatieve setting, 
waar de dundarm de ruimte inneemt die de verwijderde baarmoeder nalaat, is dit effect nog 
groter. Met conventionele bestralingstechnieken is ernstige acute en late toxiciteit dan ook 
onvermijdbaar. De intrede van moderne RT-technieken zoals IMRT en IMAT laten toe om 
deze risico-organen beter te sparen. Dat weerspiegelt zich in een lage toxiciteit (zowel acuut 
als laattijdig) in de postoperatieve behandeling van baarmoeder- en baarmoederhalstumoren, 
zoals werd neergeschreven in publicatie 1.  
De standaardbehandeling van lokaal gevorderde baarmoederhalstumoren bestaat uit een 
combinatie van externe radiotherapie (met concomittante toediening van chemotherapie) en 
brachytherapie. Ondanks de intrede van beeldvormingsgeleide, hoge dosis brachytherapie 
blijft lokaal recidief een belangrijke oorzaak van ziekteherval. Het uitvoeren van een 
hysterectomie na chemoradiotherapie, waarbij potentieel chemo- en radiotherapieresistente 
tumorhaarden worden verwijderd, lijkt dan ook een valabele behandelingsoptie die in het 
verleden reeds met succes werd toegepast. Eén gerandomiseerde studie, waarbij geen 
overlevingsvoordeel van hysterectomie na chemoradiotherapie kon worden aangetoond, en de 
angst voor onaanvaardbare toxiciteit zorgden er echter voor dat deze behandeloptie in onmin 
raakte.  
De hoop op afname van het hoger beschreven risico op toxiciteit door middel van IMAT is 
tweeledig. Enerzijds wordt de dosis op de omliggende risico-organen beperkt, anderzijds  
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vermindert het gebruik van een simultaan geïntegreerde boost (SIB) de dosimetrische 
onzekerheid die aanwezig is bij de combinatie van een externe en brachytherapeutische 
behandeling. Het gebruik van een SIB, wat neerkomt op het toedienen van een hogere dosis 
op de tumor of aangetaste lymfeklieren zonder het aantal behandelingen te laten toenemen, 
houdt een dubbel voordeel in. Het is immers reeds lang gekend dat bij 
baarmoederhalstumoren zowel een hogere dosis als een kortere behandelingsduur beiden 
leiden tot een grotere kans op (lokale) controle van de tumor. In publicatie 2 konden we 
besluiten dat een SIB door middel van IMAT veilig kan worden geïmplementeerd in de 
behandeling van lokaal gevorderde baarmoederhalstumoren zonder een toename van dosis te 
veroorzaken in de omliggende gezonde weefsels of electieve lymfeklierregio’s. In publicatie 
3 wordt beschreven hoe deze techniek de patiënten ernstige toxiciteit bespaart en toelaat om 
op een veilige manier een hysterectomie uit te voeren na een chemoradiotherapeutische 
behandeling. De daaruit volgende lokale controle en overlevingscijfers zijn dan ook 
veelbelovend.  
Het al dan niet uitvoeren van een extrafasciale hysterectomie wordt multidisciplinair 
beslist en hangt af van de lokale respons. Deze lokale respons wordt geëvalueerd door middel 
van gynaecologisch onderzoek, NMR en  18FDG PET-CT. De evidentie voor het gebruik van 
NMR of 18FDG PET-CT in het voorspellen van radicale reseceerbaarheid van lokaal 
gevorderde tumoren na neo-adjuvante chemoradiotherapie is echter zeldzaam. Ons onderzoek 
in deze setting werd neergeschreven in publicatie 4. 
 In schril contrast met het grote aantal nieuwe chemotherapeutische en doelgerichte 
“targeted” therapieën die de laatste decennia op de markt kwamen voor de behandeling van 
gevorderde ovariumcarcinomen staat de beperkte winst in overleving.  Nog steeds zullen meer 
dan 70% van de patienten met gevorderd ovariumcarcinoom in de loop der tijd hervallen, in 
85% van de gevallen beperkt dit herval zich tot de abdominale holte. Voor patiënten met 
progressieve ziekte na 2e of derdelijnschemotherapie beperken de therapeutische opties zich 
vaak tot palliatieve zorgen. Ovariumcarcinoom is nochtans stralingsgevoelig en radiotherapie 
werd in het verleden reeds met succes toegepast in zowel de curatieve (pan-abdominopelviene 
bestraling) als de palliatieve setting. De vaak ernstige bijwerkingen en de komst van een 
arsenaal aan chemotherapeutische agentia heeft de rol van radiotherapie in deze setting echter 
in de vergeethoek geduwd. Pan-abdominopelviene radiotherapie (WAPRT) mits het gebruik 
van IMAT is in het verleden reeds veilig en uitvoerbaar gebleken. Het inzetten van WAPRT 
door middel van IMAT als wapen in de palliatieve behandeling van chemotherapeutisch 
uitbehandelde ovariumcarcinoom patienten wordt besproken in publicatie 5. De meest 
recente gegevens hieromtrent werden neergeschreven in de discussie. 
 
Intensiteitsgemoduleerde boogtherapie laat toe om gelijktijdig zowel een dosisreductie 
(omliggende organen) als een -escalatie (tumor of aangetaste lymfeklieren) uit te voeren. Dit 
resulteert zowel in de postoperatieve behandeling van endometrium- en lokaal beperkte 
baarmoederhalstumoren als in de primaire behandeling van lokaal gevorderde 
baarmoederhalstumoren in een beperkte toxiciteit en zeer goede overleving. Dit laat ons toe 
om op een veilige wijze heelkunde te implementeren in de behandeling van lokaal gevorderde 
baarmoederhalstumoren. Tenslotte kon de panabdominopelviene behandeling bij gevorderde 
ovariumcarcinomen met succes vanonder het stof worden gehaald met een goede respons op 
de behandeling en belangrijke symptoompalliatie. 
Er is nog heel wat werk voor de boeg, meerdere onderzoeksvragen en hypothesen verdienen 
verder onderzoek. De grootste uitdaging ligt echter in het overtuigen van de 
radiotherapeutische en gynaecologische gemeenschap dat dit tijdperk, met nieuwe moderne 
bestralingstechnieken, heel wat nieuwe (of oude) deuren opent.  
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Chapter 1: Introduction 
1. Intensity-Modulated Arc Therapy in cervical and endometrial cancer: rationale. 
External Beam Radiation Therapy (EBRT) (1) is a standard component in the multi-modality 
approach of cervical and endometrial carcinomas (2-5). Endometrial carcinoma and/or early-
stage cervical carcinoma patients are initially treated with a hysterectomy and lymph node 
dissection. Post-operative radiation therapy (RT) is often recommended if findings in the 
surgical specimen suggest a high-risk of pelvic recurrence.  
In case of endometrial cancer, the indication for postoperative RT is highly controversial. 
There is though agreement that the presence of 2 or more of the following findings suggest a 
high risk of recurrence: grade 3 differentiation, invasion of the outer half of the myometrium, 
lymphovascular space invasion (LVSI), pN+, age > 60 years, cervical stromal invasion (6). 
For patients with early cervical cancer the presence of LVSI and/or affected lymph nodes, 
>1/3 cervical stromal invasion or large tumours (>4cm) justifies postoperative RT, mostly 
combined with chemotherapy (7-9). In more advanced cervical cancers (≥ FIGO IIB or 
tumours ≥ 4cm) primary chemoradiation (CRT) is standard treatment.   
Although the planning target volume (PTV) differs between primary (tumour and unaffected 
cervix, uterus, parametria and superior 1/3 to half of the vagina) and postoperative (operation 
bed, superior third of the vagina) setting, the PTV encompassing the nodes (common, external 
and internal iliac nodes, the obturator region and the presacral region in case of cervical 
involvement) is identical (10, 11). This PTV structure forms a “cup” located right against the 
inner side of the bone marrow harbouring pelvic bones (itself also being an organ at risk) and 
contains large parts of the organs at risk (OARs) such as small bowel (SB), sigmoid, rectum 
and bladder (Figure 1).  
 
 
Figure 1.1: Relation of the target volume to its neighbouring organs.  
A: The PTV (encompassing the common, external and internal iliac nodes, the para-aortic nodes, the 
presacral and obturator region) forms a cup between the pelvic cavity and the pelvic bones. B: transversal 
slicing at the level of the lower sacro-iliacal joints results in a horseshoe-shaped PTV lying against the 
pelvic bones and encompassing large parts of the intestine (small intestine: green; sigmoid: brown). C: 
transversal slicing at the level of the coccyx shows that the bladder (blue), small intestine (green) and the 
rectum (light brown) are sandwiched between the left and right side of the PTV.   
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With traditional conformal RT delivered in an “anteroposterior-posteroanterior (APPA)” or 
“four-field” (box) technique based on bony anatomic landmarks, it is impossible to treat this 
cup without irradiating its content (figure 1.2. A-C). Intensity Modulated RT (IMRT) with 
fixed gantry angles allows sparing of the OARs by moulding the prescribed dose to the shape 
of the target tissues resulting in reduced toxicities (13-16). With a large inner radius of the 
target volume, as in pelvic gynaecologic malignancies, a higher number of beam incidences is 
needed for homogeneous coverage of the target volumes and sparing of the OARs (17-19) 
(figure 1.2. D and E).  Intensity Modulated Arc Therapy (IMAT) is a fast and easy way to 
deliver a large number of beam incidences (20) achieving beam intensity modulation by 
superimposing multiple arcs and/or by regulating the dose-rate and the MLC leaf movement 
dynamically and relatively to the speed of the rotating gantry. An example of the target 
coverage achieved with IMAT while sparing the OAR is illustrated in Figure 1.2 F. The use 
of positioning devices proved to be efficient in reducing irradiated SB volume. As compared 
to the supine position or the prone position alone, a prone treatment position combined with a 
belly board resulted in a  decrease of irradiated SB volume for both 3D-conformal RT and 
IMRT treatment plans (21). The benefit of a prone position with belly board in combination 
with IMRT is though smaller to absent in low dose areas when using extended arc techniques 
(22). Moreover, there is no proven benefit towards other OAR such as bladder, rectum and 
bone marrow. 
 
   
 
Figure 1.2 Treatment of a horseshoe-shaped PTV with conventional techniques and IMAT. 
A conventional APPA (A) or box (B) treatment of a horseshoe-shaped PTV (blue structure) leads  to 
inclusion of large parts of the OARs (SB: green; sigmoid: brown) in the treatment fields (orange bars). In 
the case of a box treatment this results in a rectangular high dose area (red area) encompassing all OARs 
lying within the PTV (C). Using IMAT (D and E) the high dose area (F, red area) is limited to the PTV 
resulting in gradually lower doses (from yellow to blue as the dose decreases) to the OARs. 
 
In cervical cancer, the positive relationship between higher dose and tumour control is 
well established (23, 24). Ideally, this higher dose should be given without prolonging the 
overall treatment time (OTT) to avoid loss of tumour control by cancer cell proliferation (25-
28). In addition to generating concave dose distributions and tight dose gradients for dose-
escalation, IMRT (29-33) and IMAT (34) allow simultaneous treatment of multiple targets 
with different total doses. This simultaneous integrated boost (SIB) technique is also known 
as  dose-painting (35-37)(Figure 1.3). 
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Figure 1.3: Dose-painting for lymph node positive locally advanced cervical cancer (LACC) using IMAT. 
A: coronal view of the isodoses for a patient with LACC with affected lymph nodes. The median 
prescribed dose to the primary tumour and affected lymph nodes (both contoured in red) is 62 and 60Gy 
respectively. This dose is delivered simultaneously and in the same amount of fractions as the minimal 
prescribed dose of 45Gy to the clinical target volume (CTV, pink) and PTV (blue) without influencing the 
dose on the OARs. B: transversal view at the level of the two affected lymph nodes. C: transversal view at 
the level of the cervical tumour and the affected lymph node in the right external iliac lymph node area. 
 
2. Intensity-Modulated Arc Therapy in ovarian cancer: rationale. 
Ovarian cancer tends to metastasize through the peritoneal cavity, mandating the inclusion of 
the whole peritoneal cavity in the treatment fields. Renal and hepatic tolerances are often set 
at a median dose of 18 and 33 Gy respectively (38). Consequently, with conventional APPA 
treatment, underdosage of peritoneal regions after blocking the kidneys and/or liver for 
radiation is unavoidable if a dose higher than their tolerance levels is prescribed (Figure 1.4 
A-B). Moreover, the entire lumbar spine and pelvic bones are irradiated leading to substantial 
haematological toxicity. The potential of arc therapy to spare kidneys, liver and bone marrow 
in this setting stands out and was investigated before (17, 39) (Figure 1.4 C-D). 
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Figure 1.4: Whole abdominal pelvic RT (WAPRT) with conventional techniques and IMAT. 
Conventional WAPRT (A and B) leads to underdosage (green to yellow isodose lines entering the blue  
PTV structure) of large parts of the peritoneal cavity (= PTV = blue) after blocking the kidneys as well as 
to important overdosage near the bone marrow harbouring pelvic bones (red lines). IMAT (C and D) 
enables sparing the OARs (bone marrow (D) and kidneys (C)), avoids large high dose areas as well as it 
results in adequate target (PTV, blue) coverage. 
 
 
3. IMRT/IMAT at Ghent University Hospital (GUH) as it applies to this thesis. 
 
Until the 90s, radiation oncologists employed beams with aperture shapes that encompassed 
the whole tumor and had an equal intensity across this aperture. In the mid-90s, a handful of 
research centers including GUH, explored a technique of narrower beams (beamlets) that 
irradiated only a part of the tumor each (40). By putting many beamlets upon and next to each 
other, all with their own tuned or modulated intensity, new beams with modulated intensity 
across there aperture were created. This approach, called IMRT, has the unique potential to 
create homogeneous concave dose distributions for target volumes wrapped around an OAR 
(41) (Figure 1.5; avoidance IMRT). Shortly after, GUH again was one of the leading centres 
to investigate the hypothesis that IMRT could decrease radiotherapy-induced toxicity in 
several tumour types (19, 42-44), confirmed by clinical studies a decade later (45). In 2002, 
after adaptation of IMRT planning tools for IMAT, GUH became one of the very few and first 
centres that could apply IMAT as a routine treatment (17, 34, 46). Details concerning 
technical aspects, treatment planning flow charts and general rationale of IMAT can be found 
in the theses of Werner De Gersem (43), Wim Duthoy (19) and Valérie Fonteyne (44). 
Subsequently, by its ability to avoid toxicity in surrounding organs, IMRT/IMAT was used to 
study dose-intensification to obtain better cancer cure rates, without loosing the OARs–
sparing effect. Where dose-intensification using biological image guided IMRT was obtained 
in whole tumour regions first (Figure 1.5: Regionally intensified IMRT), research rapidly 
evolved towards targeted dose-intensification on, by 18FDG-PET or MR-spectroscopy,  
estimated radio-resistant regions (Figure 1.5: Dose-painting IMRT) within the tumour (35, 43, 
44, 47, 48). Ongoing research focuses now on the paradoxical combination of further 
reduction of toxicity (by regularly adapting the treatment to changing anatomy; Figure 1.5: 
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Adaptive dose-painting) and dose-intensification (by simultaneously updating the dose-
painting and hereby securing optimal targeting of radioresistant parts of the tumor). 
 
 
 
 
Fig.1.5 Evolution of IMRT/IMAT at GUH. 
The technological research and development (left side) and the translational and clinical research (right 
side) resulted from close collaboration between engineers, radiation physicists, technologists, nurses and 
radiation oncologists. DP = dose-painting; ADP = adaptive dose-painting; ROI = region of interest. 
(Figure courtesy W. De Neve). 
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Chapter 2: Objectives and outlines  
1. Endometrial/cervical cancer 
Conventional two-field or box irradiation of the pelvis encompasses large parts of OARs: SB, 
rectum, sigmoid, bladder and bone marrow. Rates of severe (≥ grade 3) complications, even 
with modest doses of 45–50 Gy, as high as 7% (urinary), 8% (intestinal) and 13% 
(hematologic) are reported (4, 49). This is even more pronounced in the postoperative setting 
where small bowel tends to fall into the vacated space in the true pelvis.  
 
1.1. Postoperative treatment of cervical and endometrial cancer. 
Combining chemo- and radiotherapy improves overall survival (OS) in patients with cervical 
cancer needing an adjuvant therapy (7). A similar tendency has been shown in the adjuvant 
treatment of endometrial cancer (50) and currently the effect of adding chemotherapy to 
postoperative irradiation in the treatment of high-risk endometrial cancers is evaluated in the 
randomized phase III PORTEC-3 trial (clinical trials.gov: NCT00411138). In exchange for an 
improved OS, adding chemotherapy to RT for cervical cancer has doubled the risk of severe 
acute hematologic and gastro-intestinal toxicity and tripled platelet toxicity (49). Life-
threatening GI-toxicity occurred in 8% of the patients (49). Up to 27% of patients were not 
able to finish their programmed treatment if chemotherapy was given before RT in 
endometrial cancer (50).  
Intensity Modulated Radiotherapy has been available and in use for over 10 years and has 
shown considerable promise in reducing toxicity in numerous tumor sites (45, 51). Also in 
pelvic gynaecological tumours, the dosimetric superiority of IMRT and IMAT over conformal 
techniques has been demonstrated. An overview is presented in table 1.1 (18, 52-61). Several 
studies have demonstrated that this dosimetric superiority also translated into reduced 
treatment toxicity (13-16, 62, 63). In 2007, IMAT has been implemented clinically in the 
adjuvant treatment of cervical and endometrial cancer at GUH. The first results on toxicity 
have been reported in Publication 1: Post-operative Intensity-Modulated Arc Therapy for 
cervical and endometrial cancer: a prospective report on toxicity.  
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Table 1.1: Dosimetric comparison of techniques. 
      Technique  n Dose Significant dosimetric advantage for Intensity Modulated Radiotherapy  
IMRT    Small Bowel Rectum (+ sigmoid*) Bladder Bone Marrow  
 Definitive treatment       
  Forrest et al.(54)£ 7F-IMRT vs Box 50 50,4Gy V30; V40; V45; V50 V40*; V45*; V50* V30; V40; V45; V50 V30; V40; V45; V50 
  Georg et al.(55) 7F-IMRT vs Box 10 50,4Gy V50,4 V50,4   
  Portelance et al.(18) 9F-IMRT vs APPA 10 45Gy V45 V45 V45  
   9F-IMRT vs Box 10 45Gy V45 V45 V45  
  Mell et al.(59) 9F-IMRT vs APPA 7 45Gy    V5; V10; V20; V30; V40 
   9F-IMRT vs Box 7 45Gy    -V5; -V10; V20; V30; V40 
 Adjuvant treatment        
  Ahamad et al.(52) 9F-IMRT vs APPA 10 45 Gy V30; V40; V45 V30; V40; V45 V30; V40; V45  
   9F-IMRT vs Box 10 45 Gy V30; V40; V45 V30; V40; V45 V30; V40; V45  
  Georg et al.(55) 7F-IMRT vs Box 10 50,4Gy V47,9; V50,4 V47,9; V50,4   
  Heron et al.(56) 7F-IMRT vs Box 10 45Gy V30 V30 V30  
  Lujan et al.(58) 9F-IMRT vs Box 10 45Gy    (V18; V22,5; V27; V36; V45)$ 
  Chen et al.(64) 7F-IMRT vs Box 7 45Gy V15; V45 V45 V45  
  Ghent seriesα 7F-IMRT vs Box 10 46Gy V20; V40; V45 V40*; V45*; V50* V20; V30; V45  
 Definitive and adjuvant treatment       
  Roeske et al.(60) 9F-IMRT vs Box 10 45Gy -V10; V20; V40; V45  V30; V40; V45 V30; V40; V45  
ARC        
 Definitive treatment       
  Hsieh et al.(57) HT vs Box 10 50,4Gy mean;  V20; V30; V40; V50,4 mean; V30; V40; V50,4 mean; V30; V40; V45; V50,4 V20$ 
 Adjuvant treatment        
  Wong et al.(61) IMAT vs APPA 5 45Gy V45   V30$ 
    Ghent seriesα IMAT vs Box 10 46Gy V30; V40; V45; V50 V40*; V45* V20; V30   
- = advantage conformal technique; $: only iliac crest; α: not published, no difference between IMRT and IMAT; £: significant lower integral dose with IMRT. xF-
IMRT: Intensity Modulated Radiotherapy using "x" beam angles; box: 4-field conventional radiotherapy; APPA: 2-field conventional radiotherapy; HT: Helical 
Tomotherapy; IMAT: Intensity Modulated Arc Therapy; Vx: Volume of OAR receiving a maximum of xGy; vs: versus. 
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1.2. Primary treatment of cervical cancer 
Early stage cervical cancer (tumours up to FIGO IIA and < 4cm) can be treated with surgery 
alone or, in case of unfavourable prognostic findings on pathology, with postoperative 
radiation (with or without chemotherapy). For locally advanced stages (bulky tumours > 4cm 
and/or FIGO IIB or more) definitive CRT is the treatment of choice. Two meta-analyses 
including multiple randomized trials show that CRT improves OS and progression-free 
survival (PFS), whether or not platinum is used, with absolute benefits of 10 and 13%, 
respectively (3, 65). The standard treatment of locally advanced cervical cancer (LACC) 
consists of EBRT combined with brachytherapy (BT). However, there is some evidence that 
the addition of adjuvant surgery might improve local control (66-68). Although no increase in 
grade 3 or 4 toxicity was shown in the only randomized trial evaluating the effect of an 
additional hysterectomy (69), a great reluctance to perform post-CRT hysterectomy is present. 
Indeed, some research groups have reported on excessive toxicity using completion 
hysterectomy (70). It is our hypothesis that this could be reduced by abandoning the use of 
conventional treatment fields on the one hand, and by avoiding the dosimetric uncertainty 
inherent to the combination of two - difficult to add up - RT techniques (EBRT and BT) on 
the other hand. Delivering a high dose however is important, as there is a clear dose-
relationship for cervical cancer (23, 24). This may, however, NOT lead to an extended OTT 
since the impact of a prolonged OTT with losses of pelvic tumor control from 0.6 to 0.8% per 
extra day of treatment is well established (28, 30). A SIB, within the timeframe of the pelvic 
treatment, does not only increase the physical dose to the primary tumour but also increases 
the dose per fraction, which results in a double advantage. Intensity modulated radiotherapy 
and IMAT have lead to a significant reduction of toxicity rates (14, 16, 58, 71) and should 
permit to deliver a SIB to the tumour and affected lymph nodes (as visualized on Magnetic 
Resonance Imaging (MRI) and 2-deoxy-2-[18] fluoro-D-glucose positron emission 
tomography (18FDG PET-CT)). The planning procedure, quality control and the clinical 
implementation of IMAT with image-guided SIB in LACC is described in publication 2: 
Intensity-Modulated Arc Therapy with Simultaneous Integrated Boost in the Treatment of 
Primary Irresectable Cervical Cancer. Treatment Planning, Quality Control, and Clinical 
Implementation. 
 
Intracavitary brachytherapy is still considered as a standard component of radical treatment of 
cervical cancer. Unfortunately, pooled results from 5 randomized trials (2065 patients) show 
local recurrence rates (LRR) of 7%, 16% and 26% in stage I, II and III respectively.  This is 
similar with the LRR of 15 to 20% achieved with CRT as described in the meta-analysis 
performed by Lukka et al. (4). Compared to the conventional BT used in the former series, 
image guided adaptive BT (IGABT) has lead to a better local control without increasing 
toxicity (72-74). Despite the fact that complementary hysterectomy could be a treatment 
option (75) with the aim to remove potentially chemo- and radioresistant foci and hereby 
seeking better local control rates, adjuvant hysterectomy is not generally used as a 
randomized study shows no benefit on survival (69). This randomized study however, clearly 
suggests that patients with tumours measuring 4 to 6 cm, may benefit from extrafascial 
hysterectomy (69). And moreover (as described before) a great reluctance to perform post-
CRT hysterectomy is present due to the fear for an excess in toxicity. Introducing toxicity 
reducing IMAT with a SIB, which from a technical point of view replaces the 
brachytherapeutic boost, might open a window for securing the safety of complementary 
surgery and subsequently improve local control. Whether IMAT with SIB allows post-CRT 
hysterectomy and the corresponding toxicity and control rates are discussed in publication 3: 
Intensity Modulated Arc Therapy ± Cisplatin as neo-adjuvant treatment for primary 
irresectable cervical cancer: toxicity, tumour response and outcome. 
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Forty percent of our population showed a pathologic complete response (pCR) and did, 
hypothetically, not need a hysterectomy. Furthermore, hysterectomy is a fair treatment option 
if residual tumour is present after definitive CRT (67) but, due to fibrosis, its morbidity rate 
seems to be higher if performed more than 6 weeks after CRT (76). Reliable early assessment 
of treatment response and local extent after CRT is thus essential and could hypothetically 
lead to a further patient-individualized approach according to the tumour characteristics 
during and shortly after CRT. The role of MRI and 18FDG PET-CT in staging and assessment 
of resectability in (non-treated) cervical cancer is established. Although this was also 
recognized by the International Federation of Gynaecology and Obstetrics (FIGO), they can’t 
be used for (FIGO) staging purpose due to their limited accessibility. With a negative 
predictive value of 94-100% for parametrial invasion and its superior soft tissue resolution, 
MRI is the best for defining the local extent of the tumor (77, 78)  as where 18FDG PET-CT is 
superior for diagnosing lymph node or distant metastasis (78, 79).  
More sparse are reports concerning the value of MRI and 18FDG PET-CT in predicting radical 
resectability of LACC after neo-adjuvant CRT (80, 81). Also the correlation with post-therapy 
18FDG uptake and pathology is rarely reported. This was the subject of research and 
discussion and is presented in publication 4: “Value of Magnetic Resonance and 18FDG 
PET-CT in Predicting Tumor Response and Resectability of Primary Locally Advanced 
Cervical Cancer after Treatment with Intensity-Modulated Arc Therapy. A Prospective 
Pathology-Matched Study.” 
 
2. Ovarian Cancer 
In Belgium, ovarian cancer is the 2nd most frequent gynaecological cancer and the 5th cause 
of cancer death in females (82). Over 70% of patients with epithelial ovarian cancer (EOC) 
present with advanced (FIGO stages III and IV) disease. Although the 5-year OS rate for 
ovarian cancer has improved significantly in the past 30 years, the prognosis for ovarian 
cancer remains poor and is closely related to the stage at diagnosis, as determined according to 
the staging system developed by the FIGO. Approximately 60%, 20-30%, and 10-20% of 
women presenting with FIGO stage II, III, and IV respectively, will survive 5 years (83). For 
advanced stages, in the ’50s, surgery and adjuvant whole abdomino-pelvic radiotherapy 
(WAPRT) were the dominant treatment modalities (84, 85). However, using conventional 
techniques, WAPRT was associated with a high rate of severe side effects (particularly SB 
toxicity and myelosuppression)(86). Whole abdomino-pelvic RT based on conventional 
technology was not able to deliver adequate radiation doses to the upper abdomen due to 
OARs tolerance limits (liver, kidney) and was considered ineffective for patients with 
macroscopic disease after chemotherapy (87, 88). Moreover, platinum-based chemotherapy 
has dramatically changed the course for these patients and WAPRT has been almost totally 
excluded from the treatment of EOC. Despite the advances in surgical therapy and expanding 
choices for adjuvant therapy in advanced EOC, over 70% of women will relapse of whom the 
tumor is confined to the abdominal cavity in 85% of these (83, 85). For patients with 
progressive disease after second- or third-line chemotherapy, therapeutic options are very 
limited and often restricted to the best supportive care. Being the primary cause of 
hospitalization in palliative setting (89), a difficult problem to palliate is malignant bowel 
obstruction (MBO) in platinum-resistant patients. Most patients show multiple intestinal 
levels of obstruction precluding any surgical intent. The mean OS of MBO patients is 
between 20 and 75 days and the 3- month life expectancy is lower than 25% (83). Palliative 
RT has shown to relieve most symptoms in 50–80% of patients, with complaints of bleeding 
and pain responding the best (87, 90). Only 2 reports reported on the palliative effect for 
patients with MBO (91, 92). In 2003, our research group reported on the feasibility of IMAT 
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in the treatment planning of WAPRT as palliative treatment of bulky peritoneal relapsed 
ovarian cancer (17). The first clinical results are presented in publication 5:   Whole 
abdominopelvic radiotherapy using intensity-modulated arc therapy in the palliative 
treatment of chemotherapy-resistant ovarian cancer with bulky peritoneal disease: a single-
institution experience. 
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Summary 
A prospective report on toxicity in cervical (n=25) and endometrial (n=41) cancer patients 
treated with postoperative radiotherapy using intensity modulated arc therapy (IMAT). Apart 
from 12% grade 3 hematologic toxicity, ≥ grade 3 acute toxicity was very low (2% genito-
urinary and no gastro-intestinal). No severe (≥ grade 3) late toxicity was noted. Para-aortic 
lymph node (PALN) irradiation is feasible when IMAT is used. Concomitant chemotherapy 
and PALN irradiation influences acute but not late toxicity. 
 
Abstract 
 
Purpose 
To report on toxicity after postoperative Intensity-Modulated Arc Therapy (IMAT) for 
cervical (CC) and endometrial cancer (EC).  
 
Methods and Materials 
Twenty-four CC and 41 EC patients were treated with postoperative IMAT. If indicated, para-
aortic irradiation (preventive or when affected, PALN) and/or concomitant cisplatin (40 
mg/m², weekly) was administered. The prescribed dose for IMAT was 45 Gy (CC, 25 
fractions) and 46 Gy (EC, 23 fractions), followed by a brachytherapeutic boost if possible. 
Radiation related toxicity was assessed on in a prospective way. The effect of concomitant 
cisplatin and PALN irradiation was evaluated. 
 
Results 
Acute toxicity (n=65): Grade 3 and 2 acute gastrointestinal (GI) toxicity was observed in zero 
and 63% patients (79% CC; 54% EC) respectively. Grade 3 and 2 acute genito-urinary (GU) 
toxicity was observed in 1 and 18% of patients. Grade 2 (21%) and 3 (12%) hematologic 
toxicity (n=41) occurred only in CC patients. 17% CC patients and 2% EC patients 
experienced grade 2 fatigue and skin toxicity respectively. Adding cisplatin lead to an 
increase in > G2 nausea (57% vs 9%; p=0,01), G2 nocturia (24% vs 4%; p = 0,03), ≥ G2 
hematologic toxicity (38% vs nil, p=0,003),≥ G2 leucopenia (33% vs nil, p=0,009) and a 
strong trend towards more fatigue (14% vs 2%; p=0,05).  PALN irradiation lead to an 
increase of G2 nocturia (31% vs 4%, p=0,008) and a strong trend towards more > G2 nausea 
(44% vs 18%; p=0,052), 
Late toxicity (n=45):  
No Grade 3 or 4 late toxicity occurred. Grade 2 GI, GU toxicity and fatigue occurred in 4%, 
9% and 1% of the patients. Concomitant cisplatin nor PALN irradiation increased late toxicity 
rates.  
 
Conclusions 
Postoperative IMAT for EC or CC is associated with low acute and late toxicity. Concomitant 
chemotherapy and PALN irradiation influences acute but not late toxicity. 
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Introduction 
Postoperative pelvic radiotherapy is a standard component of the multimodality treatment in 
cervical and endometrial cancer (1). Conventionally, opposed fields or a 4-field box technique 
are used to try to ensure adequate coverage of the target volume leading to large volumes of 
gastrointestinal and urinary tracts within the treatment field, inevitable leading to important 
acute and late toxicity. Adding chemotherapy to the postoperative irradiation in cervical 
cancer has proven superiority by improving overall survival with some studied 
chemotherapies (1). A similar tendency has been shown in the adjuvant treatment of 
endometrial cancer (2) and currently the effect of adding chemotherapy to irradiation in the 
treatment of high-risk endometrial cancers is evaluated in the PORTEC-3 trial (Randomized 
phase III trial comparing concurrent chemoradiation and adjuvant chemotherapy with pelvic 
radiation alone in high risk and advanced stage endometrial carcinoma; clinical trials.gov: 
NCT00411138). Adding chemotherapy leads to a significant twofold increase in acute 
hematologic and gastro-intestinal acute toxicity, with 8% of chemoradiation patients suffering 
severe to life threatening adverse events (3). In the recent report of Hogberg et al. 27% of 
patients were unable to complete their scheduled chemotherapy schema (2). Conventional 
para-aortic lymph node (PALN) irradiation combined with chemotherapy has proven to be 
highly toxic with 50% grade 4 bowel-related acute and 34% grade 3 and 4 late toxicity (4).   
Evidence of reduced toxicity by the use of Intensity Modulated Radiotherapy (IMRT) is 
provided for various tumour sites. In gynaecologic malignancies, dosimetric studies have 
reported reduced volumes of normal tissue irradiated using IMRT when compared to 
conventional techniques (5). This has been confirmed in the clinical setting (6-10).  IMRT 
generates concave dose distributions to deliver a radical dose to the target volume, while 
reducing the volume of bladder, small bowel and rectum irradiated. With an increasing inner 
radius of the target volume, as in gynecologic malignancies, a greater number of beam 
incidences is needed to combine sufficient coverage of the PTV and sparing of the organs at 
risk (OAR) (5). Intensity-Modulated Arc Therapy (IMAT) is a fast and easy way to deliver a 
large number of beam incidences. The theoretical benefits of IMAT have been reported (11). 
This manuscript reports on the clinical benefits of IMAT (± chemotherapy) concerning acute 
and late toxicity in the postoperative treatment of cervical and endometrial cancer. 
 
Materials and Methods 
This monocentric, prospective study (approved by the local ethical committee), was 
undertaken between January 2007 and April 2011. Inclusion criteria were: endometrial (EC) 
or cervical cancer (CC) patients eligible for postoperative pelvic radiation therapy after 
hysterectomy (with or without lymphadenectomy) or resection of a local recurrence, absence 
of distant metastases (apart from affected para-aortic lymph nodes); World Health 
Organization (WHO) score 0-2 (12); absence of any condition hampering compliance with the 
study protocol and follow-up; ability to understand and sign informed consent.  
Patients were assessed on and operated by the referring gynaecologic oncologist. Surgery 
consisted of hysterectomy ± pelvic lymphadenectomy or resection of the local recurrence; 
suspicious (clinically or radiographically) pelvic or periaortic lymph nodes were removed. 
FIGO (International Federation of Gynecology and Obstetrics) 2009  staging (UICC TNM 
Classification of Malignant Tumours, 7th edition) was assigned on the basis of surgical and 
pathological findings. Eligibility for postoperative radiotherapy was assessed on in a 
multidisciplinary consult meeting (gynaecologic oncologists, radiotherapists, medical 
oncologist, radiologists and pathologists). If indicated, concomitant cisplatin (40 mg/m², 
weekly) was administered.  
Postoperative radiotherapy consisted of IMAT followed by a brachytherapeutic boost (n=58) 
to the vaginal vault or an external boost if brachytherapy was technically or medically not 
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feasible (n=2). From 1/2/2009 onwards, if pelvic positive lymph nodes were found in the 
pathologic specimen of CC patients, preventive PALN irradiation was performed. Para-aortic 
irradiation was always performed if PALN were affected. 
 
Patients 
Twenty-four CC and 41 EC patients were included (n=65). Median age at diagnosis was 65 
years (35-83 years); Referred CC patients were significant younger than EC patients (median 
age: 49 vs 67 years; p<0,001; unpaired 2 sample t-test). Twenty CC patients (83%) received 
concomitant chemotherapy in comparison with 1 EC patients (2%). The reason for 
administering cisplatin to this EC patient was the extent of disease (FIGO IIIC1, 5 nodes 
positive).  
Details on patient and tumour characteristics and therapy can be found in table 1 and Figure 1. 
Reasons for not performing a boost were: refusal by the patient (n=4) or progression of 
disease (n=1, metastatic disease). 
 
Table 1: patient characteristics 
ALL PATIENTS CERVIX ENDOMETRIUM
n=65 n=24 n=41
Age (yrs) at diagnosis 
median 65 49 67
range 35-83 35-71 50-83
Follow-up in months 
median 18 23 15
range 3-53 5-53 3-51
N+ at diagnosis
n patients 29 (57%) 17 (74%) 12 (43%)
Chemotherapy 
n 21 (32%) 20 (83%) 1 (2%)
Para-aortic irradiation 
n 16 (25%) 12 (50%) 4 (10%)
Histology
squamous 17 (71%) 17 (71%) 0
adeno 10 (15%) 6 (25%) 4 (10%)
endometroid adeno 37 (57%) 1 (2%) 36 (88%)
serous papillary 1 (1%) 0 1 (2%)
Grade
1 14 (22%) 0 14 (34%)
2 23 (35%) 12 (50%) 11 (27%)
3 26 (40%) 11 (46%) 15 (37%)
not reported 2 (3%) 1 (4%) 1 (2%)
FIGO stage (TNM 2009)
I 28 (43%) 13 (54%) 15 (37%)
II 11 (17%) 5 (21%) 6 (15%)
III 17 (26%) 2 (9%) 15 (36%)
IVA 1 (1%) 1 (4%) 0
IVB 3 (5%) 2 (8%) 1 (2%)
recurrence 5 (8%) 1 (4%) 4 (10%)
Boost
external 2 (3%) 0 2 (5%)
brachytherapeutic 58 (88%) 22 (92%) 36 (88%)
    median dose 17Gy 17,5Gy 17Gy
    min-max dose 11-21Gy  11-21Gy 15-20Gy
no boost 5 (8%) 2 (8%) 3 (7%)  
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Figure 1:  
EC: endometrial cancer; CC: cervical cancer; RT: radiotherapy; CT: Chemotherapy; PALN: Para-aortic 
Lymph node irradiation. 
 
 
IMAT 
Pre-treatment imaging consisted of CT (Siemens Somatom 4+, Siemens, Erlangen, 
Germany) performed in treatment position. If distant metastasis still had to be excluded, CT 
was replaced by 18FDG PET-CT (Gemini, Philips, Eindhoven, The Netherlands). The CT 
images were considered as the primary image data set. CT slice thickness and interslice 
distance were 5 mm. No attempts were made to reduce bladder and rectal filling. IV- contrast 
(Visipaque TM, GE healthcare, Diegem, Belgium) was used to improve the visibility of the 
iliac vessels. 
Target delineation  
The clinical target volume (CTV) was the union of the CTV_T (operation bed, superior third 
to half of the vagina) and the CTV_N (presacral and obturator region, common, internal and 
external iliac lymph nodes; para-aortic lymph nodes were included when proven positive or if 
preventive irradiation was needed). The planning target volume of the CTV_T (PTV_T) was 
created using a 3-dimensional anisotropic expansion of 10, 7 and 7 mm in the anteroposterior, 
left-right and supero-inferior direction respectively. Using a 3-dimensional expansion of 
respectively 5 mm around CTV_N, PTV_N was created. For planning reasons, PTV_N and 
PTV_T were summed to form the definitive PTV. As from 2008, target delineation was 
performed in consensus with the guidelines of Small et al. (13). The rectum, sigmoid, small 
bowel, bladder and cauda equina (in case of PALN irradiation also both kidneys and the 
spinal cord) were defined as organs at risk.  
Dose objectives for planning: 
The dose to be received by 98% of the volume (D98) of the PTV was 45 Gy (cervical cancer) 
and 46 Gy (endometrial cancer) delivered in 25 and 23 fractions respectively. The treatment 
fractionation was altered to 25 fractions of 1, 8 Gy for the one EC patient who received 
concomitant cisplatin. Dose objectives/constraints can be found in table 2. 
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Table 2: Dose objectives and constraints. 
Target dose objectives
D98 ≥ 45 Gy (CC) or 46 Gy  (EC)
PTV_N/T and PTV and
D02 < 52 Gy (CC) or 53 Gy (EC)
organ at risk dose constraints
D02 ≤ 66.9 Gy
rectum V41 < 84%
 V50 < 69%
D02 ≤ 66.9 Gy
sigmoid V41 < 84%
 V50 < 69%
D02 ≤ 66 Gy
V40 < 30%
bladder D02 ≤ 69.3 Gy
cauda equina D02 ≤ 50 Gy
spinal cord D02 ≤ 50 Gy
kidney D50 ≤ 18 Gy
small bowel
 
PTV_N/T: PTV_N, PTV_T; Dx < z Gy: no more than x% of the volume should receive more than z Gy; 
Vx < z%: the volume receiving more than x Gy should not exceed z%. 
 
Planning procedure and delivery 
The IMAT planning procedure and Quality Assurance has been described previously (14). An 
example of a dose distribution can be found in figure 2. The arcs for PTV_T were generated 
using an anatomy based segmentation tool with the rectum as exclusion structure. The arcs for 
PTV were created using a manually delineated exclusion structure including large parts of the 
intestinal cavity and bladder (14). All arcs used a 0° couch isocenter rotation and a single 
isocenter. If PALN were included, a separate 360° arc around this region was created. 
All patients were treated in supine position using a knee and ankle fix (Cablon Medical, 
Leusden, The Netherlands), arms above the head. Treatment was done with 18-MV photons 
of an Elekta SL18 series Linear Accelerator (SliPlus, Elekta, Crawley, UK) equipped with  
standard MLC and prototype dynamic control software to deliver IMAT in local service 
mode. Patient positioning was controlled by electronic portal imaging (14). Brachytherapy 
(vaginal ovoids) was given within 14 days after the end of external beam RT. The technique 
used pulsed dose rate with hourly pulses of 0.6 Gy at 0.5 cm from the surface of the 
applicator, including overnight treatment (microSelectron PDR, Nucletron BV, Veenendaal, 
the Netherlands or GammamedPlus, Varian Medical Systems Inc., Palo Alto, USA).  Doses 
from 11 to 21 Gy were given. 
Follow-up and assessment of disease control  
Patients were seen weekly during treatment, 1 and 3 months thereafter. Thereafter, follow-up 
was scheduled three-monthly (first two years), 6-monthly (year 3-5) and annually.  
 
Endpoints and analysis. 
The endpoint of this study was the evaluation of radiation related toxicity (acute and late) for 
the whole treatment group and both groups separately. The effect of concomitant 
administration of cisplatin and PALN irradiation was evaluated (within the whole treatment 
group). 
Acute radiation toxicity was scored weekly during IMAT and at 10 days, 1 and 3 months 
thereafter. Late radiation toxicity (toxicity occurring >3 months after IMAT or acute toxicity 
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lasting longer than 3 months) was scored at every follow-up visit. Used scoring systems can 
be found in table 3 and 4 (15-17). 
For statistical analysis a chi-square test (SPSS 15.0, SPSS, Inc., Chicago, IL) was performed. 
Statistical significance level was set at p < 0, 05. 
 
 
Figure 2: Dose distributions. 
Dose distribution through the target volume in a coronal plane (A) and in a transversal plane at the level of 
the kidneys (B) and the pelvis (C). 
 
Results 
Acute and late toxicity was scored in all and 45 (69%) patients respectively.  
1. Acute radiation related toxicity  
Details concerning acute toxicity are presented in table 3.  
Gastro-intestinal toxicity  
No CC or EC patient experienced Grade 3 or more GI toxicity. One EC patient was operated 
on for intestinal sub-obstruction within 1 week after ending IMAT. The first signs of sub-
obstruction already started after the second fraction of radiotherapy (4Gy). Postoperative 
anatomopathologic findings demonstrated postoperative adhesions without any sign of 
radiation-enteritis. The patient is free of GI symptoms 24 months after surgery. 
We observed grade 2 toxicity in 19 CC (79%) and 22 EC (54%) patients respectively. The 3 
most frequent symptoms for grade 2 toxicity were increased frequency (54%), nausea (50%) 
and abdominal cramps (17%) in CC patients and frequency (49%), abdominal cramps (22%) 
and abdominal discomfort (12%) in EC patients. 
Adding cisplatin (n=21) lead to a significant increase in ≥ G2 nausea (57% vs 9%, p < 0,01). 
The irradiation of PALN showed a strong trend towards an increase in ≥ G2 nausea (44% vs 
18%; p=0,052). 
Genito-Urinary toxicity  
Only 1 patient (EC) experienced grade 3 pollakisuria. No other Grade 3 GU toxicity was 
observed. Seven CC (29%) and 5 EC (12%) patients developed grade 2 GU toxicity, with 
nocturia being the most frequently observed in CC patients (n=6). Adding chemotherapy 
significantly increased the incidence of grade 2 nocturia (24% vs 4%; p = 0,03). The same 
observation was made if PALN irradiation was added to the treatment (31% vs 4%, p=0,008). 
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Hematologic toxicity  
 Hematologic toxicity was scored in 41 patients (CC=24; EC=17).  Grade 2 (n=5; 21%) and 3 
(n=3; 12%) hematologic toxicity occurred only in CC patients and consisted mainly of 
leucopenia (G2: n=5; 21% and G3: n=2; 8%) and anaemia (G3: n=1; 4%). PALN irradiation 
did not influence hematologic toxicity. Grade ≥2 hematologic toxicity (38% vs nil, p=0,003) 
and more specifically leucopenia (33% vs nil, p=0,009) occurred only and significantly more 
if IMAT was combined with chemotherapy. 
Skin toxicity and fatigue 
Four CC patients (17%) experienced grade 2 fatigue whereas 1 EC patient (2%) developed 
grade 2 skin toxicity. 
We observed a strong trend towards more significant fatigue if chemotherapy was included 
(14% vs 2%; p=0,05). 
G1 G2 G3 G1 G2 G3 G1 G2 G3
GASTRO-INTESTINAL 32 63 0 21 79 0 39 54 0
Anorexia 17 5 0 29 8 0 10 2 0
Nausea 17 25 0 12 50 0 20 10 0
Frequency 37 51 0 37 54 0 37 49 0
Incontinence 5 1 0 4 0 0 5 2 0
Rectal Blood Loss 6 0 0 5 0 0 8 0 0
Abdominal Cramps 35 20 0 37 17 0 34 22 0
Urgency 31 6 0 32 7 0 29 4 0
Mucus Loss 8 0 0 8 0 0 7 0 0
Anal Pain 6 0 0 12 0 0 2 0 0
Abdominal Discomfort 32 8 0 27 5 0 42 12 0
URINARY 49 18 1 50 29 0 49 12 2
Pollakisuria 34 5 1 42 4 0 29 5 2
Nycturia 38 11 0 29 25 0 44 2 0
Hematuria 1 0 0 0 0 0 1 0 0
Dysuria 32 1 0 33 4 0 32 0 0
Urge 37 3 0 37 0 0 37 5 0
Incontinence 11 1 0 8 0 0 12 2 0
HEMATOLOGIC* 24 12 7 25 21 12 4 0 0
Hemoglobin 15 0 2 25 0 4 0 0 0
White Blood cell Count 22 12 5 21 21 8 24 0 0
Neutrophils 0 0 0 0 0 0 0 0 0
Platelets 2 0 0 4 0 0 0 0 0
FATIGUE 17 6 0 17 17 0 17 0 0
SKIN 3 2 0 0 0 0 5 2 0
ALL CC EC
(n=65) (n=24) (n=41)
 
Table 3: acute radiation related toxicity 
* Hematologic toxicity scoring is based on 41 patients (CC: 24 and EC: 17). 
Acute gastro-intestinal (GI) toxicity was scored using a combination of the RTOG scoring system, the scale of GI urgency 
and incontinence determined by Yeoh et al. (17) and an in-house developed scale for rectal blood loss (16).  Genitourinary 
(GU) toxicity was scored using the RTOG scale extended with an in-house developed scale for incontinence (15). 
Hematologic and skin toxicity was scored according to the RTOG scoring system.  
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2. Late radiation related toxicity  
The median follow-up (range) of all, CC and EC patients was 23 (8-53); 29 (9-53) and 22 (8-
51) months respectively. No Grade 3 or 4 toxicity occurred. Adding chemotherapy (n=17) or 
PALN irradiation (n=14) did not increase late toxicity rates. Details concerning late toxicity 
can be found in table 4. 
Gastro-intestinal (GI) toxicity  
Grade 2 GI toxicity occurred in 4% and 5% of EC and CC patients respectively and consisted 
mainly of a rise in GI frequency in both groups and abdominal cramps in the EC group. 
Genitourinary (GU) toxicity  
Grade 2 GU toxicity occurred in 5 and 12% of CC and EC patients respectively and consisted 
mainly of a rise in urinary urge/incontinence in the CC group and urinary incontinence and 
nocturia in the EC group. 
Skin toxicity and fatigue 
Grade 2 fatigue occurred in 1 CC patient. 
No late skin toxicity occurred. 
 
Table 4: late radiation related toxicity 
G1 G2 G1 G2 G1 G2
GASTRO-INTESTINAL 29 4 25 5 32 4
Anorexia 0 0 0 0 0 0
Nausea 0 0 0 0 0 0
Frequency 18 4 20 5 16 4
Incontinence 0 0 0 0 0 0
Rectal Blood Loss 2 0 0 0 4 0
Abdominal Cramps 9 2 15 0 4 4
Urgency 4 0 5 0 4 0
Mucus Loss 7 0 10 0 4 0
Anal Pain 0 0 0 0 0 0
Abdominal Discomfort 4 0 5 0 4 0
URINARY 13 9 0 5 24 12
Pollakisuria 9 0 5 0 12 0
Nycturia 2 2 5 0 0 4
Hematuria 2 0 5 0 0 0
Dysuria 2 0 0 0 4 0
Urge 4 2 0 5 8 0
Incontinence 7 7 0 5 12 8
FATIGUE 9 2 10 5 8 0
SKIN 0 0 0 0 0 0
(n=45) (n=20) (n=25)
ALL CC EC
 
Late GI toxicity was scored using the RTOG and Radiation Induced Lower Intestine Toxicity scoring scale (16). 
Genitourinary (GU) toxicity was scored using the RTOG scale extended with an in-house developed scale for 
incontinence (15). Hematologic and skin toxicity was scored according to the RTOG scoring system.  
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Discussion 
Conventional 2-field and 4-field postoperative radiation therapy for CC or EC is known to be 
associated with substantial acute and late side-effects*. This is not surprising considering the 
large volumes of small intestine, bladder, rectum and sigmoid colon within the concave 
shaped PTV.  With the introduction of IMRT, dosimetrical studies show a significant decrease 
in dose to the normal tissues (5). This was confirmed clinically by several retrospective 
studies. In 2002, Mundt et al. (9) reported a significant reduction of overall toxicity and a 
disappearance of grade 3 toxicity using IMRT (no concomitant chemotherapy) when 
compared to conventional techniques. Others compared concomitant radiochemotherapy 
using IMRT or a box technique (6, 7). A significant decrease in grade 1-2 and grade 2 acute 
GI toxicity of 44% (36% vs 80%) (7) and 31% (60% vs 91%) was noticed (9). Chronic GI 
toxicity decreased significantly by around 30% (7, 18). Although acute grade 2 GU toxicity is 
not unequivocally lowered by IMRT (7, 9) late GU toxicity rates were significantly decreased 
(9% vs 23%) (7). A similar significant reduction (29%) was seen for acute ≥ grade 2 
hematologic toxicity (6). Other series reported low toxicity rates but did not compare IMRT 
with conventional techniques (8, 10). The RTOG 0418 (A Phase II Study of Intensity 
Modulated Radiation Therapy (IMRT) to the Pelvis +/- Chemotherapy for Post-operative 
Patients with either Endometrial or Cervical Carcinoma) addressing a similar population 
reported comparable toxicity rates (19).  
To the best of our knowledge, the current study is the first to report on prospectively scored 
acute and late toxicity using IMAT in the postoperative setting for cervical or endometrial 
cancer. Our reported toxicity data lie within the spectrum of published data using intensity 
modulated techniques. 
No attempts were made to reduce bladder and rectal filling. In postoperative setting however, 
a (weak) correlation between rectal filling and position shifts of the target was found (20). 
This is an ongoing controversy that will be taken into account in our future work. 
As mentioned before, adding concomitant chemotherapy lead to superior overall survival 
above radiation therapy alone in the treatment of cervical cancer (1). However, this survival 
benefit is accompanied by a twofold increase in acute hematologic and GI toxicity, with 8% 
of chemoradiation patients suffering severe to life threatening events (3). In our series, no life 
threatening events were noted. Our acute toxicity data are consistent with the conclusions of 
Lukka et al. showing a significant increase in overall ≥ grade 2 acute GI toxicity by 25% (56 
to 81%)  and a two- (white cell count) to three-fold (platelet toxicity) increase in grade 3 
toxicity when chemotherapy was added (1). Rather unexpected, adding cisplatin lead to a 
significant increase of nocturia. A possible explanation could be the effect of hydration (and 
subsequent dehydration at night) performed when administering chemotherapy. In 
concordance with Kirwans findings (3) no rise in late toxicity due to the effect of 
chemotherapy was found. 
Prophylactic irradiation of PALN has shown to improve OS en DFS in a subgroup of cervical 
cancer patients (21). The use of concomitant chemotherapy and the resulting high toxicity 
rates (4) have lead to the omitment of this prophylactic para-aortic radiotherapy. If, however, 
prophylactic para-aortic irradiation is performed with modern radiation techniques such as 
                                                 
*Remark member of the examination committee: “Substantial acute and late effects: add references.” 
- Kirwan JM, Symonds P, Green JA, et al. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. 
Radiother Oncol 2003;68:217-226. 
- Kong A, Simera I, Collingwood M, et al. Adjuvant radiotherapy for stage I endometrial cancer: systematic review and meta-analysis. Ann 
Oncol 2007;18:1595-1604. 
- Nout RA, Smit VT, Putter H, et al. Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of 
high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. Lancet 2010;375:816-823. 
- Tan LT, Zahra M. Long-term survival and late toxicity after chemoradiotherapy for cervical cancer--the Addenbrooke's experience. Clin 
Oncol (R Coll Radiol) 2008;20:358-364. 
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IMRT (5) or IMAT, toxicity is acceptable and no increase in late toxicity nor life threatening 
toxicity is observed. We are aware that our data need to be confirmed since the number of 
patients treated with PALN is limited (n=4). However, it might be of interest to re-investigate 
the role of preventive PALN radiation with modern techniques in future randomized trials. 
Retrospective comparative studies have shown at least comparable outcomes with IMRT 
compared to conventional techniques (7, 8, 10). Considering the 45 patients of our study with 
a follow-up longer than 6 months we found no regional failure and 1 local failure thus far. 
Longer follow-up is definitely warranted and clinical outcomes will be the subject of a 
separate paper.  
It is our believe that conclusions from randomized trials always should be held in the light of 
the used technology. For instance, although a 72% reduction in pelvic relapse was seen for 
stage I endometrial cancer treated with external beam therapy, a trend towards survival 
benefit was shown only in patients with multiple risk factors such a Figo IB or grade 3. Due to 
an excess in toxicity risk the advise not to give external beam radiotherapy to patients with 
only 1 risk factor was given (22). Similarly, high GI toxicity rates are contributory to the 
conclusion of the PORTEC-2 trial (23). However, would this conclusion be the same if grade 
3 toxicity was minimal to absent and grade 2 toxicity was halved when IMRT or IMAT were 
used? Hopefully these trials will be repeated with the use of IMRT or IMAT. 
All studies, also the present one, are affected by limitations. The most important one is the 
lack of direct comparison with conventional techniques. In light of the published results 
concerning the toxicity comparison between conformal therapy and IMRT, IMAT was the 
treatment of choice for eligible patients in our treatment centre. The Ethics Committee of our 
hospital considered the use of conventional techniques not longer as ethical as it would 
expose our patients to higher toxicity rates.  
 
Conclusion 
In our experience, IMAT for endometrial and cervical cancer in the postoperative setting is 
associated with low acute and late toxicity. Concomitant chemotherapy leads to a significant 
raise in acute GI and haematological toxicity. Prophylactic para-aortic IMAT is correlated 
with an increase in acute G2 nocturia. Neither concomitant chemotherapy nor PALN 
influences late toxicity. 
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 ABSTRACT 
Purpose:  
To report on the planning procedure, quality control and clinical implementation of Intensity 
Modulated Arc Therapy (IMAT) delivering a simultaneous integrated boost (SIB) in patients 
with primary irresectable cervix carcinoma. 
Methods and Materials: 
Six patients underwent PET-CT and MRI before treatment planning. Prescription (25 
fractions) was:  
1. A median dose (D50) of 62, 58 and 56 Gy to the primary tumour (GTV_cervix), 
primary clinical target volume (CTV_cervix) and its planning target volume (PTV_cervix) 
respectively.  
2. A D50 of 60 Gy to the PET-positive lymph nodes (GTV_nodes) 
3. A minimal dose (D98) of 45 Gy to the planning target volume of the elective lymph 
nodes (PTV_nodes). 
IMAT-plans were generated using an anatomy-based exclusion tool with the aid of weight 
and leaf position optimisation. The dosimetrical delivery of IMAT was pre-clinically 
validated using radiochromic filmdosimetry. 
Results:  
Five to 9 arcs were needed to create valid IMAT plans. Dose constraints on D50 were not met 
in two patients (both GTV_cervix: 1 Gy and 3 Gy less).  D98 for PTV_nodes was not met in 3 
patients (1 Gy each). Film dosimetry showed excellent gamma-evaluation. There were no 
treatment interruptions.  
Conclusion:  
IMAT allows delivering a SIB to the macroscopic tumour without compromising the dose to 
the elective lymph nodes or the organs at risk. The clinical implementation is feasible. 
 
 
ZUSAMMENFASSUNG 
Ziel:  
Bericht über Planung, Qualitätssicherung und klinische Umsetzung einer rotations-
intensitätsmodulierten Strahlentherapie (IMAT) mit “Simultanen integrierten Boost” (SIB) 
bei Patientinnen mit primärem, nicht reserzierbarem Gebärmutterhalskarzinom. 
Material und Methodik:  
Bei sechs Patientinnen wurde vor der Behandlungsplanung eine PET/CT- und MRI-
Untersuchung durchgeführt. Die Dosisverordnung (25 Fraktionen) betrug:  
1. Mediane Dosis (D50) von 62, 58 und 56 Gy für Primärtumor (GTV_cervix), 
primäres klinisches Zielvolumen (CTV_cervix) bzw. Planungszielvolumen (PTV_cervix).  
2. Eine D50 von 60 Gy für PET-positive Lymphknoten (GTV_nodes) 
3. Eine minimale Dosis (D98) von 45 Gy für das Planungszielvolumen der elektiven 
Lymphknoten (PTV_nodes). 
Die IMAT-Pläne wurden mit einem anatomiebasierten Ausschlusswerkzeug mit Hilfe der 
“Weight-and-Leaf-Position”-Optimierung erstellt. Die Dosimetrie der IMAT wurde 
vorklinisch anhand radiochromer Filmdosimetrie validiert. 
Ergebnisse:  
Zur Erzeugung vernünftiger IMAT-Pläne wurden fünf bis neun Rotationsfelder benötigt. In 2 
Fällen konnten die Dosisbeschränkungen der D50 nicht eingehalten werden (GTV_cervix: 1 
Gy bzw. 3 Gy niedriger).  In 3 Fällen konnte D98 für PTV_nodes nicht erreicht werden 
(jeweils 1 Gy weniger). Die Filmdosimetrie ergab eine ausgezeichnete Gamma-Bewertung. 
Keine Behandlungsunterbrechungen.  
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Schlussfolgerung:  
Die IMAT ermöglicht ein SIB-Verfahren bei makroskopischen Tumoren ohne 
Dosiskompromisse bei den elektiven Lymphknoten oder den Risikoorganen eingehegen zu 
müssen. Die klinische Umsetzung ist möglich. 
 
Introduction 
Based on randomized trials [34, 36, 41, 45, 46, 52] and meta-analyses [19, 30], the standard 
treatment for irresectable cervical cancer is concurrent cisplatin-based chemoradiation. The 
survival benefit above radiotherapy alone is 10% [19, 30]. Local recurrence is present in 6-
14% and 20-25% of the patients with and without additional hysterectomy respectively [25, 
30, 34, 41, 45, 46, 52]. The largest advantage for additional hysterectomy is observed for 
tumours ≥ 4 cm [25]. The rate of residual tumor in hysterectomy specimens after 
chemoradiation followed by “conventional” brachytherapy is 45-61% [1, 5, 25, 32, 44].  
Residual tumor increases the rate of pelvic recurrence [5, 22, 39] and reduces progression-free 
survival [25]. 
With conventional technology, late grade ≥ 3 toxicity is present in up to 23% of the patients*. 
Cisplatin does not increase late toxicity [27, 31], suggesting that radiotherapy is the major 
determinant. Concerning brachytherapy (after external therapy), image guidance and MRI-
guided target volume adaptation have led to acceptable toxicity and better local control [16, 
43]. However, efforts to improve the external beam radiotherapy are needed.   
Intensity Modulated Radiotherapy (IMRT) results in a better therapeutic ratio concerning 
pelvic tumours [2, 3, 6, 21, 23, 35, 42, 51]. In case of cervical cancer, the planning target 
volume (PTV) has a concave shape with a large internal radius (small intestine and bladder 
are positioned within). In such situations, a large number of intensity-modulated beams are 
needed to ensure adequate PTV coverage and sufficient sparing of the organs at risk [6, 11].  
Intensity Modulated Arc Therapy (IMAT) is a new mean to deliver IMRT and is implemented 
for several tumor sites [11, 53]. IMAT has an infinite number of beams and is therefore 
theoretically a good solution to treat locally advanced cervical cancer. We developed a 
schedule of pre-operative radiochemotherapy that delivers a higher dose the primary tumor 
and involved lymph nodes without compromising the dose to the rest of the clinical target 
volume or OAR. This manuscript reports on the planning procedure, prescription levels, 
quality control and feasibility of IMAT in this indication. 
 
Materials and Methods 
This study involves 6 patients with irresectable cervical cancer. Staging and resectability were 
determined by gynaecological examination and imaging (magnetic resonance imaging (MRI) 
and 18FDG PET-CT) [10, 20, 40]. If bladder or rectal invasion was suspected, cystoscopy 
and/or rectoscopy were performed 
                                                 
* Remark member of the examination committee:  “late grade ≥ 3 toxicity is up to 23%. This seems a high number, please give a reference 
and add more series,  especially series published after 2006” 
- Kirwan JM, Symonds P, Green JA, et al. A systematic review of acute and late toxicity of concomitant chemoradiation for cervical cancer. 
Radiother Oncol 2003;68:217-26. 
- Maduro JH, Pras E, Willemse PH, et al. Acute and long-term toxicity following radiotherapy alone or in combination with chemotherapy 
for locally advanced cervical cancer. Cancer Treat Rev 2003;29:471-88. 
- Tseng CJ, Chang CT, Lai CH, et al. A randomized trial of concurrent chemoradiotherapy versus radiotherapy in advanced carcinoma of the 
uterine cervix. Gynecol Oncol 1997;66:52-58. 
Both reviews (Kirwan et al. & Maduro et al). criticise the lack of data on late toxicity. In the series reporting late toxicity 0 to 15% severe  (≥ 
3) late urologic toxicity and 0-23% severe (≥ 3) total (GI + urologic) toxicity is reported. This article was submitted in 2008, this is the 
reason why series after 2006 are lacking here. Possible more recent series where less toxicity is described could be: 
- Pötter R, Georg P, Dimopoulos JCA, et al. Clinical outcome of protocol based image (MRI) guided adaptive brachytherapy combined with 
3D conformal radiotherapy with or without chemotherapy in patients with locally advanced cervical cancer. Radiother Oncol 2011;100:116-
123. 
- Hasselle MD, Rose BS, Kochanski JD, et al. Clinical Outcomes of Intensity-Modulated Pelvic Radiation Therapy for Carcinoma of the 
Cervix. Int J Radiat Oncol Biol Phys 2011;80:1436-1445. 
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For planning, an 18FDG PET-CT (Gemini, Philips, Eindhoven, The Netherlands) was 
performed in treatment position. The CT images were considered as the primary image data 
set. CT slice thickness and interslice distance were 5 mm. No attempts were made to reduce 
bladder and rectal filling. IV-contrast (Visipaque™, GE Healthcare, Diegem, Belgium) was 
used to improve the visibility of the vessels. PET-images were acquired 50-60 minutes after 
injection of 18FDG. The dose was calculated using the formula: ((body weight/10) +1) x 37 
MBq. The PET-images were on-line fused with the CT images. All images were transferred 
through a local network to the Pinnacle planning system, version 6.2b (Philips Medical 
Systems, Andover, MA).  
MR-images were acquired on a 1.5 Tesla MRI (Magnetom Symphony, Siemens, Erlangen, 
Germany) using T1-weighted gradient-echo localizer sequences, followed by 4 mm thick 
transverse, sagittal and coronal T2-weighted turbo spin-echo (TSE) images and T1 TSE 
images in the transverse plane. Together with a specialized radiologist (GV), the PET-CT and 
MR images were co-registrated. This method has been previously implemented for prostate 
cancer [50]. 
 
Target volume delineation 
A. Primary tumor 
The gross tumor volume of the primary tumor (GTV_cervix) was defined as the union of 
the PET-positive cervical lesion and the MRI-defined cervical tumor. The clinical target 
volume (CTV_cervix) was defined as the GTV_cervix, uterus, both parametria and vaginal 
upper 1/3. In cases with vaginal involvement, the CTV_cervix was caudally extended with 2 
cm below the vaginal involvement. The planning target volume of the CTV_cervix 
(PTV_cervix) was created using a 3-dimensional anisotropic expansion of 10, 7 and 7 mm in 
the anteroposterior, left-right and supero-inferior direction respectively.  
B. Lymph nodes. 
FDG-avid lymph nodes were considered as malignant and delineated as GTV_nodes. The 
elective lymph node areas (nodes) included the common, internal and external iliac nodes, the 
obturator and presacral region. Using a 3-dimensional expansion of respectively 2 mm and 7 
mm around nodes, the CTV_ nodes and PTV_ nodes was created. For planning reasons, 
PTV_nodes and PTV_cervix were summed: PTV_all. 
C. Organs at Risk  
The rectum, sigmoid, small bowel, bladder and femoral heads were defined as OAR . 
D. Optimization Aid Volumes (OAV). 
To avoid dose deposit at distance we created 3 OAV [8]: 
1. A rim of 3 cm around the PTV_all (rim3_el). 
2. A rim between 3 and 6 cm away from the PTV_all (rim6_el). 
3. The tissue between rim6_el and skin: sur6. 
Constraints for the OAV are presented in Table 1. 
 
 
Dose objectives for planning 
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Details are presented in Table 1 and 3. The prescribed median dose (D50) to the GTV_cervix, 
GTV_ nodes, CTV_cervix and PTV_cervix was 62, 60, 58 and 56 Gy respectively. D98 (dose 
exceeded by 98% of the volume) in the PTV_ nodes was 45 Gy. The treatment was delivered 
in 25 fractions. Consequently, the GTV_cervix, GTV_ nodes, CTV_cervix and PTV_cervix 
received 2.48, 2.40, 2.32 and 2.24 Gy per fraction respectively, resulting in a simultaneous 
integrated boost (SIB). 
 
Physical and dosimetric quality assurance (QA) aspects 
We developed an IMAT class solution for rectum carcinoma and whole abdominopelvic 
radiotherapy [12]. The arcs for PTV_cervix were generated using an anatomy based 
segmentation tool [7] with the rectum as exclusion structure. The arcs for PTV_all were 
created using a manually delineated exclusion structure (large parts of the small intestine and 
bladder). All arcs used a zero couch isocenter rotation and a single isocenter.  
3D polymer gel dosimetry as validation method was described elsewhere [9, 49]. Following 
the strategy outlined in reference 34, (pages 117-128 by De Wagter) further QA was 
Table 1: Volume and dose results of the different OAR. 
  cc D98 D50 D02 Dmean V35 (%) V40 (%) V45 (%) V50 (%) V35 (cc) V40 (cc) V45 (cc) V50 (cc) 
    Constraint Results          
rectum 37 (33-50) 25 (14-35) 48 (46-52) 65 57 (57-58) 47 (44-49) 92 (84-97) 86 (75-92) 75 (56-88) 58 (39-73) 34 (25-49) 31 (22-45) 28 (17-38) 15 (7-28) 
sigmoid 118 (77-202) 1 (0-4) 44 (42-50) 65 57 (56-59) 39 (34-42) 70 (65-71) 57 (43-65) 52 (35-66) 44 (21-63) 80 (66-99) 77 (45-84) 65 (43-72) 50 (33-56) 
small intestine 896 (597-1402) 24 (17-29) 51 (50-52) 65 59 (59-60) 47 (45-50) 24 (14-25) 17 (9-20) 11 (5-15) 6 (2-8) 123 (102-201) 88 (73-159) 50 (46-120) 24 (19-66) 
bladder 87 (60-97) 29 (19-29) 53 (51-53) 65 59 (59-61) 49 (46-50) 93 (82-94) 86 (76-87) 74 (68-79) 60 (54-66) 81 (57-90) 75 (52-84) 65 (46-76) 50 (37-60) 
femoral head 44 (34-51) 24 (20-30) 36 (32-42) 60 49 (43-54) - - - - - - - - - 
rim3_el - - - 60 53 (46-56) - - - - - - - - - 
rim6_el - - - 45 40 (34-44) - - - - - - - - - 
sur6 - - - 30 26 (23-27) - - - - - - - - - 
The results are presented as median (25th - 75th percentile). V35, V40, V45, V50: volume receiving 35, 40, 45 and 50 Gy expressed as percentage (%) and absolute volume 
(cc).  
Tabelle 1:. Volumen- und Dosisergebnisse der verschiedenen OAR. Die Ergebnisse werden als Medianwerte (25 – 75 Perzentile) wiedergegeben. V35, V40, V45, V50: 
Volumina die 35, 40, 45 und 50 Gy erhalten, jeweils normiert aufgetragen über dem absoluten Volumen in cm3.  
 
 
Table 3: Data on volume, dose objectives and dose results of the target volumes. Results are presented as median 
  volume (cc) D98 (Gy)  D50 (Gy)  D02 (Gy)  Dmean (Gy) 
  Dose objectives Results  Dose objectives Results  Dose objectives Results  Results 
GTV_cervix 104 (54-121) 58 58 (57-59)  62 62 (61-62)  ≤ 64 64 (63-64)  61 (61-62) 
GTV_nodes 4 (1-5) 58 60 (58-60)  60 61 (60-61)  ≤ 62 61 (61-61)  60 (60-61) 
CTV_cervix 201 (186-245) 54 55 (54-56)  58 60 (59-61)  ≤ 64 63 (63-64)  60 (59-60) 
CTV_nodes 322 (250-397) 46 47 (46-47)  48 53 (52-54)  ≤ 62 60 (59-61)  53 (52-54) 
PTV_cervix 462 (431-504) 50 50 (48-51)  56 58 (57-59)  ≤ 64 63 (63-63)  58 (57-58) 
PTV_nodes 693 (604-785) 45 44 (44-45)  47 52 (51-53)  ≤ 62 60 (59-60)  52 (51-53) 
 (25th - 75th percentile). D98, D50, D02: dose received by 98, 50 and 2% of the volume respectively. Dmean: mean dose; GTV_cervix, CTV_cervix, PTV_cervix: gross tumor 
volume, clinical target volume and planning target volume of the primary tumor respectively. GTV_nodes, CTV_ nodes, PTV_ nodes: gross tumor volume, clinical target 
volume and planning target volume of the lymph nodes.  
Tabelle 3: Daten zu Volumen, Dosiszielen und Dosisergebnissen der Zielvolumen. Die Ergebnisse werden als Medianwerte (25 – 75 Perzentile) wiedergegeben. D98, D50, 
D02: Dosis die in 98%, 50% und 2 % des Volumens absorbiert wurde. Dmean: Mittlere Dosis; GTV_cervix, CTV_cervix, PTV_cervix: “Gross Tumor Volume“, Klinisches 
Zielvolumen und Planungszielvolumen des Primärtumors. GTV_nodes, CTV_ nodes, PTV_ nodes: “Gross Tumor Volume“, Klinisches Zielvolumen und 
Planungszielvolumen der Lymphknoten.  
streamlined into patient-specific QA by delivering the clinical treatment plan to “CarPet,” an 
anthropomorphic pelvic phantom [18], transversally loaded with one or more radiochromic 
energy independent EBT films (International Specialty Products Corporation, Wayne, NJ, 
USA) [38] and by comparing the measured dose distributions to the ones that were computed 
for CarPet using the Pinnacle treatment planning system. This comparison was done using the 
gamma evaluation method [29] implemented in a MATLAB environment. 
 
Clinical implementation 
All patients were treated in supine position using a knee and ankle fix (Cablon Medical, 
Leusden, The Netherlands), arms above the head. Treatment was done with 18-MV photons 
of an Elekta SL18 series Linear Accelerator (SliPlus, Elekta, Crawley, UK) equipped with  
standard MLC and prototype dynamic control software to deliver IMAT in local service mode 
[12]. Patient positioning was verified using daily electronic portal imaging (EPI) with online 
adaptations for the first 4 days. At the 5th treatment day, the mean isocenter correction in all 
directions was used for patient’s setup. If the mean correction was ≤ 2 mm, EPI was repeated 
weekly. If not, daily EPI was repeated until ≤ 2 mm was reached. 
 
 
Figure 1: Transversal and Sagittal dose distributions and presentation of the targets/isodoses and their 
allocated colours. A-B: Transverse dose distribution at the level of the presacral nodes (1A) and common 
iliac nodes (1B). C: Sagittal dose distribution at the level of the primary tumor, iliac and presacral nodes.  
Abbildung 1: Transversale und sagittale Dosisverteilungen und Darstellung der Zielvolumina/Isodosen 
und ihrer dazugehörigen Farben. A-B: Transversale Dosisverteilung auf Höhe der präsakralen Knoten 
(1A) und der Lymphknoten der A. iliaca communis (1B). C: Sagittale Dosisverteilung in Höhe des 
primären Tumors, der Lymphknoten der A. iliaca communis und der präsakralen Lymphknoten. 
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Results 
The patient and tumor characteristics are presented in Table 2. All tumours were FDG-avid.  
Four to 9 arcs were needed. Figure 1 depicts transverse and sagittal dose distributions of 
patient 4. 
 
Table 2: Patient, tumor and IMAT characteristics. 
Patient # Age FIGO   Grade pathology PET pos lnn chemotherapy GTV_cervix (in cc)  arcs sum degrees
1 57 IIIA 3 SCC internal iliac node left yes 125,32 7 1064 
2 72 IIB 3 SCC external iliac node left no 26,76 9 1424 
3 79 IIB 3 SCC none no 101,42 5 560 
4 55 IVA 2 SCC external iliac node left yes 147,29 8 1088 
     common iliac node left     
5 40 IIB 2 AC none yes 106,18 4 360 
6 52 IIB 3 AC none yes 37,71 6 1008 
SCC: squamous cell carcinoma; AC: adenocarcinoma; pos: positive; lnn: lymph nodes. Tabelle 2: Patientin, Tumor und 
IMAT-Eigenschaften. SCC: Plattenepithelkarzinom; AC: Adenokarzinom; pos: positiv; lnn: Lymphknoten. 
 
 
Figure 2: Dose volume histograms for rectum (2A), sigmoid colon (2B), small intestine (2C) and bladder (2D). 
Figures 2A, 2C and 2D depict also the dose-volume constraints as proposed by Emami [13]. Figures 2A and 2B depict 
the dose-volume constraints as proposed by Fonteyne [14]. Figure 2D also shows the dose-volume constraints 
suggested by Marks [33]. 
Abbildung 2: Dosisvolumenhistogramme für Rektum (2A), Sigma (2B), Dünndarm (2C) und Blase (2D). Die 
Abbildungen 2A, 2C und 2D zeigen die Dosisvolumenbeschränkungen laut Emami [13]. Die Abbildungen 2A und 2B 
zeigen die Dosisvolumenbeschränkungen laut Fonteyne [14]. Abbildung 2D zeigt außerdem die 
Dosisvolumenbeschränkungen laut Marks [33]. 
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Table 3 summarizes the obtained physical doses for the different target volumes. Considering 
the whole patient group, constraints on D50 of the GTV_cervix, GTV_ nodes, PTV_cervix and 
PTV_nodes were met. On individual patient base, the dose constraints on D50 for GTV_cervix 
were not fulfilled in 2 patients (deviation of 1 and 3 Gy). The constraint on D98 of the PTV_ 
nodes was not met in 3 patients (1 Gy difference).  
Table 1 depicts the physical dose-volume data concerning the OAR. For bladder, also D20 and 
D33 were considered. The results were 57 Gy (56-57 Gy; 25-75th percentile) and 55 Gy (54-56 
Gy; 25-75th percentile) respectively. 
Figure 2 depicts the dose-volume histograms for OAR.  
Table 4 shows the results of the gamma evaluation of patient 4. For a gamma [3mm, 3%] 
criterion, 93% of the measured points showed a value <1, >98% showed a gamma value <1.4. 
For a gamma [3mm, 5%] criterion, the results are 98% and >99% respectively. Figure 3 
depicts the results of the radiochromic film dosimetry, Pinnacle calculation and gamma 
evaluations. This quality control was performed for every patient showing similar results (not 
shown). 
 
Clinical implementation 
All treatments were delivered without discontinuation. Except for one patient, daily delivery 
time was <15 minutes.   
 
Table 4: Results of the gamma evaluation. 
gamma value 3mm, 3% 3mm, 5%
[0-1.0] 92.97 98.35
]1.0-1.2] 3.99 1.01
]1.2-1.4] 1.67 0.31
]1.4-1.6] 0.62 0.10
]1.6-1.8] 0.27 0.02
]1.8-2.0] 0.14 0.01
[2.0-... 0.34 0.20
number of points (%)
 
 
Column 2 shows the percentage of points per gamma interval for a [3mm, 3%] criterion. Column 3 
shows the same for a [3mm, 5%] criterion.  
Tabelle 4: Ergebnisse der Gamma-Bewertung. Spalte 2 zeigt den Prozentsatz der Punkte pro Gammaintervall 
für ein [3 mm, 3 %]-Kriterium. Spalte 3 zeigt das gleiche für ein [3 mm, 5 %]-Kriterium. 
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Figure 3: Transverse dose distribution on radiochromic film dosimetry (row 1), Pinnacle (row 2) and 
gamma evaluations (row 3 and 4) of patient 4, at the level of the common iliac lymph nodes (panel A) and 
primary tumor (panel B). The gamma maps at rows 3 and 4 show differences between Pinnacle and 
radiochromic film for a 3 % and 5 % dose gamma criterion respectively. The computed and measured 
isodoses have been superimposed.  Abbildung 3: Transversale Dosisverteilung bei radiochromer 
Filmdosimetrie (Reihe 1), Pinnacle (Reihe 2) und Gamma-Bewertungen (Reihe 3 und 4) von Patientin 4 in 
Höhe der Lymphknoten der A. iliaca communis (Bild A) und des primären Tumors (Bild B). Die Gamma-
Verteilungen in den Reihen 3 und 4 zeigen Unterschiede zwischen Pinnacle und der Filmdosimetrie für ein 
3 %- bzw. 5 %-Gammakriterium. Die berechneten und gemessenen Isodosen wurden übelagert.  
 
A B
1 
2 
4 
3 
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Discussion 
IMAT is an extension of arc therapy using a combination of rotating gantry and dynamic 
multileaf collimator. From a treatment planning perspective, IMAT is closer to IMRT wherein 
the elementary beam segments are designed and sequentially organized to synthesize a 
number of dynamic arcs. In our approach, each arc is decomposed into multiple segments at 
8° intervals. The segment shapes and weights are quasi-simultaneously optimized [7] taking 
into account the machine and MLC constraints of the SL18 series linear accelerator. IMAT is 
an excellent solution for pelvic cancers because of the large internal radius of the PTV and the 
presence of OAR within this concavity [12].  
Combined cisplatin-based radiochemotherapy (RCT) is the standard treatment for these 
tumours [24, 41, 45, 46]. Two meta-analyses expressed concern regarding an excess in acute 
grade 3-4 toxicity [27, 30], which is due to the cisplatin [45, 47] but also to the conventional 
radiotherapy technique that was used. To reduce the volume of OAR treated, modern 
radiotherapy techniques such as IMRT or IMAT are needed [2, 3, 6, 15, 35, 42, 53]. Previous 
work demonstrated the superiority of IMAT above conventional technology for rectal cancer 
[11]. Because of the high similarity between the target volume of rectal and cervical cancer, 
repeating such a comparison would be a waste of time.  
IMAT requires an adequate delineation of target volume(s) and OAR. The delineation of the 
pelvic lymph nodes was done according to the suggestions of other research groups [6, 48]. 
Several dose-volume constraints have been proposed for the OAR. Concerning rectum, data 
on mean dose (Dmean ≤ 44 Gy), maximal dose (Dmax ≤ 54 Gy) and rectal volume receiving 40 
Gy (≤ 40%) and 45 Gy (78-85 cc) were proposed [3, 6, 17]. Our Dmean and Dmax are higher 
because of the higher IMAT prescription dose. In other series, brachytherapy is added to the 
treatment. Data on the summation of EBRT and brachytherapy doses are unfortunately 
missing [34, 45, 46]. Intermediate rectal doses are very important in predicting late rectal 
toxicity [14]. When comparing our data with the ones D’Souza proposed [6], IMAT lowered 
R45 (28 vs. >75 cc). We plotted our IMAT results against the data suggested by Fonteyne and 
Emami (Figure 2A) [13, 14]. Fonteyne’s data were recalculated for 25 fractions. Due to the 
larger margin in the posterior direction in the present study, the rectal volume receiving an 
intermediate dose was higher [14]. Emami’s constraints were easily met [13]. 
For small bowel, data on Dmax (≤ 50 Gy), Dmean (≤ 33 Gy) and volume receiving 35 Gy 
(SB35≤ 35%) and 45 Gy (SB45 ≤ 14% and ≤ 360 cm3) were proposed [3, 6, 17, 42]. 
Concerning Dmean and Dmax, the same conclusions as for the rectum can be drawn. Figure 2C 
shows that the constraint on SB35 was easily met as well as Emami’s data [13]. Concerning 
SB45, the 14% that Portelance proposed [42] was not met in 2 patients (positive lymph nodes). 
Fonteyne found dose-volume data concerning sigmoid. From Figure 2B, it is clear that IMAT 
generated safe DVH’s [14].  
Concerning bladder, Dmax and D50 ≤ 50 Gy were proposed [17]. The higher IMAT 
prescription dose combined with the close vicinity of the bladder and the GTV_cervix 
explains our higher Dmax. The dose-volume constraints proposed by Emami [13] and Marks 
[33] were easily met (Figure 3D). The D20 and D33 proposed by the latter were 8 Gy and 2 Gy 
lower in our patients.  
Concerning the OAR, we also provided data on real volume (cc) (Table 1).  
Whitney suggested that local control might be increased with higher dose. He concluded that 
radiotherapy failure rate for stage IIB and III was 20-50% and 50-76% [5, 52]. EBRT doses 
varied from 40.8 to 61 Gy [52]. This dose-response relationship was confirmed by others [4, 
28, 37]. To improve local control, EBRT followed by MRI-guided brachytherapy including 
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adaptive planning is a valid option with local control rates of 90% at 3 years [43]*. However, 
local control drops to 80% in case of tumours >5 cm. Secondly, MRI-guided brachytherapy 
needs specialized logistics and is not possible wheresoever’s. With less advanced 
brachytherapy techniques, 3-years local control of only 65% for tumours >5 cm was achieved. 
Isn’t it therefore worth the effort to look for alternatives such as a radical hysterectomy after 
chemoradiation?  
A postchemoradiation extrafascial hysterectomy was part of the treatment in GOG123 [46], 
Keys‘ work [24] and in single-institution studies. The concern that this leads to an excess in 
toxicity was not confirmed in recent series [5, 25] while a significant benefit towards local 
control [24, 25, 32], progression-free survival [25] and a favourable trend towards overall 
survival was suggested [5, 25]. IMAT copes with the “dose-escalation” question and the 
concern regarding safety of post-RCT hysterectomy. IMAT performs dose escalation by 
means of a SIB to the GTV_cervix and GTV_nodes. The D50 to the GTV_cervix in our study 
was 62 Gy. Hypothesizing that the α/β ratio of cervix carcinoma is 10 [21], this corresponds 
to a normalized iso-effective dose of 64 Gy at 2 Gy per fraction. Because a prolongation of 
overall treatment time worsens disease-free survival [26], we kept the total number of 
fractions (25) unchanged [21].  Although we consider this SIB boost to be safe as no critical 
doses are given to the surrounding tissues, we are aware that no late toxicity data are known 
concerning this regimen.  Therefore, toxicity is scored meticulously and will be discussed in a 
separate paper. 
Previously, the gamma evaluation of IMAT showed a high correlation between planning and 
treatment [12]. In the present study, >98% of the measured points showed a gamma 
evaluation >98%, independent of the criterion. This feature demonstrates the safety of 
delivering IMAT clinically. No treatment interruption occurred; this was in contradiction with 
other reports [26, 32]. 
This research only involves the IMAT planning procedure, quality control and clinical 
implementation. It’s beyond the scope of the current article to make an evaluation/comparison 
of the different treatment modalities (IMRT-IMAT-VMAT) available to deliver a SIB or to 
describe the clinical aspects of this treatment.  Both aspects however, are very important and 
interesting and will be the subject of future papers.  
 
Conclusion 
In primary irresectable cervix carcinoma, IMAT is able to create a SIB to the primary tumor 
and invaded lymph nodes combined with sparing of the OAR. The gamma evaluation shows a 
high correlation with planning. The clinical delivery is feasible. No treatment interruptions 
occurred.  
 
 
 
 
 
 
 
                                                 
* Remark member of the examination committee: “The date of Pötter are cited the wrong way: local control ameliorated from 71% (1998-
2000) to 90% (2001-2003) in tumours measuring more than 5 cm. Since, another 5 series reporting LC rates between 90% and 96% are 
published.” 
The reviewer is correct to state that local control in tumours > 5cm is 90% in 2001-2003. Since the Material & Methods section of Pötters 
series stated that all patients between 1998-2003 were treated with MR-guided BT, we referred to the local control of tumours > 5 cm in the 
whole group of patients (1998-2003). It was stated that the difference between the two periods was due to a learning curve, though also a 
learning curve is important information.  
 - 51 - 
 
 
 
 
 
 - 52 - 
REFERENCES 
 
1. Carcopino X, Houvenaeghel G, Buttarelli M, et al. Equivalent survival in patients with 
advanced stage IB-II and III-IVA cervical cancer treated by adjuvant surgery following 
chemoradiotherapy. Eur J Surg Oncol 2008;34:569-75. 
2. Chan P, Yeo I, Perkins G, et al. Dosimetric comparison of intensity-modulated, 
conformal, and four-field pelvic radiotherapy boost plans for gynecologic cancer: a 
retrospective planning study. Radiat Oncol 2006;1:13. 
3. Chen MF, Tseng CJ, Tseng CC, et al. Clinical outcome in posthysterectomy cervical 
cancer patients treated with concurrent Cisplatin and intensity-modulated pelvic radiotherapy: 
comparison with conventional radiotherapy. Int J Radiat Oncol Biol Phys 2007;67:1438-44. 
4. Choy D, Wong LC, Sham J, et al. Dose-tumor response of carcinoma of cervix: an 
analysis of 594 patients treated by radiotherapy. Gynecol Oncol 1993;49:311-7. 
5. Classe JM, Rauch P, Rodier JF, et al. Surgery after concurrent chemoradiotherapy and 
brachytherapy for the treatment of advanced cervical cancer: morbidity and outcome: results 
of a multicenter study of the GCCLCC (Groupe des Chirurgiens de Centre de Lutte Contre le 
Cancer). Gynecol Oncol 2006;102:523-9. 
6. D'Souza WD, Ahamad AA, Iyer RB, et al. Feasibility of dose escalation using 
intensity-modulated radiotherapy in posthysterectomy cervical carcinoma. Int J Radiat Oncol 
Biol Phys 2005;61:1062-70. 
7. De Gersem W, Claus F, De Wagter C, et al. Leaf position optimization for step-and-
shoot IMRT. Int J Radiat Oncol Biol Phys 2001;51:1371-88. 
8. de Neve W, Duthoy W, Claus F, et al. Dose conformation in IMRT for head and neck 
tumors: which solution to apply? Cancer Radiother 2002;6 Suppl 1:32s-6s. 
9. De Wagter C. QA-QC of IMRT: European Perspective. In: Bortfeld T, Schmidt-
Ullrich R, De Neve W, et al., editors. Image-guided IMRT. Berlin: Springer-Verlag; 2005, p. 
117-28. 
10. Dimopoulos JC, Schirl G, Baldinger A, et al. MRI assessment of cervical cancer for 
adaptive radiotherapy. Strahlenther Onkol 2009;185:282-7. 
11. Duthoy W, De Gersem W, Vergote K, et al. Clinical implementation of intensity-
modulated arc therapy (IMAT) for rectal cancer. Int J Radiat Oncol Biol Phys 2004;60:794-
806. 
12. Duthoy W, De Gersem W, Vergote K, et al. Whole abdominopelvic radiotherapy 
(WAPRT) using intensity-modulated arc therapy (IMAT): first clinical experience. Int J 
Radiat Oncol Biol Phys 2003;57:1019-32. 
13. Emami B, Lyman J, Brown A, et al. Tolerance of normal tissue to therapeutic 
irradiation. Int J Radiat Oncol Biol Phys 1991;21:109-22. 
14. Fonteyne V, De Neve W, Villeirs G, et al. Late radiotherapy-induced lower intestinal 
toxicity (RILIT) of intensity-modulated radiotherapy for prostate cancer: the need for 
adapting toxicity scales and the appearance of the sigmoid colon as co-responsible organ for 
lower intestinal toxicity. Radiother Oncol 2007;84:156-63. 
15. Georg D, Georg P, Hillbrand M, et al. Assessment of Improved Organ at Risk Sparing 
for Advanced Cervix Carcinoma Utilizing Precision Radiotherapy Techniques. Strahlenther 
Onkol 2008;184:586-91. 
16. Georg D, Kirisits C, Hillbrand M, et al. Preliminary results of a comparison between 
high-tech external beam and high-tech brachytherapy for cervix carcinoma. Strahlenther 
Onkol 2007;183 Spec No 2:19-20. 
17. Gerszten K, Colonello K, Heron DE, et al. Feasibility of concurrent cisplatin and 
extended field radiation therapy (EFRT) using intensity-modulated radiotherapy (IMRT) for 
carcinoma of the cervix. Gynecol Oncol 2006;102:182-8. 
 - 53 - 
18. Gillis S, De Wagter C, Bohsung J, et al. An inter-centre quality assurance network for 
IMRT verification: results of the ESTRO QUASIMODO project. Radiother Oncol 
2005;76:340-53. 
19. Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy 
for cancer of the uterine cervix. Cochrane Database Syst Rev 2005:CD002225. 
20. Grosu AL, Piert M, Weber WA, et al. Positron emission tomography for radiation 
treatment planning. Strahlenther Onkol 2005;181:483-99. 
21. Guerrero M, Li XA, Ma L, et al. Simultaneous integrated intensity-modulated 
radiotherapy boost for locally advanced gynecological cancer: radiobiological and dosimetric 
considerations. Int J Radiat Oncol Biol Phys 2005;62:933-9. 
22. Houvenaeghel G, Lelievre L, Buttarelli M, et al. Contribution of surgery in patients 
with bulky residual disease after chemoradiation for advanced cervical carcinoma. Eur J Surg 
Oncol 2007;33:498-503. 
23. Kavanagh BD, Schefter TE, Wu Q, et al. Clinical application of intensity-modulated 
radiotherapy for locally advanced cervical cancer. Semin Radiat Oncol 2002;12:260-71. 
24. Keys HM, Bundy BN, Stehman FB, et al. Cisplatin, radiation, and adjuvant 
hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical 
carcinoma. N Engl J Med 1999;340:1154-61. 
25. Keys HM, Bundy BN, Stehman FB, et al. Radiation therapy with and without 
extrafascial hysterectomy for bulky stage IB cervical carcinoma: a randomized trial of the 
Gynecologic Oncology Group. Gynecol Oncol 2003;89:343-53. 
26. King M, McConkey C, Latief TN, et al. Improved survival after concurrent weekly 
cisplatin and radiotherapy for cervical carcinoma with assessment of acute and late side-
effects. Clin Oncol (R Coll Radiol) 2006;18:38-45. 
27. Kirwan JM, Symonds P, Green JA, et al. A systematic review of acute and late 
toxicity of concomitant chemoradiation for cervical cancer. Radiother Oncol 2003;68:217-26. 
28. Lanciano RM, Martz K, Coia LR, et al. Tumor and treatment factors improving 
outcome in stage III-B cervix cancer. Int J Radiat Oncol Biol Phys 1991;20:95-100. 
29. Low DA, Harms WB, Mutic S, et al. A technique for the quantitative evaluation of 
dose distributions. Med Phys 1998;25:656-61. 
30. Lukka H, Hirte H, Fyles A, et al. Concurrent cisplatin-based chemotherapy plus 
radiotherapy for cervical cancer--a meta-analysis. Clin Oncol (R Coll Radiol) 2002;14:203-
12. 
31. Maduro JH, Pras E, Willemse PH, et al. Acute and long-term toxicity following 
radiotherapy alone or in combination with chemotherapy for locally advanced cervical cancer. 
Cancer Treat Rev 2003;29:471-88. 
32. Mancuso S, Smaniotto D, Benedetti Panici P, et al. Phase I-II trial of preoperative 
chemoradiation in locally advanced cervical carcinoma. Gynecol Oncol 2000;78:324-8. 
33. Marks LB, Carroll PR, Dugan TC, et al. The response of the urinary bladder, urethra, 
and ureter to radiation and chemotherapy. Int J Radiat Oncol Biol Phys 1995;31:1257-80. 
34. Morris M, Eifel PJ, Lu J, et al. Pelvic radiation with concurrent chemotherapy 
compared with pelvic and para-aortic radiation for high-risk cervical cancer. N Engl J Med 
1999;340:1137-43. 
35. Mundt AJ, Lujan AE, Rotmensch J, et al. Intensity-modulated whole pelvic 
radiotherapy in women with gynecologic malignancies. Int J Radiat Oncol Biol Phys 
2002;52:1330-7. 
36. Nagy V, Coza O, Ordeanu C, et al. Radiotherapy versus Concurrent 5-Day Cisplatin 
and Radiotherapy in Locally Advanced Cervical Carcinoma : Long-Term Results of a Phase 
III Randomized Trial. Strahlenther Onkol 2009;185:177-83. 
 - 54 - 
37. Niibe Y, Hayakawa K, Kanai T, et al. Optimal dose for stage IIIB adenocarcinoma of 
the uterine cervix on the basis of biological effective dose. Eur J Gynaecol Oncol 2006;27:47-
9. 
38. Paelinck L, De Neve W, De Wagter C. Precautions and strategies in using a 
commercial flatbed scanner for radiochromic film dosimetry. Phys Med Biol 2007;52:231-42. 
39. Paley PJ, Goff BA, Minudri R, et al. The prognostic significance of radiation dose and 
residual tumor in the treatment of barrel-shaped endophytic cervical carcinoma. Gynecol 
Oncol 2000;76:373-9. 
40. Pandit-Taskar N. Oncologic imaging in gynecologic malignancies. J Nucl Med 
2005;46:1842-50. 
41. Peters WA, 3rd, Liu PY, Barrett RJ, 2nd, et al. Concurrent chemotherapy and pelvic 
radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after 
radical surgery in high-risk early-stage cancer of the cervix. J Clin Oncol 2000;18:1606-13. 
42. Portelance L, Chao KS, Grigsby PW, et al. Intensity-modulated radiation therapy 
(IMRT) reduces small bowel, rectum, and bladder doses in patients with cervical cancer 
receiving pelvic and para-aortic irradiation. Int J Radiat Oncol Biol Phys 2001;51:261-6. 
43. Potter R, Dimopoulos J, Georg P, et al. Clinical impact of MRI assisted dose volume 
adaptation and dose escalation in brachytherapy of locally advanced cervix cancer. Radiother 
Oncol 2007;83:148-55. 
44. Resbeut M, Cowen D, Viens P, et al. Concomitant chemoradiation prior to surgery in 
the treatment of advanced cervical carcinoma. Gynecol Oncol 1994;54:68-75. 
45. Rose PG, Ali S, Watkins E, et al. Long-term follow-up of a randomized trial 
comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or 
hydroxyurea during pelvic irradiation for locally advanced cervical cancer: a Gynecologic 
Oncology Group Study. J Clin Oncol 2007;25:2804-10. 
46. Stehman FB, Ali S, Keys HM, et al. Radiation therapy with or without weekly 
cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group 
trial. Am J Obstet Gynecol 2007;197:503 e1-6. 
47. Sterzing F, Grehn C, Dinkel J, et al. Severe reversible toxic encephalopathy induced 
by cisplatin in a patient with cervical carcinoma receiving combined radiochemotherapy. 
Strahlenther Onkol 2007;183:487-9. 
48. Taylor A, Rockall AG, Reznek RH, et al. Mapping pelvic lymph nodes: guidelines for 
delineation in intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2005;63:1604-
12. 
49. Vergote K, De Deene Y, Duthoy W, et al. Validation and application of polymer gel 
dosimetry for the dose verification of an intensity-modulated arc therapy (IMAT) treatment. 
Phys Med Biol 2004;49:287-305. 
50. Villeirs GM, Van Vaerenbergh K, Vakaet L, et al. Interobserver delineation variation 
using CT versus combined CT + MRI in intensity-modulated radiotherapy for prostate cancer. 
Strahlenther Onkol 2005;181:424-30. 
51. Vorwerk H, Wagner D, Christiansen H, et al. An easy irradiation technique (partial 
half-beam) to reduce renal dose in radiotherapy of cervical cancer including paraaortic lymph 
nodes. Strahlenther Onkol 2008;184:473-7. 
52. Whitney CW, Sause W, Bundy BN, et al. Randomized comparison of fluorouracil plus 
cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of 
the cervix with negative para-aortic lymph nodes: a Gynecologic Oncology Group and 
Southwest Oncology Group study. J Clin Oncol 1999;17:1339-48. 
53. Wong E, D'Souza DP, Chen JZ, et al. Intensity-modulated arc therapy for treatment of 
high-risk endometrial malignancies. Int J Radiat Oncol Biol Phys 2005;61:830-41. 
 
 - 55 - 
Chapter 5 
 
Publication 3: 
 
Intensity Modulated Arc Therapy ± Cisplatin as neo-adjuvant treatment 
for primary irresectable cervical cancer: toxicity, tumour response and 
outcome. 
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Tumoransprechen und Onkologische Ergebnisse. 
 
Katrien Vandecasteele, M.D.1, Amin Makar, M.D., Ph.D.2, Rudy Van den Broecke, M.D., 
Ph.D.2, Louke Delrue, M.D.3, Hannelore Denys, M.D., Ph.D.4, Kathleen Lambein, M.D.5, Bie 
Lambert, M.D., Ph.D.6, Marc van Eijkeren, M.D., Ph.D.1, Philippe Tummers, M.D.², Gert De 
Meerleer M.D., Ph.D.1. 
 
 
Affiliation: 
Department of 1Radiotherapy, 2Gynaecology, 3Radiology, 4Medical Oncology, 5Pathology 
and 6Nuclear Medicine at Ghent University Hospital, Ghent, Belgium 
 
 
Strahlenther Onkol. 2012; accepted January 2012. 
 
 
There is no conflict of interest 
 
Key Words: IMAT; locally advanced cervical cancer; hysterectomy; locoregional control; 
acute toxicity.  
Schlüsselwörter: IMAT; lokal fortgeschrittenes Zervixkarzinom; Hysterektomie, lokal-
regionale Kontrolle, akute Toxizität. 
 - 56 - 
Abstract 
Background and Purpose 
To evaluate the feasibility and outcome of Intensity Modulated Arc Therapy ± cisplatin 
followed by hysterectomy for locally advanced cervical cancer. 
Patients and Methods 
Thirty patients participated (table 1). The primary tumour and PET-positive lymph node(s) 
received a simultaneous integrated boost. Four weeks after IMAT ± C treatment response was 
evaluated. Resection consisted of hysterectomy ± lymphadenectomy. Tumour response, acute 
and late radiation toxicity, postoperative morbidity and outcome were evaluated. 
Results 
All hysterectomy specimens were macroscopically tumor-free with negative resection 
margins; pathological complete response was 40% (table 2). In 2 patients one resected lymph 
node was positive. There was no excess in postoperative morbidity (table 3). Apart from two 
grade 3 hematologic toxicities, no grade 3 or 4 acute radiation toxicity was observed. No 
grade 3, 1 grade 4 (4%) intestinal and 4 grade 3 (14%) urinary late toxicities were observed 
(table 4).  
Two-year local and regional control rates are 96% and 100% respectively. Two year distant 
control rate is 92%. Actuarial 2- year progression free survival rate is 89%. Actuarial 1- and 
2- year overall survival rates are 96% and 91%, 3-y overall survival is 84%.   
Conclusion 
Surgery after IMAT ± C is feasible with low postoperative morbidity and radiation toxicity. 
Local, regional, distant control and survival rates are promising.  
 
Zusammenfassung 
Hintergrund und Ziel 
Endpunktergebnisse und Machbarkeitsbewertung einer intensitätsmodulierten 
Rotationstherapie ± Cisplatin vor operativer Entfernung der Gebärmutter bei lokal 
fortgeschrittenem Zervixkarzinom. 
Patienten und Methodik 
Es nahmen dreißig Patienten an dem Studie teil (Tabelle 1). Der Primärtumor und die PET-
positiven Lymphknoten erhielten simultan einen integrierten Boost. Vier Wochen nach der 
kombinierten IMAT ± C-Behandlung wurde das Ansprechen bewertet. Die Operation bestand 
aus Gebärmutter- ± Lymphknotenentfernung. Bewertet wurden das Tumoransprechen, die 
akute und späte Bestrahlungstoxizität, die postoperative Morbidität und Onkologische 
Ergebnisse. 
Resultate 
Alle Hysterektomieproben zeigten sich makroskopisch negativ aus mit negativen 
Resektionsrändern; das pathologische Gesamtansprechen betrug 40% (Tabelle 2). Bei 2 
Patienten hat  sich ein resezierter Lymphknoten positiv Befunden. Es wurde keine 
Übermäßige postoperativer Morbidität festgestellt (Tabelle 3). Es trat keine Grad-3/4-
Akuttoxizität auf abgesehen von  zwei hämatologischen Grad-3-Toxizitäten. Wohl wurde eine 
intestinaler Grad-4-Spättoxizität (4%) festgestellt (aber keine Grad-3). Urogenitaler Grad-3-
Spättoxizitäten entwickelten 14% der patientinnen (n=4) (Tabelle 4).  
Die lokalen und regionären Zwei-Jahres-Kontrollraten waren hoch: 96% bzw. 100%. Die 
Zwei-Jahres-Fernkontrollrate betrug 92%. Die statistische krankheitsfreies Überleben nach 2 
jahren betrug 89%. Die statistische 1- und 2-Jahres-Gesamtüberlebensrate betrug 96% bzw. 
91%, die 3-Jahres-Gesamtüberlebensrate 84%.   
Schlussfolgerung 
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Eine Operation nach IMAT ± C ist durchführbar. Es ergibt sich eine niedriger postoperative 
Morbidität und Bestrahlungstoxizität. Dabei sind Lokal-, Regional- und Fernkontrolle sowie 
die Überlebensrate vielversprechend.  
 
Introduction 
Chemoradiation (CRT) is the standard treatment for locally advanced and/or irresectable 
cervical cancer [10, 14, 17]. Despite the significant improvement due to the advent of 
concomitant chemotherapy, local relapse occurs in 15 to 20% [17]. Complementary 
hysterectomy is a treatment option [2, 8, 13, 19] with the aim to remove potentially chemo- 
and radioresistant foci. Within the gynaecology and radiotherapy community, however, there 
is a reticence for post-CRT hysterectomy because of the fear of an increase in treatment-
induced toxicity. However, the only randomized trial performed in this setting showed no 
increase in grade 3 or 4 toxicity [13]. Adding chemotherapy did not show any increase in late 
toxicity compared to radiotherapy alone [14]. Consequently, radiotherapy seems to be the 
main contributor in the development of toxicity, certainly when conventional techniques are 
used. 
Novel treatment techniques such as intensity modulated radiotherapy (IMRT) and arc therapy 
[5, 18, 21] have lead to a significant reduction of toxicity rates [12]. Moreover, IMRT might 
allow replacing the brachytherapeutic boost by a simultaneous integrated boost (SIB) and 
consequently reduces treatment time, the latter being strongly correlated with local control 
and survival [11]. The rationale and clinical implementation of Intensity Modulated Arc 
Therapy (IMAT) in this setting has been described in detail before [26]. 
The aim of this prospective study was to evaluate whether IMAT with SIB allows for post-
CRT hysterectomy and to evaluate treatment toxicity and outcome. 
 
Materials and Methods 
This study (local ethical committee, n° B67020072880) included 30 patients (September 2006 
- August 2010). Inclusion criteria were: biopsy-proven locally advanced (FIGO IB2-IVA) 
cervical carcinoma (LACC); absence of extra-pelvic lymph node(s) and distant metastases on 
18FDG PET-CT; WHO score 0-2; absence of any condition potentially hampering compliance 
with the study protocol/follow-up schedule; ability to understand and sign informed consent. 
All patients underwent neo-adjuvant Intensity Modulated Arc Therapy, if possible combined 
with weekly cisplatin (IMAT ± C) as per the following treatment protocol.  
 
IMAT ± C.  
Pre-treatment imaging consisted of MRI (Magnetom Symphony, Siemens, Erlangen, 
Germany) and 18FDG PET-CT (Gemini, Philips, Eindhoven, The Netherlands) in treatment 
position [1, 15]. Details concerning the dose prescription and delineation of the primary tumor 
(GTV_cervix), primary clinical and planning target volume (CTV_cervix and PTV_cervix 
respectively) and lymph nodes (GTV_nodes and PTV_nodes) were previously reported [26] 
(Figure 1). From 1/2/2009 onwards, if PET-positive lymph nodes were present, preventive 
para-aortic lymph node irradiation was performed.   
IMAT was performed in supine position using a knee and ankle fix (Cablon Medical, 
Leusden, The Netherlands), arms positioned above the head. IMAT was delivered using 18-
MV photons of an Elekta SL18 series Linear Accelerator (SliPlus, Elekta, Crawley, UK) 
equipped with a standard MLC and prototype dynamic control software to deliver IMAT in 
local service mode [7]. The IMAT-plans were generated using an anatomy-based exclusion 
tool with the aid of weight and leaf position optimisation [7, 26]. Patient positioning was 
verified online using an electronic portal imaging device (EPID) [26].  
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If the serum creatine level was lower than 0.96 mg/dl –the cut-off for normal kidney function 
in our lab- cisplatin 40mg/m² was administered weekly during radiotherapy. Kidney function 
and Peripheral Blood Count (PBC) were monitored at least twice a week. Haemoglobin levels 
less than 11 g/dL implicated a blood transfusion.  
 
Surgery. 
After IMAT ± C treatment response was evaluated by gynaecologic examination and 
imaging: 18FDG PET-CT (exclusion of new metastatic spots) and MRI (locoregional 
response). Surgery consisted of type II hysterectomy ± pelvic lymphadenectomy (if positive 
pelvic lymph nodes were present on one of the 18FDG PET-CT’s).  
 
Follow-up and assessment of disease control  
Patients were seen weekly during treatment, 1 and 3 months thereafter. Thereafter, follow-up 
was scheduled three-monthly (first two years), 6-monthly (year 3-5) and annually. The 
follow-up was performed at a multidisciplinary consultation (gynaecologist and radiation 
oncologist). Imaging (18FDG PET-CT and MRI) was performed every 6 months for the first 
two years and yearly afterwards, unless patients’ symptomatology required otherwise. 
 
Analysis  
Primary endpoints of the study were the acute and late toxicity (acute/late radiation related 
toxicity and surgery related morbidity/mortality) and pathologic response at hysterectomy 
specimen. 
Acute radiation toxicity was scored weekly during IMAT ± C and at 10 days, 1 and 3 months 
thereafter. 
Late radiation toxicity (toxicity occurring ≥3 months after IMAT ± C or acute toxicity lasting 
longer than 3 months) was scored at every follow-up visit.  
Surgical morbidity/mortality was evaluated during hospitalization (acute) and at every visit 
thereafter (late) and was classified according to the Chassagne grading system [3].  
Secondary endpoints were local (LC), regional (RC) and distant control (DC), overall survival 
(OS) and progression free survival (PFS). LC, RC and DC are defined as absence of disease at 
the primary tumor bed, the regional lymph nodes and distant sites respectively. Time to local 
relapse, regional relapse and distant relapse were defined as the time elapsed between biopsy 
and the first event (local, regional or distant relapse) or the last follow-up. PFS and OS were 
defined as the time elapsed between biopsy and any progression, death or the last follow-up. 
For statistical analysis, SPSS (v. 15.0) was used.  
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Table 1: Patient and clinicopathological characteristics. 
Patient characteristics (n=30) 
Age (yrs) at diagnosis   
 median 52 
 range 26-89 
Follow-up in months   
 median 24 
 range 8-56 
N+ at diagnosis  
 n patients 11 
 1 node + 5 
 2 node + 5 
 3 node + 0 
 4 node + 1 
 <2 cm (%pCR) 15 (100%) 
 ≥2 cm (%pCR) 4 (50%) 
Chemotherapy   
 n 25 
Para-aortic irradiation   
 n 6 
Histology  
 squamous 25 
 adeno 4 
Grade  
 1 2 
 2 9 
 3 12 
 not reported 7 
FIGO stage  
 IB2 (%pCR) 2 (0) 
 IIB (%pCR) 20 (45) 
 IIIA (%pCR) 3 (100) 
 IIIB (%pCR) 4 (0) 
 IVA (%pCR) 1 (0) 
Tumor size, cm  
 <4cm (%pCR) 2 (50) 
 4-7cm (%pCR) 23 (48) 
 ≥7cm (%pCR) 5 (0) 
Tumor Volume, cc  
 median 149 
  range 27-222 
pCR= pathologic Complete response = ypT0 or ypN0 
Tabelle 1: Patienten- und klinik-pathologische Eigenschaften der Studienpopulation. 
pCR= pathologisches Gesamtansprechen = ypT0 oder ypN0 
 
 
Results 
All enrolled patients ended IMAT ± C. Figure 1 shows a dose distribution. Patient 
characteristics are represented in Table 1. All patients underwent class II radical 
hysterectomy. In 1 patient, an extrafascial hysterectomy was needed due to fibrosis at both 
parametria. For 2 patients no data on late radiation or surgery related morbidity are available 
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Figure 1: Dose distributions. 
Dose distribution through (A) the primary tumor, (B): a PET-positive lymph node (external iliac nodes 
left), (C): the primary tumor and bilateral PET-positive lymph nodes. D: Targets/isodoses and their 
allocated colours. The GTV_cervix consisted of all visible tumor on MRI and/or 18FDG PET-CT. The 
elective lymph node regions consisted of the presacral and common, external and internal iliac lymph 
nodes and the obturator fossa region (PTV_nodes), delineated following the consensus guidelines of Small 
et al. [25]. PET-positive lymph node(s) were delineated separately (GTV_nodes) [26]. Dose prescription (25 
fractions) was: D50 of 62, 58 and 56 Gy to the GTV_cervix, CTV_cervix and PTV_cervix respectively. D50 
GTV_nodes: 60 Gy; D98 PTV_nodes: 45 Gy.   
Abbildung 1: Dosisverteilungen. 
Dosisverteilung durch (A) den Primärtumor, (B): einen PET-positiven Lymphknoten (Lymphknoten der 
A. Iliaca communis), (C): den Primärtumor und bilaterale PET-positive Lymphknoten. D: 
Zielvolumina/Isodosen und die dazugehörigen Farben. Die GTV_cervix bestand aus einem bei der MRT 
und/oder der 18FDG PET-CT vollständig sichtbaren Tumor. Die elektiven Lymphknotenregionen 
bestanden aus den präsakralen Lymphknoten, und der Lymphknoten der A. Iliaca communis, externa und 
interna und der obturator-fossa-Region (PTV-Knoten), beschrieben nach den Konsensrichtlinien von 
Small et al. [25]. Die PET-positive Lymphknoten wurde getrennt beschrieben (GTV-Knoten) [26]. Die 
Dosisverordnung (25 Fraktionen) verlief nach dem folgendem Muster: D50 von 62, 58 und 56 Gy zur 
GTV_cervix, CTV_cervix bzw. PTV_cervix. D50 GTV-Knoten: 60 Gy; D98 PTV-Knoten: 45 Gy.   
 
 
Table 2: Pathological findings per initial FIGO stage.  
  FIGO   ypT (n) 
   0   1a1   1a2   1b1   1b2   2b 
 IB2  0  1  1  0  0  0 
 IIB  9  2  2  5  1  1 
 IIIA  3  0  0  0  0  0 
 IIIB  0  2  0  2  0  0 
 IVA  0   0   0   0   0   1 
  Total   12   5   3   7   1   2 
Tabelle 2: Pathologische Ergebnisse je nach FIGO-Ausgangsstadium.  
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Pathologic results and postoperative morbidity/mortality. 
All operated patients had a clinical complete response (no visible macroscopic tumour rest on 
pathology specimen) and negative resection margins. Pathologic findings were: ypT0: 40%, 
ypT1a:  26,65%, ypT1b: 26,65% and ypT2b (solitary tumor cells in parametria) in 6,7%. 
Pathologic complete response rate per tumor size and FIGO stage can be found in table 1 and 
2. Lymphadenectomy was performed in 15 patients (median number of resected nodes: 11, 
range: 1-28). In 2 patients, one resected lymph node was metastatic invaded (respectively 4 
and 22 nodes were removed); both were 18FDG-PET positive and larger than 2 cm on pre-
treatment imaging. 
Median hospital stay was 8 days (5-137 days). There was neither postoperative mortality nor 
intra-operative complications. Median blood loss during surgery was 400cc (100cc-2000cc). 
Four patients needed a blood transfusion. Eleven patients had postoperative urinary retention 
of which 5 requiring self-catheterization, none persisting longer than 6 months. One patient 
was diagnosed with hydronephrosis due to large lymphocoeles needing a re-intervention 
(=hospital stay of 137 consecutive days). An overview of acute and late surgery complications 
can be found in table 3. 
 
Table 3: Early and late postoperative complications by Chassagne’s scoring system 
Early postoperative complications (n=30) 
Grade 1        
 n (%) complication      
2 (7) Urinary tract infection 
1 (3) Deep venous trombosis 
1 (3) Lymphocoele  
Grade 2        
 n (%) complication      
1 (3) Urinary tract infection with temporary kidney function impairment 
1 (3) Subobstruction, not requiring surgery 
2 (7) Lymphocoele  
1 (3) Neurological sensory problem with mild functional impairment 
5 (17) Urinary retention requiring self catheterization 
Grade 3        
 n (%) complication      
1 (3) Lymphocoele causing temporarily inadequate renal function (microsurgery needed)  
Late postoperative complications (n=28) 
Grade 1        
 n (%) complication      
1 (3) Lymphoedema 
Grade 2        
 n (%) complication      
2 (7) Lymphoedema 
1 (3) Neurological sensory problem with mild functional impairment 
2 (7) Urinary retention requiring self catheterization (disappeared 6 months postoperative)
Grade 3        
 n (%) complication      
1 (3) retroperitoneal fibrosis causing kidney impairment (need for nephrostomy) 
Tabelle 3: Frühe und späte postoperative Komplikationen nach dem Chassagne-Punktesystem 
 
Acute radiation related toxicity (n=30) 
No grade 4 toxicity occurred. Two patients developed grade 3 hematologic toxicity (white 
blood cell count ≥1000u/L and < 2000/uL). There was no grade 3 GI, GU or skin toxicity.  
Four patients received a blood transfusion during or shortly after (before surgery) IMAT-C. 
There were no treatment interruptions. An overview is given in Table 4. Prophylactic para-
aortic irradiation (n=19) did not lead to a significant excess in acute and late radiation related 
toxicity. The administration of chemotherapy (n=20) was associated with significant more 
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overall acute GU toxicity (Grade 1: 56%, grade 2: 24% vs grade 1: 0% and grade 2: 20%; 
p=0,02) and dysuria (Grade 1: 60%, grade 2: 4% vs grade 1: 0% and grade 2: 0%; p=0,03). 
 
Late toxicity (radiation and surgery related) (n=28) 
One patient (no para-aortic prevention) needed an intervention due to abdominal cramps 
(grade 4) caused by perforation of the ileum. The diseased ileal part was resected 
laparoscopically. Anatomopathologic findings were suggestive for radiation enteritis. She’s 
without any complaint since then. Four patients developed permanent urinary incontinence. 
Since no pre-treatment incontinence scorings were present, all four of them were scored as 
grade 3 toxicity. An overview of all surgery and radiation therapy related toxicities is given in 
Table 3 and 4.  
One patient developed retroperitoneal fibrosis leading to ureteral fibrosis needing a permanent 
nephrostomy (grade 3). No vaginal stenosis (partial nor complete) occurred. 
 
Table 4: Acute and late radiation related toxicity. 
  acute toxicity   late toxicity  
 (evaluable: n=30)  (evaluable: n=28) 
 G1 (%) G2 (%) G3 (%)  G1 (%) G2 (%) G3 (%) G4 (%) 
GASTRO-INTESTINAL 17 83 0  32 7 0 4 
Anorexia 20 10 0  0 4 0 0 
Nausea 20 50 0  4 0 0 0 
Frequency 17 73 0  11 11 0 0 
Incontinence 13 3 0  7 0 0 0 
Rectal Blood Loss 3 0 0  4 0 0 0 
Abdominal Cramps 47 13 0  7 4 0 4 
Urgency 33 7 0  25 4 0 0 
Mucus Loss 17 0 0  3 0 0 0 
Anal Pain 30 0 0  0 0 0 0 
URINARY 47 23 0  21 18 14 0 
Pollakisuria 33 13 0  4 0 0 0 
Nycturia 43 3 0  0 0 0 0 
Hematuria 3 3 0  7 4 0 0 
Dysuria 50 3 0  0 0 0 0 
Urge 37 0 0  14 0 0 0 
Incontinence 14 7 0  21 14 14 0 
HEMATOLOGIC 40 40 7      
Hemoglobin 43 27 0      
White Blood cell Count 28 24 7      
Neutrophils 13 3 0      
Platelets 10 0 0      
SKIN 3 7 0  0 0 0 0 
Acute gastro-intestinal (GI) toxicity was scored using a combination of the RTOG scoring system [4], the scale 
of GI urgency and incontinence determined by Yeoh et al. [27] and an in-house developed scale for rectal blood 
loss [6].  Late GI toxicity was scored using the Radiation Induced Lower Intestine Toxicity scoring scale [9]. 
Genitourinary (GU) toxicity was scored using the RTOG scale extended with an in-house developed scale for 
incontinence [6]. Hematologic, and skin toxicity was scored according to the RTOG scoring system [4].  
Tabelle 4: Akute und späte bestrahlungsbezogene Toxizität. 
Die akute gastrointestinale (GI) Toxizität wurde mittels einer Kombination aus dem RTOG-Punktesystem [4], 
der von Yeoh et al. [27] bestimmten GI-Harndrang- und Inkontinenzskala sowie einer intern entwickelten Skala 
des rektalen Blutverlusts [6] ermittelt. Die späte GI-Toxizität wurde mittels der Punkteskala für die 
bestrahlungsinduzierte Toxizität der unteren Darmabschnitte [9] ermittelt. Die genito-urologische (GU)-Toxizität 
wurde mittels der RTOG-Skala bewertet, die um eine intern entwickelte Inkontinenzskala [6] erweitert wurde. 
Die hämatologische und die Hauttoxizität wurden gemäß des RTOG-Punktesystems [4] bewertet.  
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Locoregional control, OS and PFS. 
One patient had a local relapse (vaginal cuff) 4 months after surgery and died. No regional 
relapses occurred. Two patients (8%) developed distant metastasis (1 in lung and 1 in liver) 6 
and 7 months after hysterectomy respectively. Both patients died (19 months and shortly after 
diagnosis of metastases respectively). Actuarial 2-year LC rate is 96%, RC rates are 100%. 
Actuarial 2- year DC and PFS rates are 92% and 89% respectively. One, 2 and 3- year OS 
rates are 96%, 91% and 84% respectively.   
 
Discussion 
For LACC, chemoradiation is the standard treatment [10, 14, 17]. However, a meta-analysis 
showed that the benefit of chemoradiation is less pronounced with bulky and Figo III-IVA 
disease [10]. The only trial randomizing patients (bulky IB tumours) to receive post-RT 
(including brachytherapy) extrafascial hysterectomy or not showed a significant (p=0.007) 
better overall survival for 4-5 and 6 cm tumours, indicating that these might benefit from 
extrafascial hysterectomy [13]. Several non-randomized trials addressing the same issue 
suggest a significant benefit of post-CRT surgery towards local control and a favourable trend 
towards overall survival [2, 8, 13, 19]. Fear for excess in treatment related toxicity could 
explain the reserved position towards post-CRT surgery. Keys et al. however could not show 
any difference in treatment related toxicity [13].  A recent long term analysis of 
chemoradiation followed by surgery showed an acceptable long-term toxicity profile [8]. Our 
own preliminary results concerning postoperative morbidity are very promising with 3% 
grade 3 and no grade 4 postoperative complications and no fistulas so far.  
A postoperative urinary retention rate of 30% (during hospitalization) was noted, higher than 
would be expected after class II radical hysterectomy. It is our hypothesis that this higher rate 
of postoperative urinary retention is due to (chemo)radiotherapy induced parametrial fibrosis. 
Also Carcopino et al. found that postoperative morbidity after chemoradiation significantly 
increases with FIGO stage [2]. Direct comparison with published results is not feasible due to 
the fact that postoperative morbidity is described differently from one study to another and 
grade I morbidity is seldom reported. However, since this morbidity is temporarily (5 
requiring self-catheterization, none persisting longer than 6 months) we find this morbidity 
rate acceptable. Further strict follow-up is definitely needed.  
The advent of new radiation treatment techniques is an important factor in reducing toxicity. 
Our study confirmed the ability of IMRT and arc therapy to lower the dose to the organs at 
risk and to reduce acute toxicity [12, 18]. Apart from 2 patients who developed an acute grade 
3 hematologic toxicity during IMAT-C, no other patients suffered grade ≥3 acute toxicity of 
any kind. This contrasts sharply with literature data, using conventional techniques. Several 
authors reported grade ≥3 acute toxicity, being mainly hematologic and intestinal with grade 
3 and 4 toxicity present in 28% and 8% respectively [14]. Four percent late grade 4 toxicity 
and 14% grade 3 urinary incontinences have been noted so far. This compares with literature 
data on treatment schedules without adjuvant surgery reporting an incidence of late grade 4 
toxicity of 2% to 8% and late grade 3 toxicity of 14 to 35%, being mainly intestinal, urinary 
or development of fistulae [14]. Although the follow-up in our study is not mature, neither 
fistulas nor grade 3 intestinal toxicities are noted so far. No partial or complete stenosis of the 
vagina has been observed. This contrasts with the 25% and 3% incidence of grade 2 and 3 
vaginal toxicity in series involving brachytherapy [24].  
Survival is higher if the post-CRT hysterectomy specimen shows a complete clinical 
response. In literature this complete clinical response rate varies between 52% and 76% [19].  
In our study, all patients had a clinical complete response with a complete pathological 
response in 40%. We hypothesize that the higher biological dose obtained by IMAT is the key 
factor in this 100% percentage of complete clinical response. Perez et al. [23] already 
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suggested a positive relation between local control and escalated radiation dose, confirmed by 
others [20]. Improved local control and survival data using dose escalation in brachytherapy 
for large (>5cm) locally advanced cervical tumours confirm this clinically [24]. Considering 
an α/β ratio of 10 for cervical cancer [11], the BED2 received by the GTV_cervix is 64 Gy, 
which is substantially higher than the doses described in literature [19], without overall 
treatment time prolongation resulting in a simultaneous integrated boost [11].  
Almost 90% of locoregional recurrences occur within 36 months after treatment with 60% 
and 80% of them occurring within 1 year and 2 years after treatment [22]. A tendency to 
develop pelvic recurrence even sooner is seen in patients with high-volume and more 
advanced disease [22]. With a median follow-up of 24 months, an actuarial 2-years 
locoregional control and 3-years OS of 96% and 84% respectively is achieved, which is 
comparable with the data published in six large randomized trials (3 years OS varying 
between 65 and 87%) [16]. Recently, results concerning dose volume adaptive brachytherapy 
have published 3-year locoregional control rates of 90%, 3-years OS was 64%. For tumours 
measuring more than 5 cm, dose escalation lead to an increase of 3-years locoregional control 
and OS from 71% to 90% and from 28% to 58% respectively [24]. Subgroup analysis of our 
patients presenting with a tumour >5 cm (n=21; 70%) showed actuarial 2 and 3-years LRC of 
both 94% and 3 years OS of 80% respectively.  
Few data are published concerning the treatment of FDG positive lymph nodes in patients 
treated with definitive chemoradiation.  If no lymphadenectomy is performed, what dose 
should be given to FDG positive lymph nodes? In our series 100% complete pathological 
remission is found in FDG-positive lymph nodes < 2 cm with a BED2 of 62Gy. In larger (≥ 2 
cm) lymph nodes pCR could be reached in only 50%, suggesting the need for a higher dose in 
this setting. Further research is indispensible to confirm this finding.   
Considering the combination of low toxicity and excellent local control, hysterectomy after 
IMAT-C should be considered in the multimodality treatment of locally advanced cervical 
cancer.  
 
 
Conclusion 
IMAT ± cisplatin has low acute and late toxicity and allows post-CRT hysterectomy without 
excess in surgical morbidity. LC, RC, DC and OS rates are promising.  
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Chapter 6 
 
Publication 4: 
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Abstract 
Objective 
To report on the value of MRI and 18FDG PET-CT in predicting resectability and pathological 
response of primary locally advanced cervical cancer following neo-adjuvant intensity-
modulated arc therapy (IMAT) ± cisplatin (C). 
Methods/materials  
Twenty-seven patients with FIGO IB2 – IVA cervical cancer were treated with IMAT-C 
followed by extrafascial hysterectomy (EH). All patients received MRI and 18FDG PET-CT 
after IMAT-C. The endpoints of this study were to: 
1. Assess the ability of MRI to predict negative surgical margins (R0).  
2. Assess the sensitivity, specificity, PPV and NPV of MRI in predicting the following 
situation at the EH specimen: “no residual disease or minimal microscopically visible 
residual tumor”. 
3. Assess the sensitivity, specificity, PPV and NPV value of 18FDG PET-CT in 
predicting “no residual viable tumor cells” at the EH specimen.     
Results 
An R0-resection was obtained in all patients. None of the EH specimens contained 
macroscopically visible tumor. In 13 patients, no viable tumor cells were found, 14 only had 
residual microscopic disease. 
24/27 MRI’s were able to correctly predict R0 resection. A negative MRI was 100% 
predictive for the endpoint “R0 resection”. 
The specificity and NPV of MRI (endpoint 2) was 74% and 100% respectively. No sensitivity 
or PPV could be calculated. The sensitivity, specificity, PPV and NPV of 18FDG PET-CT 
were 29, 62, 44 and 44% respectively (endpoint 3).      
Conclusions 
A negative MRI post-IMAT-C predicts 100% correctly for “R0 resection”. The role of 18FDG 
PET-CT in predicting viable tumor cells at EH specimen is at least debatable.   
 
Introduction 
For FIGO stage IIB – IVA cervical cancer, chemoradiation (CRT) is the standard treatment 
(1). Brachytherapy increases the dose to the primary tumor (2). A randomized trial showed that 
hysterectomy post-CRT does not increase toxicity and improves locoregional control (3). 
Intensity-modulated radiotherapy (4-8) and intensity-modulated arc therapy (IMAT) (9, 10) lower 
the dose to the organs at risk and increase the dose to the primary tumor without prolongation 
of treatment time (which is a determinant of tumor control) (11-13). In stage IB2-IIB disease, 
brachytherapy is dispensable, provided radical hysterectomy with pelvic lymphadenectomy is 
performed (14).  
At Gent University Hospital, combined cisplatin-IMAT (IMAT-C) followed by extrafascial 
hysterectomy (EH) gives excellent local control of FIGO IIB-IVA cervical cancer (15). The 
decision about EH is made multidisciplinary and depends on local response diagnosed 
clinically and by Magnetic Resonance Imaging (MRI) and 2-deoxy-2-[18] fluoro-D-glucose 
positron emission tomography (18FDG PET-CT) as suggested in the literature (16-22). 
 18FDG PET-CT is superior in detecting lymph nodes to CT alone leading to improved 
coverage of target volumes and modified radiation fields in 20% of patients (16, 23). The 
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maximal standardized uptake value (SUVmax) at diagnosis predicts disease-free (DFS) and 
overall survival (OS) (22-24). Post-therapy FDG-uptake is inversely correlated with cause-
specific survival (CSS) and OS (25). The use of 18FDG PET-CT during radiotherapy to predict 
outcome is not unequivocally proven (26, 27).  
The current paper reports on the value of: 
1. MRI in predicting resectability of primary locally advanced cervical cancer (LACC) 
following IMAT-C. 
2. MRI in predicting tumour response as evaluated on EH specimen. 
3. 18FDG PET-CT in predicting tumour response as evaluated on EH specimen. 
 
Materials and methods 
Between 01/2007 and 01/2010, 27 consecutive patients with primary LACC (bulky IB2 in 1, 
IIB in 18, IIIA in 2, IIIB in 4 and IVA in 2 patients respectively) were referred for 
multimodality treatment. Median age was 49 years. The tumor characteristics are presented in 
Table 1.  
The multimodality treatment protocol consisted of IMAT-C followed by EH. Chemotherapy 
consisted of cisplatin, 40 mg/m2 weekly. Before starting treatment, all patients received an 
18FDG PET-CT and a MRI in radiotherapy treatment position. 
MRI was performed on a 1.5 Tesla system using a pelvic phased array body. Scopolamine 
was administered intravenously to avoid motion artefacts by bowel peristalsis. The MRI 
consists of fast T2 weighted imaging in 512 matrixes in a sagittal plane and in a plane 
perpendicular to the cervical axis, and a spin-echo T1 weighted imaging also in a 512 matrix 
in the transverse plane. Locoregional assessment was made by tumor detection, measuring 
tumor volume and assessment of stromal, parametrial, pelvic side-wall, bladder and rectal 
invasion. 
Concerning 18FDG PET-CT, patients fasted ≥4 h prior to IV injection of 18FDG (7-12 mCi, 
administered approximately 60 minutes before scanning). Patients were imaged with a 
Gemini PET-CT camera (Philips, Cleveland, USA) consisting of a gadolinium 
oxyorthosilicate full-ring PET scanner with 5 mm spatial resolution and a 16-slice helical CT 
scanner. A CT without specific breath-holding instructions was performed using IV contrast. 
Without changing patient position, the PET scan was acquired immediately thereafter. PET 
images were reconstructed using an iterative 3D-RAMLA (Row Action Maximum Likelihood 
Algorithm). Low-dose CT data were used for attenuation correction. A region of interest was 
drawn around the tumour and lymph nodes on the fused images. The SUVmax was calculated 
on the co-registered attenuation corrected PET images.  
The primary tumor as visualized on imaging was called “gross tumor volume” (GTV) and 
treated with 62 Gy. If the PET-CT showed FDG-avid lymph nodes, these were considered as 
bearing tumor cells and treated with 60 Gy. The clinical target volume (CTV) consisted of the 
GTV complemented by the cervix, uterus, vagina and parametria and was treated to 58 Gy. 
The elective pelvic lymph nodes were treated to 45 Gy. All treatments were performed in 25 
fractions resulting in a simultaneous integrated boost to the GTV and affected lymph nodes. 
Details concerning target volume delineation, planning objectives and acute toxicity have 
been described (9). 
All patients underwent gynaecological examination, MRI and 18FDG PET-CT within 24 days 
after IMAT-C. The clinical examination was performed within 10 days after the MRI. The 
gynaecologists were blinded to the results of the MRI. 
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  Tumor characteristics 
 Timing: before IMAT-C Timing: after IMAT-C Timing: after EH 
 Clinical Magnetic resonance (MR) 18FDG-PET MR 18FDG-PET       
 Figo stage Pathology Figo stage Tprim volume (cc) Tprim SUVmax Node SUVmax Figo stage Tprim SUVmax Node SUVmax MR-Category AP-Result AP-category 
Patient 1 IIB G3 SCC IIIA 172 4.14 1.39 IB1 (<4 cm) no no 2 y pT1B1 2 
Patient 2 IIIB G2 adenoca IIIB 101 8.13 no 0 no no 1 y pT1A1 2 
Patient 3 IIIB G2 adenoca IIB 127 5.62 no 0 no no 1 y pT1B1 2 
Patient 4 IIIA G3 SCC IIIA 78 14.3 1.70 0 no no 1 y pT0 1 
Patient 5 IIB G3 SCC IIB 179 9.58 no 0 no no 1 y pT1A2 2 
Patient 6 IIB G3 SCC IIB 140 10.4 no IIA no no 2 y pT0 1 
Patient 7 IIB G2 adenoca IIB 17 4.34 no IIB 5.70 no 3 * y pT1B1 2 
Patient 8 IIB G3 SCC IIB 230 3.34 no 0 7.10 no 1 y pT0 1 
Patient 9 IVB G2 SCC IVB 69 3.06 2.85 0 no 1.23 1 y pT0 1 
Patient 10 IIIB G3 SCC IIB 66 6.13 2.76 0 no no 1 y pT1B1 2 
Patient 11 IVA G2 SCC IVA 48 4.60 1.87 IIIB (HUN) no no 2 y pT0 1 
Patient 12 IIB G3 SCC IIB 79 4.92 no 0 3.20 no 1 y pT0 1 
Patient 13 IIB G2 SCC IIB 215 7.30 2.70 IB1 (<4 cm) no no 2 y pT2b 2 
Patient 14 IIB G1 adenoca IIB 135 2.50 no 0 no no 1 y pT1B1 2 
Patient 15 IIB G3 SCC IIB 83 5.55 no 0 no no 1 y pT0 1 
Patient 16 IIB G2 SCC IIB 58 5.18 no IB1 (<4 cm) no no 2 y pT0 1 
Patient 17 IIIB G3 SCC IVA 154 7.84 4.41 IIIB (HUN) no no 2 y pT1B1 2 
Patient 18 IIB G3 SCC IIB 99 6.37 3.57 0 3.89 2.02 1 y pT0 1 
Patient 19 IIIA G3 SCC IIIA 27 7.34 no 0 no no 1 y pT0 1 
Patient 20 IIB G1 SCC IIB 161 13.89 1.60 0 4.82 no 1 y pT0 1 
Patient 21 IIB G3 SCC IIB 205 7.49 4.35 0 3.33 3.80 1 y pT1A2 2 
Patient 22 IIB G3 SCC IIB 48 14.76 no 0 no no 1 y pT0 1 
Patient 23 IIB G2 SCC IIB 188 15.85 9.65 0 no no 1 y pT1B1 2 
Patient 24 IB2 G3 SCC IB2 59 17.63 no 0 5.29 no 1 y pT1A2 2 
Patient 25 IIB G3 SCC IIB 113 6.50 no 0 no no 1 y pT1B2 2 
Patient 26 IIB G2 SCC IIB 82 4.46 no 0 4.39 no 1 y pT0 1 
Patient 27 IIB G3 SCC IIB 20 8.61 2.68 0 4.37 2.82 1 y pT1B1 2 
Table 1: Patient and tumor characteristics at diagnosis, after IMAT-C and after EH. 
IMAT-C: Intensity-Modulated Arc Therapy ± cisplatin; MR: magnetic resonance; FDG: fluoro-deoxy glucose; AP: anatomo-pathology; G1, G2, G3: well, moderate or poorly differentiated respectively; N-/N+: node 
negative – node positive respectively; SCC squamous cell carcinoma; adenoca: adenocarcinoma; HUN: hydro-uretronephrosis. Three patients presented with a urinary derivation due to hydro-uretronephrosis (HUN) 
causing impairment of renal function. One patient suffered HUN without impairment of renal function. There were two patients with stage IV disease. Patient 9 had a 4 cm large lymph node above the level of the aortic 
bifurcation (M1 disease), pathologically confirmed (CT-guided biopsy) as lymph node metastasis from a moderately differentiated squamous cell carcinoma. Patient 11 had both on cystoscopy and MRI (vide infra) 
suspicion of urinary bladder invasion. IMAT-C was delivered in 23 patients, 4 patients received IMAT without chemotherapy (patients 2, 5, 11 and 15). Reasons for omitting were impaired kidney function in 3 and age 
in 1 patient. Patient 7: *: MRI post-IMAT-C still suggested invasion of the left parametrium because of disruption of the cervical ring at that level. Clinical examination confirmed the left parametrium to be less mobile, 
but without clear evidence of tumoural invasion. Pathology showed only residual microscopic tumor with an invasion depth of 7 mm (y pT1B1). 
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Analysis of images 
The post-treatment MR images were analyzed by two experienced radiologists (LD – GV), 
independently. They agreed in all cases. Patients were classified as MR-Category 1: complete 
disappearance of the tumor and total restoration of the normal cervix anatomy;  MR-Category 
2: residual tumor <4 cm and/or no longer invading parametria, lower vaginal third or adjacent 
organs or with imaging uncertainties such as radiation-induced fibrosis causing hydro-
uretronephrosis (HUN) (“unclassified modifications”); MR-Category 3 with no response to 
IMAT-C.  
The post-treatment 18FDG PET-CT images were analyzed jointly by a radiologist (LD) and 
nuclearist (BL). In accordance with Schwarz et al. (27) they were classified as FDG-Category 
1: disappearance of FDG uptake in the tumor; FDG-Category 2: a response >25% in SUVmax 
or FDG-Category 3: ≤25% response or stable/increased tumor metabolic activity.   
 
Pathology 
Extrafascial hysterectomy specimens, including vaginal section margins, were completely 
sectioned into 3 mm slices and entirely embedded in paraffin blocks. Of each block levels of 3 
micrometer each were cut and meticulously evaluated on haematoxylin and eosin stain. In 
cases of reactive features, these were confirmed by immunohistochemistry broad spectrum 
cytokeratin. If a lymph node dissection was performed, the different sites were evaluated 
separately. Residual tumor on the surgical specimen was staged according to FIGO (TNM 
classification, 5th edition). To indicate that this staging was after neo-adjuvant CRT, all pTN-
stages were preceded by “y”.  The pathologist classified the tumor response in three 
categories as well: AP-Category 1: no viable tumor cells (ypT0); AP-Category 2 and AP-
Category 3 with microscopically and macroscopically visible tumor respectively. The vaginal 
section margin was considered negative or positive depending on the absence (R0) or 
presence (R1) of tumor cells at this margin. 
 
The endpoints of this study were to: 
1. Assess the ability of MRI to predict tumor resectability (R0 resection). 
2.  Assess the sensitivity, specificity, positive predictive value (PPV) and negative predictive 
value (NPV) of MRI in predicting tumor response. MR category 1 & 2 was considered 
predictive for the endpoint “no residual disease or minimal microscopically visible 
residual tumor” as evaluated on the EH specimen. (21). 
1. Assess the sensitivity, specificity, PPV and NPV of 18FDG PET-CT in predicting ypT0 
disease as evaluated on the EH specimen. A negative 18FDG PET-CT was considered 
predictive for the endpoint “no residual viable tumor cells”. 
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Figure 1. Sagittal MR-image of patient 4 (see Table 1) presenting with a FIGO IIIA disease at initial 
diagnosis. The left panel shows the tumor as a grey mass invading the vagina. The right panel shows the 
situation 27 days after the end of IMAT-C: there is no longer tumor present on the MR-image and the 
cervical anatomy has returned to normal. T: tumor; B: bladder; U: uterus; SB: small bowel; S: symphysis 
pubis; C: cervix. R: rectum. 
Figure 2.  Axial PET-CT images 
of patient 25 (see Table 1) presenting 
with a FIGO IIB disease at initial 
diagnosis. Panel A depicts the pre-
treatment PET-CT image showing 
intense FDG uptake at the primary 
tumor (T). Panel B depicts the PET-
CT image taken 17 days after the end 
of IMAT-C: there is no longer FDG 
uptake at the cervix (presented in 
green). The FDG-PET was false 
negative; the hysterectomy specimen 
showed ypT1b2 poorly differentiated 
SCC with a depth invasion of 8 mm 
and a diameter exceeding 4 cm. The 
red dashed line surrounds the tumor; 
the green dashed line surrounds the 
cervix. 
T: tumor; B: bladder. 
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Results 
Details concerning patient and tumor characteristics and pre-treatment imaging are 
summarized in Table 1. Pre-treatment 18FDG PET-CT showed uptake in the primary tumor 
and lymph nodes in all and 12 patients respectively. In the primary tumor, mean (± standard 
deviation (SD)) and median SUVmax was 7.77 (± 4.16) and 6.50. Concerning positive nodes, 
mean (±SD) and median SUVmax was 3.29 (± 2.24) and 2.73. Mean and median pre-treatment 
MR-derived tumor volume was 109 and 91 cc.    
The mean and median time between the end of IMAT-C and imaging post-IMAT-C was 21 
and 20 days. The mean and median time between the post-IMAT-C MRI and EH was 27 and 
25 days. Imaging of tumor response is presented in Figures 1-3.  
None of the 18FDG PET-CT images post-IMAT-C showed evidence of progressive disease at 
regional lymph nodes or distant sites.  
 
 
 
Figure 3.  Axial PET-CT images of patient 8 (see Table 1) presenting with a FIGO IIB disease at 
initial diagnosis. Panel 3.1 depicts the pre-treatment PET-CT image showing FDG uptake at the primary 
tumor (T). Panel 3.2 depicts the PET-CT image taken 11 days after the end of IMAT-C: there is still FDG 
uptake at the cervix (presented in red). The FDG-PET was false positive, the hysterectomy specimen 
showed y pT0 disease. Foamy histiocytes were present abundantly. The cervix is surrounded by a green 
dotted line (panels A and B), the uterine corpus is surrounded by a blue line (panel B). The remaining 
FDG-activity is surrounded by a red line (panel B).  
C (T): cervix containing primary tumor; B: bladder; R: rectum; SB: small bowel 
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Results for endpoint 1 
All patients received EH. Surgical margins were negative in all cases (R0 resection). No EH 
specimen showed macroscopically visible tumor. In 13 patients, no viable tumor cells were 
found at pathological examination (AP-category 1). All other patients had residual 
microscopic disease (AP-category 2). The 2 patients with y pT1A1 disease had solitary tumor 
cells without measurable invasion depth. The 3 patients with y pT1A2 disease had residual 
isolated tumor cells with a stromal depth invasion of 3, 3.5 and 5 mm respectively. For the 7 
patients with residual y pT1B1 disease, stromal depth invasion was 6, 7 and 11 mm in 2 
patients and 10 mm in 1 patient. One patient had y pT1B2 disease with isolated tumor cells 
spread out over >4 cm. One patient had a residual microscopically tumor focus in the left 
parametrium and therefore was scored as y pT2B disease.  
24/27 MRI’s post-IMAT-C correctly predicted R0 resection (true negative rate 89%). A 
negative MRI post-IMAT-C predicted 100% correctly. Additionally, 3/27 MRI examinations 
falsely predicted an R1-resection (false positive rate 11 %). In 2 patients, the MRI post-
IMAT-C still showed HUN (category 2), leading to the conclusion of MR-stage IIIB. 
However, at EH specimen, there were no viable tumor cells left in 1 patient and microscopic 
tumoural nests in the other. In 1 patient, the MRI post-IMAT-C suggested left parametrial 
invasion. Clinical examination could not confirm this. Pathology showed residual microscopic 
tumor with an invasion depth of 7 mm (y pT1B1). 
 Results for endpoint 2 
 The results are summarized in Table 2. The sensitivity and positive predictive value could not 
be calculated as there were no events, i.e. macroscopically visible tumor. The specificity and 
negative predictive values of MRI was 74% and 100% respectively. There were no false 
negative results. 
 
Table 2: Correlation between MRI and residual tumor as derived from surgical specimen. 
Number of patients 
Residual disease at MRI Residual disease at surgical specimen 
 macroscopic rest ypT0 - microscopic rest 
Yes 0 7 
No 0 20 
 
Results for endpoint 3 
a. Primary tumor 
There was remaining 18FDG uptake in 9 patients with a mean (± SD) and median SUVmax of 
5.12 (± 1.17) and 4.84. In 2/9 patients, SUVmax after was higher than before treatment. In 5/9 
patients with remaining 18FDG uptake (mean SUVmax of 4.68 (± 1.48), no residual disease 
was found (y pT0). One of those patients had an increase of SUVmax compared to the pre-
treatment situation (7.10 vs. 3.34). The 4 other patients with remaining 18FDG uptake (mean 
SUVmax of 4.67 (± 1.05)) had y pT1A2 (n=2) and y pT1b (n=2). In 1 out of those 4 patients, 
there was an increase in SUVmax (5.70 vs. 4.34). The results concerning 18FDG PET-CT are 
summarized in table 3. Of the 18 patients presenting without 18FDG uptake at the primary 
tumor after treatment, 10 of them still had persistent tumor at the surgical specimen (y 
pT1A1: n=2; y pT1A2: n=1; y pT1B1: n=5; y pT1B2: n=1; y pT2B: n=1). The sensitivity, 
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specificity, positive and negative predictive values of 18FDG PET-CT with regard to 
remaining tumor at EH specimen were 29, 62, 44 and 44% respectively.      
b. Lymph nodes 
There was remaining 18FDG uptake in 4 patients with a mean (±SD) and median SUVmax of 
2.47 (± 1.10) and 2.42 respectively. None of these lymph nodes contained viable tumor cells. 
 
Table 3: Correlation between 18FDG PET-CT and remaining viable tumor cells present on the surgical specimen. 
Number of patients 
Residual disease at 18FDG PET-CT Viable tumor cells at surgical specimen 
 Yes No 
Yes 4 5 
No 10 8 
 
 
Discussion  
In the European Society of Medical Oncology (ESMO) clinical recommendations for 
treatment of FIGO stage IB2 and IIB-IVA cervical cancer, “external irradiation combined 
with brachytherapy” is the treatment of choice (2). Information concerning adjuvant EH is 
sparse; despite neo-adjuvant chemoradiation followed by EH is emerging as a relevant 
therapeutic option (14, 28-30). For tumours >4 cm, there might be a survival benefit in favour of 
the latter (3). This “>4 cm”-condition was present in 22 of our patients, which justifies EH 
certainly in view of the IMAT that was used. IMRT and IMAT have major advantages when 
compared to conventional radiotherapy. There is proof of improved CSS (13) and significantly 
reduced dose received by small bowel (8, 31), rectum (8), bladder (8) and bone marrow (32-34). The 
implementation of IMAT has been facilitated by incorporating MRI and 18FDG PET-CT in 
the radiotherapy planning (9, 21).  
None of the EH specimens showed residual macroscopic tumor and there was a complete 
microscopic disappearance of tumor in almost 50% of the patients. This is at least comparable 
to published data (14, 20, 35). 
Although MRI is considered almost as a necessity in modern radiotherapy planning for 
cervical cancer (36, 37), it’s value in staging is only recently been prudently appreciated by the 
editorial office of the FIGO (38), although accuracy has already been shown to be as high as 
90% more than a decade ago (39). Although the American College of Radiology Imaging 
Network (ACRIN) Intergroup study recognized the low accuracy of MRI to diagnose minimal 
parametrial extent (18), this does not apply to our patients as parametrial extent was bulky in all 
our stage IIB patients. 
Reports concerning the value of MRI in predicting radical resectability of primary LACC 
after neo-adjuvant (C)RT are sparse but not new. Almost 20 years ago, Flueckiger reported 
the results of serial MR imaging after primary radiotherapy in 28 patients (40). Although the 
histopathology in this series was comparable to ours, the tumor volume was clearly smaller 
(21 cc vs. 109 cc). At MRI performed 1 month after radiotherapy, they noted a complete 
disappearance of the tumor in 3 patients (11%) compared to 20 patients (74%) in our series 
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(40). This difference might have different causes: first of all, the majority of our patients 
received CRT which improves local control when compared to radiation alone (1).  Secondly, 
IMAT delivered a higher dose to the tumor. Flueckiger’s main conclusion was that MR 
imaging allowed for accurate assessment of the response of cervical cancer to primary 
radiation (40). Recently, Vincens published their experience with MRI performed on 44 
patients treated with CRT, brachytherapy and subsequent surgery for FIGO IB2-II cervical 
cancer. Their results demonstrate that surgery is safe after CRT and that MRI performs 
excellent in predicting resectability of the tumor. The sensitivity, specificity and NPV for 
MRI concerning the endpoint “no residual disease or only isolated cells” was 80%, 55% and 
83% respectively (20) compared to a specificity and NPV of 74% and 100% in our series. Due 
to the absence of events we could not calculate sensitivity in our treatment group.  
The optimal timing of MRI post IMAT-C is debatable. Most frequently, this MRI is 
performed within 4 to 6 weeks (20). In contradiction, Hatano performed MRI 3 months after 
treatment to optimize accuracy. A major drawback was the correlation between MRI and 
histopathology being performed on cervical biopsy only (39). We agree with Vincens (20), who 
performed an MRI to check for resectability earlier than 3 months. If the time gap is longer, 
surgery would be jeopardized by an increased risk of fibrosis.  
Our data prove that MRI is an excellent imaging modality in predicting radical resectability. 
All patients showing MR-categories 1 or 2 were operated with pathological R0 resection. This 
translates in a 100% true negative predictive value. Because of the growing evidence that 
additional surgery after chemoradiation improves patient’s outcome (3, 30, 41-43), a negative MRI 
after chemoradiation could safely be followed by EH. 
More difficult is the “IIIB” situation which implies HUN present on imaging (44). In our series, 
2 patients with HUN at MRI post-IMAT-C were successfully operated, both with R0 
resections and with ypT0 and ypT1B1 as remaining disease. The remaining HUN in these 
patients must be due to radiotherapy induced fibrosis. In both patients, there was no 18FDG 
avidity anymore. Combining MRI with 18FDG PET-CT might be necessary in this particular 
situation. 
Posttherapy PET using 18FDG has been used to predict outcome after combined 
chemoradiation. In a retrospective series of 152 patients, persistent or “any new” FDG uptake 
predicted for an at least 50% drop in CSS and OS, with persistent post-therapy FDG uptake 
being the most significant predictor for CSS and recurrence-free survival (13, 25, 45). In our 
series, 5/9 18FDG-positive post-treatment PET-CT’s were false positive. Histopathology 
examination revealed no viable tumor cells but chronic inflammation and abundant number of 
histiocytes and foamy macrophages, 2 types of inflammatory cells that contribute to FDG-
PET positivity (46). The lack of correlation between 18FDG-PET-CT and histology might be 
the timing of the PET-CT. Our post-treatment PET-CT was performed within 1 month, while 
the correlation between PET-CT and outcome was demonstrated only when 18FDG PET was 
done 3 months after treatment (47). 
The SUVmax as measured on pre-treatment 18FDG PET is associated with local response and 
OS (13, 22, 23). Xue defined a SUVmax >10.2 as predictive for a 20% decrease in disease-free 
survival (22). Kidd demonstrated a significant drop in overall and progression-free survival 
when SUVmax  increased from 5.2 to >13.3 (13). 
Studies evaluating the changes in imaging during treatment are sparse. Schwarz investigated 
the correlation between changes in SUVmax during radiotherapy with outcome. They defined 
complete metabolic response as absence of abnormal 18FDG uptake at sites that showed 
abnormal uptake at the pre-treatment scan. Partial response was defined as a >25% decrease 
in 18FDG uptake on a scan performed 47 days after treatment start, which corresponds with 
the timing from our study. Mean SUVmax  for all patients as measured at the 18FDG PET after 
IMAT-C was 1.28, a value corresponding well with the SUVmax  of 1.9 as measured by 
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Schwarz and a representing a 83% decrease, which is identical at the one measured by 
Schwarz (27).  
Mayr correlated the rate of tumor regression as measured on MRI with treatment outcome. 
Time of measurements were pre-treatment and after 40-50 Gy of external beam radiotherapy. 
Tumor regression to <20% was correlated with a significantly lower rate of local recurrence 
(10 vs. 77%; p<0.001) (48). Although not presented in detail in this paper, all our patients had a 
tumor regression to <20 % of their initial volume.            
Although the number of patients is fairly low, this is to the best of our knowledge the largest 
series correlating the imaging with surgery-derived pathology. An important clinical 
conclusion can be drawn from our results: a negative MRI post-treatment has 100% negative 
predictive value when resectability of primary locally advanced cervical cancer is the 
endpoint. In view of the 100% locoregional control at 24 months achieved in our patients (15), 
we consider MRI as a necessity in the modern treatment of primary locally advanced cancer. 
The role of 18FDG PET-CT in predicting viable tumor cells at EH specimen is at least 
debatable. Its role in adaptive radiotherapy for cervical cancer should be clearly examined 
before this could become the standard way of irradiation.   
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Abstract 
Purpose: To retrospectively review our experience with whole abdominopelvic radiotherapy 
(WAPRT) using Intensity Modulated Arc Therapy in the palliative treatment of 
chemotherapy-resistant ovarian cancer with bulky peritoneal disease. 
Material and Methods: Between April 2002 and April 2008, 13 patients were treated with 
WAPRT using intensity modulated arc therapy. We prescribed a dose of 33 Gy to be 
delivered in 22 fractions of 1.5 Gy to the abdomen and pelvis. All patients had International 
Federation of Gynecology and Obstetrics stage III or IV ovarian cancer at the initial 
diagnosis. At referral, the median age was 61 years and patients had been heavily pre-treated 
with surgery and chemotherapy. All patients had symptoms from their disease: gastro-
intestinal (sub)obstruction in 6, minor gastro-intestinal symptoms in 2, pain in 4, ascites in 1, 
and vaginal bleeding in 2. A complete symptom or biochemical response required complete 
resolution of the patient’s symptoms or cancer antigen125 level. A partial response required ≥ 
50% resolution of these parameters. The actuarial survival was calculated from the start of 
radiation therapy. 
Results: The median overall survival was 21 weeks with a 6-month overall survival rate of 
45%. The 9 patients who completed treatment obtained a complete symptom response, except 
for ascites (partial response). The median and mean response duration (all symptoms grouped) 
was 24 and 37 weeks respectively. Of the 6 patients presenting with obstruction or 
subobstruction, 4 obtained a complete symptom response (median duration, 16 weeks).  
Conclusions: WAPRT delivered using intensity-modulated arc therapy offers important 
palliation in the case of peritoneal metastatic ovarian cancer. WAPRT resolved intestinal 
obstruction for a substantial period. 
 
Introduction 
Ovarian cancer still is an important cause of death of women in Western countries (1-4). Both 
the International Federation of Gynecology and Obstetrics (FIGO) stage and the histologic 
grade are important predictors of overall survival (OS) rates at 5 years, varying from 75% 
(stage II) to 10% (stage III-IV) (5, 6). For FIGO stages III-IV, the survival rate decreases with 
increasing grade varying from 38% (grade 1) to 25% (grade 2) and 19% (grade 3) (6). Failure 
particularly occurs intraperitoneally and can reach 85% in patients with high risk features (4, 
7, 8). Secondary cytoreductive surgery is usually insufficient to treat intraperitoneal failure 
and second-line chemotherapy has been the treatment of choice at most centres. The choice of 
second-line chemotherapy depends on the recurrence-free period. In the case of platinum-
resistance defined as a recurrence-free period of < 6 months after six cycles of platinum, the 
response rates of topotecan and liposomal doxorubicin have been disappointing with a median 
progression-free survival < 6 months (3, 7-10) and a 3-year survival rate of about 10% (7). 
Toxicity of these agents is not negligible (10). When the recurrence free interval is > 6 
months, the tumor is considered platinum-sensitive and retreatment with combination of 
platinum based chemotherapy induce a response in more than one-half of the patients (10). 
For patients with progressive disease after second or third-line chemotherapy (including 
hyperthermic intraperitoneal chemotherapy), the therapeutic options are very limited and 
often restricted to best supportive care only. Nevertheless, palliative radiotherapy (RT) has 
been shown to relieve most symptoms in 50-80% of patients, with complaints of bleeding and 
pain responding the best (3, 8, 11, 12). Most reports on the palliative effect of RT have not 
included patients with intestinal obstruction (3, 11). 
In 2003, our research group reported on the feasibility of intensity-modulated arc therapy 
(IMAT) in the treatment planning of whole abdominopelvic RT (WAPRT) as palliative 
treatment for bulky peritoneally relapsed ovarian cancer. (13). The present study reports on 
the clinical results of WAPRT using IMAT in a platinum-resistant patient cohort. Of special 
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interest was the presence of a gastro-intestinal obstruction or subobstruction in almost half of 
the patients. 
  
Material and methods: 
Patient characteristics: 
The data from all patients who underwent treatment of persistent or recurrent epithelial 
ovarian cancer with WAPRT using IMAT at Ghent University Hospital between April 2002 
and April 2008 were analysed retrospectively. The inclusion criteria to receive WAPRT were 
histologically proven epithelial ovarian carcinoma, a minimal Karnofsky performance score 
of 50, evidence of peritoneal relapse after cytoreductive surgery and platinum containing 
chemotherapy and no previous abdominal or pelvic RT. A total of 13 women were included in 
the present analysis. 
The following information was obtained: cancer antigen-125 (CA-125) level, clinical 
symptoms, radiological data, Karnofsky score, initial FIGO stage and previous surgical and 
medical therapies.  
The diagnosis of (sub)obstruction was made on the basis of the symptoms reported by patients 
( at least two of following symptoms: nausea, vomiting, abdominal pain and/or diarrhoea, 
need of parenteral nutrition) and by the clinical evaluation findings and were confirmed by 
computed tomography (CT) in all cases. The CT diagnosis of obstruction or subobstruction 
was determined using previously published criteria (14, 15). Ascites was scored by the 
number of needed paracenteses needed weekly. Other symptoms were scored as present or 
absent. 
 
Characteristics and treatment at initial diagnosis. 
Figure 1A shows the initial stage and treatment schedules (surgical interventions and 
chemotherapy regimens) administered before referral. At initial diagnosis, the median age was 
57.5 years [range: 30-73]. All patients had advanced stages of ovarian cancer (stage III or IV).  
 
Characteristics at referral for WAPRT.  
The median patient age at referral was 61 years [range: 31-75]. The median Karnofsky index 
was 70 [range: 50-90]. All patients had bulky (>2cm3) disease and in all but one patient, 
CA125 serum levels were elevated (median:  343 U/ml; mean: 2159 U/ml; range: 20-13796 
U/ml).  
The indication for referral was symptomatic progression in all patients and radiologic 
progression in 12 (documented by abdominopelvic CT findings in all and 
fluorodeoxyglucose-positron emission tomography CT in 4 patients).   
All patients had symptoms due to their disease (Figure 1B). Six patients presented with 
gastro-intestinal obstruction or subobstruction. Those patients all required parenteral nutrition 
and presented with a nasogastric tube. Two patients had minor gastro-intestinal symptoms, 
despite massive tumor bulk threatening gastrointestinal peristalsis. Other symptoms included 
pain (n=4), ascites requiring therapeutic paracentesis (n=1), and vaginal bleeding (n=2).  
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Fig. 1. (A) Overview of therapy administered before whole abdominopelvic radiotherapy and (B) 
symptoms at referral for whole abdominopelvic radiotherapy for each patient.  
 
WAPRT  details 
We prescribed a dose of 33 Gy to be delivered in 22 fractions of 1.5 Gy. Treatment was daily 
except for the weekend. The clinical target volume (CTV) and organs at risk were delineated 
as described by Duthoy et al. (13). In brief, the CTV was defined as the whole peritoneal 
cavity, supplemented by the aortocaval and iliac nodes. In the case of extraperitoneal gross 
disease (e.g. perirectal mass, inguinal lymph nodes), the latter was included in the CTV. To 
create the planning target volume (PTV), the CTV was expanded with an isotropic margin of 
5 mm in all directions. The following organs at risk were delineated: liver, both kidneys and 
spinal cord. A dose distribution in the transverse and coronal plane is depicted in Fig. 2 and 3 
respectively. 
Follow-up. 
Toxicity and clinical symptoms were scored weekly during treatment, again at the end of 
treatment, 14 days after treatment, and monthly thereafter. If necessary or if signs of relapse 
developed, the patient was examined sooner. 
Cancer-antigen 125 was measured at end of treatment, 1 month after treatment and at 2-
months interval thereafter or when suspicion of relapse was present. At each follow-up visit, 
the patient was asked whether she was able to consume normal food or liquid food. The 
number and aspect of stools (diarrhea, blood, mucus loss) was registered. Others symptoms 
checked included nausea, vomiting, and abdominal cramps. Bowel peristalsis was checked 
clinically. 
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Figure 2 (left): Transverse dose distribution at the level of (A) both kidneys and (B) umbilicus in patient 
with intestinal obstruction. Note the combination of the conformal avoidance of kidneys and sufficient 
coverage of the PTV (A). (B) Inverted axial CT view showing a pathologically distended small bowel loop 
with air/fluid levels. This patient had a complete intestinal obstruction which completely recovered after 
whole abdominopelvic radiotherapy. The patient is alive and well 42 weeks after treatment.  
PTV: Planning Target Volume (blue); RK: right kidney; LK: left kidney (green); SB: small bowel (16). 
Figure 3 (right): Coronal dose distribution of the same patient shown in Fig. 2 at the level of both kidneys 
(A) and intestines (B). Note, combination of the conformal avoidance of kidneys and sufficient coverage 
of the PTV (A). PTV: Planning Target Volume (blue); RK: right kidney; LK: left kidney (green); L: 
liver.  
 
Statistical analysis: 
Both the symptom and CA-125 response rates were classified according to the best response 
obtained by the patient. The response to RT was defined as a complete or partial response, 
stable disease or disease progression, according to the clinical records for the two parameters. 
A complete symptom or biochemical response required complete resolution of the patient’s 
symptoms or CA-125 level to within normal laboratory limits (0-35 U/ml). A partial response 
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was defined as ≥50% reduction of these parameters. Stable Disease was defined as < 50% 
reduction. Disease progression was defined as an increase in symptoms or an increase in CA-
125 serum levels, defined as more than two times the nadir value on two occasions, separated 
by > 1 week.  
The duration of the dominant symptom (Fig. 1B) was defined as the interval from the end of 
RT to the reappearance or worsening of the symptoms or last follow-up visit or death. OS was 
defined as the time from the start of RT to death from any cause. Abdominopelvic 
progression-free survival (APFS) was defined as the time from the start of RT to documented 
progression (clinical or radiological evidence of abdominopelvic tumor) or death without 
progression. The OS and APFS distributions were estimated using the Kaplan-Meier method. 
The log-rank test was used to assess whether APFS or OS differed with respect to Karnofsky 
(< 70 or ≥ 70), intestinal obstruction and mean CA-125 level (>2159 U/ml or <2159 U/ml), all 
at referral. A p-value <.05 was considered significant. 
Acute toxicity was defined as RT induced toxicity during or within 3 months after the end of 
RT. Late toxicity was defined as an increase of RT induced toxicity starting ≥3 months after 
RT, or as any acute toxicity that lasted > 3 months. The Common Toxicity Criteria were used 
to register acute and late genitourinary and gastrointestinal toxicity (17).  
 
Results: 
Symptom response: 
Figure 4 provides a schematic overview of the symptoms at the start of RT and symptom-free 
survival in relation to overall survival. All patients who completed or restarted (patient 9 in 
Fig. 4) treatment obtained a complete response, except for the symptom ascites where only a 
partial response was reached (need for therapeutic paracentesis reduced by 50%). The median 
and mean response duration (all symptoms grouped) was 24 and 37 weeks [range: 6-99 
weeks], respectively.  Of the 6 patients who presented with obstruction or subobstruction, 4 
obtained a clinical complete response as determined by the return of peristalsis, normal food 
intake and normalization of stools (median duration of 16 weeks, range: 6-30). For vaginal 
bleeding (n=2) and pain (n=4), the complete response rate was 100% and 75% respectively.  
Biochemical response: 
Only patients completing WAPRT were considered. At the end of WAPRT, 6 patients had a 
biochemical response with a mean decrease in the CA-125 serum level of 59% [range: 34-
75%]. One patient had an increasing CA-125 serum level at the last day of WAPRT, probably 
because of RT-induced peritoneal inflammation (patient 5 in Fig. 4). The CA-125 serum level 
was not verified at a later point. One patient had a normal CA-125 level at start and end of RT 
(patient 11 in Fig. 4). 
Correlations among responses: 
A significant correlation (p < .05; Pearson correlation = .720) was found between the 
biochemical response and symptom response. Previous platinum-resistant disease (relapse 
within < 6 months) did not correlate with WAPRT response (p =NS) nor did a previous 
chemotherapy response (p = NS). 
Overall and abdominopelvic progression-free survival: 
For the intention-to-treat population, the median OS was 21 weeks, with a 6-month OS 
rate of 45%. At the present analysis, 2 patients were still alive, respectively 20 and 42 weeks 
after WAPRT. Of the patients who completed treatment, median OS was 35 weeks with a 6-
month OS rate of 60%. Univariate analysis of all patients showed a significant increase in OS 
for women with a Karnofsky score ≥70  (median OS, 35 vs. 9 weeks; P < 0.05) and a CA-125 
of <2159 U/ml at referral (median OS, 39 vs. 9 weeks respectively; P < 0.05)compared with 
those with a Karnofsky score <70 and CA-125 >2159 U/mL. Age had no influence on 
outcome. Median APFS duration was 16 weeks with an estimated 6-month APFS rate of 29%. 
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Figure 4: Overview of symptoms at referral (Panel A) and (B) the results of whole abdominopelvic radiotherapy for each patient. 
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Only Karnofsky performance score of <70 correlated with significantly worse APFS (P < 
0.05).  
Tolerance of WAPRT 
Figure 4b depicts the duration of WAPRT and treatment interruptions. The median number of 
arcs to deliver WAPRT was 7 [range: 4-10]. Eight patients received the treatment objective of 
33Gy. One patient was interrupted at 15 fractions because of acute postrenal failure due to 
obstruction by a tumor mass and underwent additional conventional pelvic irradiation (12 x 
2.5Gy) after normalisation of renal function. 
Three patients stopped treatment after 6, 12, and 13 fractions respectively because of a 
worsening of gastrointestinal obstruction that did not respond to conservative treatment. 
These patients died shortly afterwards (patients 1-3 in Fig. 4). One patient died after 
developing pneumonia (patient 12). No link was seen between Karnofsky status (< 70 vs. ≥ 
70) at referral and treatment continuation (chi-square test). 
None of the patients developed genitourinary toxicity. For patients presenting with 
gastrointestinal symptoms, acute gastrointestinal toxicity was impossible to score. This 
resulted in 5 patients eligible for the acute gastrointestinal toxicity evaluation. Two patients 
developed Grade 3 diarrhea –combined with Grade 3 nausea in 1- during WAPRT but with a 
complete recuperation within 2 weeks afterward. One patient experienced Grade 2 nausea and 
diarrhea during WAPRT that had resolved within 3 weeks afterward. None of the patients 
developed late gastrointestinal or genitourinary toxicity. 
 
Discussion 
The present study has reported on the palliative effect of WAPRT using IMAT in ovarian 
cancer patients with progressive peritoneal disease after undergoing treatment with multiple 
lines of palliative chemotherapy and several surgical interventions. Although the 
radiosensitivity of ovarian cancer cells has been well established for > 2 decades, WAPRT as 
adjuvant or palliative treatment has been abandoned in many centers mainly because of 2 
reasons.  
First, in the case of platinum-resistant disease, second-line chemotherapy using topotecan or 
liposomal doxorubicin has become the treatment of choice. The response rates have varied 
from 7 to 25% (18, 19) and the incidence of Grade 4 toxicity (20) has not been negligible (10, 
21). The review by Salom et al. included information on new products and ongoing trials but 
did not, surprisingly enough, mention RT at all (10). Data from the 1980s and 1990s, 
however, have demonstrated the (even possible curative) role of WAPRT in the treatment of 
ovarian cancer (22, 23). Some trials have clearly demonstrated a progression-free survival 
benefit (24, 25) and OS benefit (24) when RT was applied in the treatment of FIGO stage III 
ovarian cancer. If women with initially advanced ovarian cancer have minimal residual 
disease after second-look laparotomy, adjuvant WAPRT may be effective with a median 
progression-free survival of up to 3.5 years (7, 26, 27), 5-10 years overall survival rates of up 
to 53% (5, 12, 28, 29) and up to 49% respectively (28) and a median survival of 63 months in 
the case of microscopic disease compared with 9 months if disease was >2 cm (30). In 
patients for whom second-look laparotomy showed a complete pathologic response after 
primary treatment, WAPRT significantly improved progression-free survival at 5 years 
compared to consolidation chemotherapy (25) or intraperitoneal chemotherapy (7). 
Secondly, conventional WAPRT has been considered to be too toxic by referring clinicians. 
WAPRT is a technological challenge because it must combine sufficient coverage of the 
peritoneal cavity with sparing of the organs at risk such as the kidneys, liver and bone 
marrow. If conventional technology is used, treatment interruptions because of acute toxicity 
have been reported in up to 70% of the patients, with myelosuppression and bowel toxicity 
being the most important (7, 12, 28). Treatment interruptions are inversely correlated with OS 
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with a decrease of > 2 years and a risk ratio > 2.5 (26). MacGibbon et al. (12) confirmed this 
by showing that completion of the planned WAPRT was associated with improved survival 
with a highly significant difference of 37% versus 0%. However, severe late small bowel 
toxicity still occurs in ≤20% of the patients and is most pronounced in case of a pelvic boost 
(2, 7, 25, 26, 28, 31, 32). Modern advances in RT such as IMAT will allow us to overcome 
the shortcomings of conventional techniques (13) and are currently being applied in new 
phase I-II studies (4). 
External beam RT has, however, clearly demonstrated an important palliative effect in 
platinum-refractory ovarian cancer. Gelblum et al. (33) noted a complete and partial response 
rate of 70% and 24%, respectively, combined with a good acute tolerance profile. Vaginal 
bleeding and persistent disease at exploratory laparotomy were the most frequent treatment 
indications (33). 
Our study differs from earlier reports demonstrating the palliative effect of radiotherapy in the 
treatment of chemotherapy-refractory ovarian cancer in several ways. First, we prescribed an 
IMAT-generated dose of 33 Gy to be delivered in 20 fractions. Most published data have  
reported on  median WAPRT doses of 19-25 Gy (2, 5, 7, 8, 12, 26, 29, 31) and used 
conventional technology, leading to suboptimal dose distributions especially at the level of the 
kidneys (7, 8), (13).  Firat et al. (28) prescribed 36 Gy to be delivered in 1 Gy fractions as 
adjuvant treatment. Radiobiologically, this was almost equal to our prescription (normalized 
iso-effective dose (NID2), i.e. the dose recalculated in 2 Gy fractions) of 32 in 2 Gy fractions 
for an α/β-value of 10). This NID2 of 32 Gy has been reported to be a threshold to predict for 
better OS (28). Nevertheless, and because of the palliative setting of our treatment schedule, 
additional research should emphasize obtaining the least radiation dose that induces important 
symptom relief. Perhaps 33Gy (at 1,5Gy/fraction) is not needed, and a lower dose might 
obtain the same palliation as reported in the present study. 
Second, our patients were heavily pre-treated with chemotherapy, reflecting aggressive and 
refractive disease and resulting in suboptimal Karnofsky scores at referral.  
Third, all patients had gross disease on imaging (>2 cm3 in all cases), a feature categorized, 
by itself, as a “poor-prognostic” finding (5).  
Finally, and most important, 6 out of 13 patients presented with intestinal obstruction, which 
is an often-observed clinical feature associated with recurrent ovarian cancer (34). Survival 
has ranged from 3 to 12 months, with 20% of the patients surviving >1 year (35) 
Although Gelblum et al. (33) described 1 patient with “abdominal discomfort” and Tinger et 
al. (8) described “obstruction” in 12 out of 72 patients (including ureter, oesophagus and 
stomach obstruction), to the best of our knowledge, this is the first report showing the 
possibility of resolving intestinal obstruction with WAPRT for a substantial period (median 4 
months). Tinger et al. (8) found relief of “obstruction” in 75% of their patients. However, it 
was not clear from their study how many patients had ureteral obstruction or how obstruction 
or obstruction relief was defined. Other reports of the palliative effect of radiotherapy for 
ovarian cancer did not include patients with intestinal obstruction (3, 11).  
Therefore, WAPRT delivered by IMAT deserves a clear and well-defined place in the 
palliative treatment of recurrent ovarian cancer. The results presented in the present study add 
to that opinion by providing data on substantial and long-lasting palliation in heavily pre-
treated women. Moreover, intestinal obstruction or subobstruction was palliated in 4 of 6 
patients for a period of several months, with an impressive improvement in their quality of 
life and social life. The results of other treatment options such as chemotherapy and palliative 
surgery have been disappointing in this particular situation (13, 34). Our study had some 
shortcomings. Its retrospective character made exact comparisons between the clinical 
symptoms before and after WAPRT less stringent. However, we consider that for food intake 
and the production of stools, the dichotomy between ‘‘yes’’ and ‘‘no’’ is of much more 
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importance, because ‘‘no’’ food intake vs. ‘‘yes’’ food intake and/or ‘‘no’’ production of 
stools vs. ‘‘yes’’ production of stools have a huge effect on patients’ quality of life. In 
addition, our study had the disadvantage of being a single-institution study. This was because 
of the paucity of IMAT availability in Belgium and surrounding countries. Thus, the number 
of patients was low, and definitive conclusions should be taken prudently. Nevertheless, we 
consider the clinical message of our results to be of importance to clinical oncologists, 
certainly in view of the important palliation of intestinal obstruction.  
 
Conclusion 
Whole abdominopelvic RT delivered using IMAT offers important palliation in the case of 
peritoneal metastatic ovarian cancer. WAPRT can resolve intestinal obstruction for a 
substantial period. 
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Chapter 8: Discussion and Perspectives. 
1. Cervical and endometrial cancer  
1.1. Reducing Toxicity 
 
Pelvic RT for gynaecologic malignancies has a long history. The first report on the use of 
pelvic EBRT was published by Lacassagne et al. in 1932. Since the refinement of this 
technique by Rutledge and Fletcher in the 50’s, the basic treatment technique has not changed 
significantly (1, 2). Although the introduction of megavoltage machines and cerrobend blocks 
allowed for better sparing of superficial and deep tissues such as bladder and small bowel, 
large areas of OARs could only be spared if coverage of lymph node regions was 
compromised. If target volume coverage was not sacrificed, the delivery of even modest doses 
of 45–50Gy was accompanied by substantial incidences of severe acute and late toxicity (3-
5). With the advent of concomitant chemotherapy severe acute hematologic and gastro-
intestinal (GI) toxicity doubled, acute platelet toxicity tripled (3) and life-threatening GI-
toxicity even occurred in 8% of the patients (3). This important increase in toxicity has 
prompted the radiotherapy community to intensively put research efforts in treatment 
planning improvement. Switching patient positioning from supine to prone and the additional 
use of a belly board in combination with 3D conformal RT brought a first significant 
reduction in irradiated SB volume (6). However, SB is not the only OAR. A major 
improvement was the introduction of IMRT, which significantly reduced volumes of normal 
tissue irradiated at high dose when compared to conventional techniques (see table 1.1 
introduction) (7-17). The resulting lower toxicity has been described in the postoperative (18, 
19) as well as in the LACC setting (20, 21), but mostly for a group of patients consisting of 
both populations (18-24). For rectal cancer treatments, IMRT in supine position significantly 
decreased GI toxicity when compared to 3D conformal RT in prone position (+ belly board) 
(25). Although IMRT in prone position + belly board can provide a supplemental reduction in 
irradiated volume of SB (26), this benefit diminishes (and disappears in low dose regions) 
when using extended arc techniques (27). Taking into account the unknown effect on the 
other OARs (27), the potential increased set-up error and internal organ motion (6), we 
decided to treat our patients with IMAT in supine position. 
It is clear from publication 1 that IMAT results in low grade 2 or more acute toxicity when 
applied in the postoperative setting, both for cervical and endometrial cancer. The same is 
observed when IMAT is applied in the primary setting, where the cervix is in loco 
(publication 3). Our results fit within those reported in literature after IMRT for gynaecologic 
malignancies, although comparisons should be taken with high caution. Not only has one to 
take into account the different scoring systems used (e.g. RTOG vs. CTC), most publications 
contain a rather small number of patients and are very heterogeneous with a mixture of 
“postoperative” and “primary” setting (22-24), variations in chemotherapy schedules and 
inclusion of other than cervical or endometrial tumours (20, 22, 23). Although it is impossible 
to distinguish between acute toxicity rates after postoperative and primary IMRT, they all 
show the same and often strong trend: compared to conventional pelvic radiotherapy, IMRT 
significantly decreases acute GI toxicity in all, and acute genito-urinary (GU) toxicity in the 
majority of the cited reports. The only exception are the results published by Bouchard et al 
(18), who reported a significant better disease control, but also an increase in acute grade 2 or 
more GI toxicity. However, reading the paper in detail reveals that in the IMRT group, most 
patients were treated with an endovaginal boost during EBRT while no patients were treated 
this way in the conventional RT arm. Moreover, scoring of toxicity differed substantially 
between IMRT (prospective) and conventional RT (retrospective). 
Lukka et al. concluded that adding chemotherapy to radiotherapy lead to a significant increase 
in overall ≥ grade 2 acute GI toxicity by 25% (56 vs. 81%)  and a two- (white cell count) to 
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three-fold (platelet toxicity) grade 3 toxicity (4). Despite also we demonstrated a 
chemotherapy-related increased toxicity (publication 1), the toxicity rate after IMAT 
(publication 1 and 3) was very low and certainly lower than those reported by others using 
conventional techniques. This supports the hypothesis that IMAT leads to a decreased 
toxicity. 
The rather limited amount of (small-numbered) studies and the lack of long-term follow-up 
prohibit definitive conclusions regarding toxicity. Only randomized trials comparing 
conventional with IMRT definitively will solve this question. However, based on all the 
preliminary results (including ours), one could ask the question whether starting such a trial 
would be ethical. Our toxicity results re-inforced us to question whether conclusions from 
randomized trials that used conventional RT would hold true if IMRT or IMAT were used. It 
is our viewpoint that communications concerning such trials should at least include the note 
that old fashioned technology was used.  
 A more controversial issue is the use of prophylactic irradiation of para-aortic lymph 
nodes (PALN). This approach improved OS en DFS in a subgroup of cervical cancer patients 
(investigated group: FIGO IB and IIA, > 4cm and FIGO IIB) in the RTOG 79-20 trial (28). 
No OS benefit was found by Haie et al. (investigated group: node positive and/or all >IIB 
with lateral parametrial involvement) but they suggested a benefit for those patients with a 
high probability of local control (29). However, its use has been largely omitted since the 
advent of concomitant chemotherapy and the resulting high toxicity rates (30, 31). If 
IMRT(15, 32-36)  is used to treat the PALN together with the pelvis (extended field) acute 
toxicity is acceptable and no increase in severe late or life threatening toxicity is observed. In 
10 patients treated this way at our centre (with IMAT and concomitant chemotherapy, if 
pelvic nodes were present), no ≥ grade 3 toxicity was noticed (publication 1 and 3). Further 
maturation of data is obviously needed. However, these premature data and the dispersed 
availability of IMRT and rotational therapy might reinforce the set-up of randomized trials 
that re-evaluate the important OS and DFS benefit that was demonstrated decades ago.  
 
 
 
Future perspectives. 
Volumetric modulated arc therapy (VMAT) is an advanced form of IMAT available at GUH. 
VMAT provides the opportunity of simultaneous but independent variation of the gantry 
speed, leaf position and dose rate. Currently, planning studies comparing the results of VMAT 
with IMAT are developed. The tested hypothesis is that VMAT significantly reduces the dose 
to the organs at risk as compared to IMAT without compromising the dose to the target. 
  
1.2. Does the use of IMAT imply a survival benefit? 
 
Contrary to other sites (37, 38), the use of IMRT or IMAT in pelvic gynaecological tumours 
has not proven to be advantageous on locoregional control, distant control or survival. Yet, 
there are some arguments this might change in the future. First, using standard conventional 
fields, underdosage of elective lymph node regions in 30 to 40 % of patients and geographical 
misses of gross tumour volumes up to 56% of the cases are described (39). Secondly, Brixey 
et al. saw that acute hematologic toxicity resulted in missing ≥ 1 chemotherapy cycles in 40% 
of patients treated with CRT compared to 12,5% in the IMRT group (20).  One might also 
expect a decrease of RT treatment interruptions (40) or chemotherapeutic dose modifications.  
Finally, the ability of IMRT to reduce normal tissue toxicity allows for more aggressive 
locoregional therapy (dose-escalation or SIB) and/or systemic therapy. This in turn has the 
potential to enhance tumour control and long-term OS. 
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1.3. Tumour and organ motion 
 
In our work (both the postoperative and primary setting), no attempts were made to control 
bladder and rectal filling, although this is an ongoing controversy. The relationship between 
organ motion and organ filling during fractionated pelvic RT is complex. Both bladder and 
rectal filling show weak correlations with anteroposterior shifts of the target in the primary as 
well as the postoperative setting (40-43). Bladder filling, however, seems to have more impact 
on uterine than on cervical movement, certainly in the supero-inferior direction (41-43). With 
this information the following picture emerges. A full bladder pushes the CTV and GTV 
towards the rectum. Similarly an increase in rectum volume results in a shift in the anterior 
direction. In LACC, the orientation of the tumour is also bounded by the orientation of the 
uterus, and a bladder volume change may change this orientation, provided the vacated 
volume is not occupied by small bowel.  The combination of variation in rectum and bladder 
volume results in changes in the position and shape that are difficult to describe and as a 
consequence to influence. Although positional variations might be reduced by counselling 
patients to have a full bladder during treatment, it is known that even with careful counselling 
patients may not be able to achieve consistent bladder filling. Consequently efforts to 
influence bladder or rectal filling have not yet proven to have any impact on the reduction of 
treatment margins. Treatment with a (comfortably) filled bladder, however, is advocated since 
it tends to push the intestine out of the pelvis (44, 45) and leads to significant reductions of 
bladder dose (46).  
 
Future Perspectives 
The adoption of IMRT in pelvic gynaecologic oncology, and more specifically LACC, has 
been limited by the complex organ and tumour motion exhibited in this cancer site. Concerns 
about tumour movement during treatment and geographic target misses have resulted in the 
proposal of generous PTV margins (up to 4 cm around the uterine fundus!), which increases 
the volume of normal tissue irradiated. The inter- and intrafractional uterine and cervical 
motion and margins to ensure 95% target coverage is presented in table 8.1. As we expect 
instinctively, expansion of margins leads to significant increases of dose delivered to the 
OARs, especially in the volumes receiving high doses (7, 47, 48). Finding a solution to cope 
with the complex motion of the uterus is one of the foremost challenges to reduce further 
toxicity and ensure adequate target coverage. The answer is certainly not unequivocal and 
consists most probably out of a combination of multiple little parts. 
Three different methods to reduce safety margins and irradiated volume of organs at risk are 
subject of further research and perspectives:  
 
 a. Cone beam CT (CBCT, both postoperative and primary setting) 
Daily verification and management of patient movement and internal organ motion is 
warranted when applying IMAT. Although intra-fractional cervical and uterine motion is 
smaller than inter-fractional motion, they are still relevant (40, 42, 49, 50), especially at the 
level of the uterine fundus, where 10mm safety margins are suggested (42) compared to the 
5mm needed for the rest of cervix and uterus (42, 47).  
Implementation of CBCT and accordingly reduced margins requires a correct interpretation of 
the CBCT. The inter- and intra-observer variability of interpreting CBCT in both the primary 
as the postoperative setting will be quantified. 
Table 8.1: Inter- and intrafractional uterine and cervical motion and proposed margins to ensure 95% PTV coverage. 
    Target Antero-Posterior  (mm) Latero-Lateral (mm) Supero-Inferior (mm) Set-up 
   mean ± SD [range] M I mean ± SD [range] M mean ± SD [range] M I  
Locally Advanced Cervical Cancer           
 Haripotepornkul et al. (10) CTV 4,2 ± 3,5 [0-18]   1,9 ± 1,9 [0-18]  4,1 ± 3,2 [0-18]   daily X-rays (s) 
   2,9 ± 2,7 [0-15]   1,6 ± 2 [0-15]  2,6 ± 2,4 [0-15]   pre and post RT  
 Tyagi et al. (10)  CTV  15 B  15  15   
 Collen et al. (10) Cervix A: 0,4 ± 10,1 A:17  L: -3,5 ± 4,9 L: 9 S: 2,2 ± 8 S: 15   
   P:-3 ± 6,9 P:12  R: 0,2 ± 4,5 R: 8 I: 0,5 ± 5 I: 9   
  Uterus A: 3,3 ± 11,9 A:19  L: -3,5 ± 8,1 L: 13 S: 6,1 ± 11,6 S: 20   
    P: 0,3  ± 11,7 P:19  R: -0,6 ± 7,5 R: 13 I: 5 ± 11,2 I: 19   
  Patient 1,1 ± 1,3    -0,3 ± 1,6   0,2 ± 2,3    pre and post  RT 
 Lim et al. (20) GTV 4 ± 4   2 ± 4  3 ± 4    
  Cervix 4 ± 4   1 ± 3  2 ± 4    
  Uterus 6 ± 2   4 ± 2  5 ± 2    
 Beadle et al. (16) cGTV 16 [5,1-25]  B 8,2 [4,4-14]  21 [12-33]  B  
  pCervix A: 17 [7,8-29]   L: 9,4 [3,9-18]  S: 23 [13-35]    
   P: 18 [7,8-63]   R: 7,6 [2,9-18]  I: 13 [2,5-30]    
 van de Bunt et al. (20) GTV  A:12    L:11  S:4   
     P:14   R: 12   I:8   
  CTV  A:24    L:16  S:11   
     P:17   R: 12  I:8   
 Taylor et al. (33) Cervix 4,1 ± 4,4 [0-19]   R 0,3 ± 0,8 [0-3]   2,7 ± 2,8 [0-12]   B 2 cons. MRI  
  Uterus 7± 9 [0-48]   B 0,8 ± 1,3 [0-5]   7,1 ± 6,8 [0-32]   B  
  Vagina 2,6 ± 3 [0-10]   R 0,3 ± 1 [0-5]       
  CTV  15   7  15   
  Nodes  7   7  7   
 Chan et al. (20) Cervix 2,4 [0-11,2] 15   15 1,5 [0-11,3] 15  weekly MRI 
   -0,1 [0-10,6] 5   5 -0,5 [0-11,2] 5  6 MRI, every 6' 
  Uterus (C) 4,8 [0-13,1]     5,7 [0-15,7]    
   0,3 [0-11,3] 5   5 -1,8 [0-12,8] 5   
  Uterus (F) 4,6 [0-14,5] 40 B   7,8 [0-24,4] 40   
   -1,1 [0-12]     -3,1 [0-18,8]    
 Kaatee et al. (10) CTV  9,7   8,9  10,8  daily portals (m) 
Postoperative           
 Jürgenliemk-Schulz et al. (15) CTV  15 R  15  15  weekly MRI 
  Harris et al. (22) CTV 4 ± 3,7 [0-19,3]  12,1   1,2 ± 1 [0-8]  3,1 4± 2,9 [0-15]  9,5   daily MVCT (f) 
 Intrafractional uterine and cervical motion and proposed margins are in italic. cGTV: center of GTV; pCTV: perimeter of CTV; C: Canal; F: Fundus; M: proposed margins to 
encompass 95% of target volume; I: Influence of bladder (B) or rectum (R) on organ motion; MRI= Magnetic Resonance Imaging; MVCT = megavoltage CT: CBCT = Cone Beam 
CT; s: seeds; m: markers; f: fiducials; cons.: consecutive.  
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 b. Studying the relation between uterus and CTV (primary setting). 
A major contributor to the large margins needed is the uterus and certainly the fundus as it is 
the most mobile part of the uterus. The uterine body and fundus are connected to the bony 
pelvis laterally via broad ligaments which, although constraining large lateral motion, permit 
significant motion in the anterior-posterior (AP) and superior-inferior (SI) directions. Notably, 
influenced by bladder, bowel and rectal filling, the uterus can tilt from ante-flexed to retro-
flexed positions.  
We couldn’t find unequivocal evidence to support the need to include the whole uterus in the 
CTV (51). This “dogma” results from the era of conventional treatments without image-
guided target volume delineation and image-guided radiotherapy. Excluding non-affected 
parts of the uterus might lead to significant reductions in bladder and small bowel volumes 
irradiated to high doses. As a consequence, since the fundus is the most mobile part of the 
uterus, tighter treatment margins can be used leading to a further sparing of OARs (7).  
 
 
Figure 8.1: Example of Dose Volume Histograms (DVHs) of 2 patients when treated with a partial 
(yellow) or entire uterus (red) included in the PTV. A and C: red contour = entire uterus included in the 
PTV; yellow contour = only the parts of the uterus closer than two cm of the GTV (red flooded contour) 
are included in the PTV. C and D: DVHs of patient A and C respectively; the red DVHs correspond with 
the red contour (whole uterus); the yellow DVHs correspond with the yellow contour (selected parts of the 
uterus included in the CTV). The tail towards 62 Gy in the DVH of the PTV corresponds with the SIB 
given to the GTV. 
In the first patient (A) the uterus lies in anteflection causing high doses to the bladder when irradiated 
entirely. A small reduction of PTV by reducing the amount of uterus included in the PTV causes a huge 
reduction in dose delivered to the bladder (B). A reduction of the PTV in case of a normal positioned 
uterus causes mainly a reduction in the irradiated volume of small bowel (D). Due to the large amounts of 
small bowel delineated, the percentual reduction seems small. In this case the amount of small bowel 
receiving 45 Gy is reduced with 8% which corresponds with 59cc.   
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 A comparison of treatment plans with the currently used and reduced PTV will allow 
interpreting and evaluating differences in dose at the OARs. Subsequent a multidisciplinary 
trial, in which we hypothesize that current modern imaging techniques such as 18FDG-PETCT 
and dynamic contrast enhanced (DCE) MRI allow accurate definition of the part of the uterus 
to be irradiated, will be initiated. Since all patients are treated with an adjuvant hysterectomy, 
stringent pathological examination of the hysterectomy specimen will serve as proof of our 
hypothesis.  
 
c. Adaptive treatment 
Substantial tumour regression over the course of treatment further complicates the issue of 
organ motion (Figure 8.2). Reduction in the GTV from baseline to the end of EBRT varies 
from 48 to 96% (41, 52-54). Median time to 50% regression is 20 days (range: 7-34days) 
(41). A relative reduction of the initial tumour volume of 7%, 24%, 44% and 59% was found 
after the first, second, third and fourth week respectively (53). Tumour regression induced 
target volume/position changes necessitate larger margins and lead to movement of OARs 
into the high dose area. The benefit of adaptive re-planning is therefore two-fold. First, 
adaptive treatment might allow tighter margins around the target (54), consequently leading to 
sparing of OARs (7). Secondly, by conforming the high dose area to the regressed tumor 
adaptive re-planning leads to significant lower doses on OARs (55, 56) as well. The latter is 
illustrated in figure 8.2, where shrinkage of tumour and uterus leads to a movement of OARs 
in the initially delineated PTV. If the treatment plan is not adapted at that moment, those 
OARs will be treated as they were PTV and receive high doses. 
Currently, adaptive re-planning - plan of the day - is under investigation. With such complex 
and interwoven physical changes, simple pointwise assessment of anatomical motion provides 
incomplete information on target coverage and OAR sparing during treatment. A more 
accurate appraisal must include volumetric and dosimetric knowledge. Non-rigid image 
registration might allow us to integrate dose distributions of consecutive treatment plans with 
acceptable accuracy, merging of changed anatomical and biological imaging data enables us 
to reduce time-consuming efforts of re-delineation of all targets and OARs. 
 
 
 
 
Figure 8.2: MRI imaging of a patient with LACC before (A), after 11 fractions (B) and after CRT (C). The 
volumes of the CTV before (red), during (blue) and after treatment (yellow) are projected on the post-
treatment MRI. As visible in figure C, after shrinkage of the tumour and uterus, the small bowel, rectum 
and bladder have moved into the high dose area.  The volume of the CTV reduced from 349cc before 
treatment to 213cc (-39%) during and 85cc (-70%) after treatment. 
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1.4. Primary treatment of locally advanced cervical cancer 
1.4.1. Simultaneously Integrated Boost 
Obtaining a maximal reduction of tumour is of utmost importance since negative resection 
margins are necessary to obtain local control (57) and the complication rate after surgery is 
correlated with the extent of tumour (58). Local control and escalated radiation dose are 
closely linked (59-62). At least of equal importance is the relationship between OTT and local 
control with an estimated loss of 0,6% to 1% for each additional treatment day (63-68). 
Escalation of the dose without increasing the number of fractions (SIB) should therefore 
theoretically result in a double advantage. The feasibility of performing a SIB using IMRT 
without compromising the dose to surrounding tissues has been proven before (69, 70). We 
demonstrated that IMAT easily succeeded in performing SIB (publication 2).  The result of 
delivering a higher dose was described in publication 3. None of the patients had 
macroscopically visible tumour on the hysterectomy specimen. This compares favourable 
with literature data from series concerning EBRT + ICBT. In these series macroscopically 
visible rest tumours in 23-50% (60Gy) (57, 58, 71, 72) and 16% (75Gy) (73) of the cases are 
described. Although further maturation of our data is warranted, we hypothesize that this 
difference in macroscopic response rates endorses the double advantage of performing a SIB.   
Another area of interest is the use of a SIB to deliver higher than conventional doses in 
women with documented pelvic or even para-aortic macroscopic lymph node involvement 
(18FDG-PETCT). Results on the use of SIB on enlarged PALN, extended field IMRT and 
concurrent cisplatin are very encouraging with good loco-regional control and a significant 
lowering of morbidity when compared to conventional techniques (32, 34, 74). In our 
population, a SIB on the affected pelvic lymph nodes (up to 4) of 60 Gy was delivered while 
maintaining a dose of 45 Gy to the remaining elective lymph nodes. There was no increased 
toxicity (publication 1 and 3). Because all suspicious lymph nodes as visible on pre- and/or 
post treatment 18FDG-PETCT were removed during surgery, assessment of local lymph node 
failure rate after lymph node SIB (without surgery) was impossible. This combined approach 
however leads to a 100% 2-year regional control rate (publication 3). Few data are published 
concerning the dose required to adequately treat FDG-positive lymph nodes. In our series 
100% complete pathological remission (pCR) is found in FDG-positive lymph nodes < 2 cm 
with a NID2 of 62Gy. In lymph nodes ≥ 2 cm pCR was only achieved in 50% of the nodes, 
suggesting the need for a higher dose in this setting. An obvious radiobiological explanation 
of this finding is that the number of tumour clonogens increases with tumour volume. Cell kill 
by radiotherapy increases roughly exponential with dose and is modelled using the linear-
quadratic formulation (75). The resulting dose-response curves demonstrate that for a given 
dose increment always the same fraction of cells is killed. However, the number of cells killed 
depends on the absolute number of cancer cells and/or volume of the tumour. Consequently, 
the dose of irradiation to eradicate a certain volume of cancer (clonogen) cells increases with 
increasing volume. The effect of tumour volume on tumour control probability is less 
unequivocal than expected from a simple proportionate increase in tumour clonogen number 
with tumour volume. Other biologic events such as hypoxia or tumour characteristics such as 
tumour grade influence radioresistancy as have been proven in several tumour types (76). 
Further research is indispensible and will be executed to confirm this hypothesis.   
At this moment 18FDG-PETCT and MRI are used to delineate the primary tumour and 
affected lymph nodes which are to receive a SIB. This planning strategy is also known as dose 
painting by contours. Both imaging modalities could also provide biological data which have 
proven to be correlated with outcome. Kidd et al. showed that increased pre-treatment 
SUVmax is significantly associated with persistent abnormal 18FDG uptake in the cervix at 3 
months, higher pelvic recurrence and worse survival (77).  SUVmax has also shown to be 
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correlated with histology and tumour proliferation rate, reflecting tumor aggressiveness (78). 
The cause of a higher FDG uptake in these more aggressive tumours remains uncertain, 
although there might be a role for glucose transporter gene expression (GLUT-1) (78), whose 
expression is enhanced by the hypoxia driven hypoxia-inducible factor 1- α (HIF 1-α) (79). 
By increasing the number of glucose transporters on the tumoural cell surface, HIF-1α 
enhances FDG-uptake leading to a high SUVmax. HIF-1α (a factor also playing an important 
role in other tumours such as renal cell carcinoma) drives tumour growth and progression, for 
instance by promoting neo-angiogenesis (80), resulting in a strong negative correlation with 
prognosis (81). This leads to the assumption that a high SUVmax is correlated with intra-
tumour hypoxic radio-resistant foci which might need a more aggressive treatment, a 
hypothesis supported by the observation of Schütze et al. By using human FaDu head and 
neck squamous cell carcinomas in nude mice, they observed a greater effect on local control 
by increasing the radiation dose in tumours with higher FDG-uptake, where the dose-response 
relationship appears to be steep, than in tumours with a low FDG-uptake (82). Mayr et al. 
evaluated several parameters of DCE-MRI studies before and during combined CRT. They 
found that the degree of very-low-dynamic contrast-enhancement regions within the tumour, 
represented by the lowest relative signal intensity (RSI), correlated with tumour recurrence. 
Patients with a 10th percentile RSI of 2.5 or less had a significantly higher tumour recurrence 
rate (88%) compared with patients with a 10th percentile RSI higher than 2.5 (0%). If a 10th 
percentile RSI of 2.0 was used as a threshold value, all tumour recurrences could be predicted.  
They proposed that regions of very-low dynamic contrast enhancement are correlated with 
therapy-resistant hypoxic tumour cells (83). The use of both imaging modalities could allow 
detecting those intra-tumoural hypoxic radio-resistant foci in need for a more aggressive 
treatment to higher doses.  
 Planning and optimization tools for dose painting which enable to integrate intensities of any 
(biological) image type are developed at GUH (84, 85) and integration of biological 
information into the treatment planning (dose painting by numbers) has shown to be feasible 
and promising (86). Initial results of the integration of biological imaging in prostate cancer, 
using dose painting by contours, suggest a significant improvement in disease control (87).  
 
Future perspective: 
We hypothesize that further integration of biological information will lead to higher complete 
pathological response rates which are correlated with better outcome (71, 72). A 
multidisciplinary phase I-II dose-escalation trial using dose painting by numbers will be 
initiated. The continuous tumoural changes (biological AND volumetric) imply that this 
should be closely connected with gained insights in adaptive treatment planning. 
 
1.4.2. Hysterectomy or not? 
 
Whether a hysterectomy should be performed after CRT or not has been a source of 
controversy for several years. There are some clear arguments in favour of this approach. 
At first, pCR rates after definitive CRT are only in the range of 39 to 55%. Macroscopic 
tumour rest is found in 16 to 50% of the cases (57, 58, 71-73, 88-90) and these rates increase 
with tumour stage (57). In our series we found pCR in 40% of the cases. Additional therapy 
thus might be beneficial, as residual tumour is known to be associated with a higher rate of 
pelvic recurrence (57, 60, 71) and appears to be the major cause of treatment failure (91, 92). 
This is reflected in overall LRR of 15 to 26% (4, 93). Moreover, the risk for technical 
unsuccessful intracavitary BT insertions (up to 10%) (94), increases with tumour stage (95) 
and results in incomplete treatments and higher risk of pelvic recurrence. Adjuvant 
hysterectomy removes potential chemo- and radioresistant foci, which might improve local 
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control. Moreover, detailed evaluation of pathological response after CRT can only be 
achieved on the hysterectomy specimen. 
Yet, there is huge reticence towards hysterectomy, based on the fear of an increase in 
treatment-induced toxicity on the one hand and the absence of hard data on an OS benefit on 
the other hand. 
The fear of increased treatment-induced toxicity results mainly from small single institution 
retrospective studies reporting high rates of late bowel and GU toxicity after using 
conventional radiation technology. However, the only randomized trial performed in this 
setting showed no increase in grade 3 or 4 toxicity (89) nor did two non-randomized 
retrospective comparative trials (73, 88). Surgical complications consisted mainly out of 
lymphocoeles, fistulae and hydronephrosis. A higher frequency of GI toxicity such as proctitis 
was observed after high dose brachytherapy (88). It is our hypothesis that the incorporation of 
new radiation techniques such as IMAT will lower the surgical complication rate. This is 
supported by our preliminary results concerning postoperative morbidity: there were only 3% 
grade 3 and no grade 4 postoperative complications so far (publication 3). Probably, the 
absence of macroscopic disease could be one of the reasons, as surgical morbidity is 
significantly correlated with residual disease > 1 cm (58). 
Thorough evaluation of complications should also take into patients’ quality of life (QOL). In 
this context scoring of vaginal/sexual morbidity is indispensible. Even with MRI guided 
adapted brachytherapy vaginal toxicity is described in 84% of the patients, with at least 30% 
grade 2 or more (adhesions, telangiectasia, dyspareunia). Although our study was not meant 
to score sexual morbidity and follow-up is not mature, neither fistulas nor partial or complete 
vaginal stenosis have been observed (publication 3).  
In a randomized trial Keys et al. evaluated the benefits of adjuvant hysterectomy in 256 
patients with bulky stage IB2 disease compared to RT alone (89). The exact conclusion was 
(citation): “Overall, there was no clinically important benefit with the use of extrafascial 
hysterectomy. However, there is good evidence to suggest that patients with 4-, 5-, and 6-cm 
tumours may have benefitted from extrafascial hysterectomy (URR of progression; 0.58; URR 
of death, 0.60).” While the OS rate was not significantly different in both groups, after 
adjusting for age, performance status and tumour size they reported a 5-year disease free 
survival (DFS) rate of 62% after surgery versus 53% in the control group (RR: 0,72; p=0,04). 
This benefit was mainly due to a reduced local recurrence rate (15% versus 27% 
respectively). In addition, a significant correlation was found concerning OS, favouring 
hysterectomy in increasing tumour size (p = 0,007). This indicates that patients with tumours 
measuring 4 to 6 cm on the hysterectomy regimen had a lower risk of death than the radiation-
alone patients (RR:0,6).  
Additionally, although this study was a keystone in abandoning adjuvant surgery (even in 
FIGO stages not studied), some other issues force us to caution the reader. At first, the 
publication included only 78% of the deaths targeted for final analysis of OS (sufficient to 
detect a 39% reduction in death rate with 80% statistical power). Secondly, this study only 
included patients with stage IB2 tumours (89). 
In absence of randomized or non-randomized prospective comparative trials, our answers 
must be found in single-institution retrospective series. Several retrospective studies 
demonstrate that surgery is feasible and may be beneficial in terms of removing residual 
disease (57, 71-73, 88, 90, 96, 97) when compared to the results from 2 meta-analyses 
(including patients with stage II or more is), in which the LRR  present in 17% to 25% (4, 93). 
Local recurrence rates for the same population in our single-institution series was 4% 
(publication 3) and was never more than 12% in others (57, 88, 97, 98). We hypothesize that 
these lower LRR will result in an OS benefit, certainly in more advanced stages. Carcopino et 
al. showed equivalent survival in patients with advanced stage IB-II and III-IVA cervical 
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cancer treated by adjuvant surgery following CRT (57). Three groups published 5-year OS 
rates for stage III and IV disease 60 to 69% (57, 71, 72) after adjuvant hysterectomy. With 
advanced brachytherapy techniques, these 3y-OS rates are maximal 45% (99).  
This is not a plea against brachytherapy. In the last decades, major developments in BT with 
image-guided brachytherapy allowing contour-based conformal BT planning as well as 
adaptive treatment allowed dose-escalation without increase in toxicity. Results concerning 
IGABT are promising. Mono-institutional experience using MR (100-102) or CT-based 
IGABT (103, 104) reported a favourable outcome with increased local control. The largest 
single-institution series by Pötter et al. (FIGO IB –IVA, 156 patients) reports 3-year 
locoregional control (LRC) and OS rates of 90% and 64% respectively. For tumours 
measuring more than 5 cm, dose escalation lead to an increase of 3-years LRC and OS rates 
from 71% to 90% and from 28% to 58% respectively.  Additionally, morbidity using adaptive 
therapy has significantly decreased (62, 99). To confirm these results, a prospective 
collaborative international observational study on the parameters and the effects of MRI 
guided brachytherapy in locally advanced cervical cancer (EMBRACE) was initiated. 
However, we should be aware that these highly effective but specialized techniques are 
certainly not widely spread. Nevertheless we support a plea NOT to abandon adjuvant 
hysterectomy from the treatment options, to agree that hysterectomy could be performed 
without an excess in morbidity in this subset of patients and to be open minded in order to 
recognize adjuvant hysterectomy as a treatment option for patients with LACC.  
 
Future perspectives: 
- Further maturation of the study including multidisciplinary and stringent follow-up. 
- Assessment of sexual morbidity (and subsidiary to this: QOL) in patients treated with 
adjuvant hysterectomy and comparison with a similar group of patients treated with exclusive 
CRT and BT. 
- The true clinical role of adjuvant surgery remains to be verified, ideally in a prospective 
randomized multi-institutional study. Being aware that this will most probably never happen, 
pooling our data with those from other hysterectomy performing centres is a first step 
forward. 
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2. Ovarian Cancer 
2.1. The role of radiotherapy in the palliative care of Epithelial Ovarian Cancer. 
2.1.1. Update of publication 5 
 
Radiotherapy has been used effectively to relieve symptoms of patients with EOC (105, 106). 
The results presented in publication 5 add to that evidence by providing data on substantial 
and long-lasting palliation with WAPRT in heavily pre-treated women. Conclusions, 
however, were presented prudently because of the low patient number. Since the publication 
of these data, 29 additional patients with the same inclusion criteria have been treated likewise 
and the analysis, including 42 patients, has been updated (unpublished data). From here on, all 
data refer to the updated patient series. Patient characteristics are presented in table 8.2. 
 
Table 8.2: Patient Characteristics 
Characteristic 
 All patients Complete treatment Incomplete treatment
  n=42 n=30 n=12 
Age (start WAPRT)   
 median  59 59 61 
 range 31-76 31-76 39-75 
KPS (start WAPRT)   
 median  80 80 60 
 range 40-90 60-90 40-80 
 ≥ 80 (n) 22 21 1 
 < 80 (n) 20 9 11 
 ≥ 70 (n) 31 27 4 
 < 70 (n) 11 3 8 
Platinum-S (1st relapse)    
 yes 25 19 6 
 no 13 9 4 
 refractory 4 2 2 
FIGO (diagnosis)    
 I 4 3 1 
 II 0 0 0 
 III 33 25 8 
 IV 5 2 3 
CA 125 (at start)    
 median (U/ml) 421 345 2263 
 range 6-13769 6-8636 60-13769 
"x" lines chemotherapy   
 median  4 3 5 
 range 1-8 1-7 1-8 
"x" laparatomies    
 median  2 2 2 
 range 0-5 0-5 1-4 
Post WAPRT chemotherapy   
  n 16 15 1 
WAPRT: Whole abdomino-pelvic radiotherapy; KPS: Karnofsky 
Performance Status; Platinum-S: platinum sensitive; “x”: number of; 
numbers in bold: significant difference (p<0,05) 
 
 
 
2.1.1.1. Symptom response 
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Patients were treated for one (or multiple) of the following indications: pain, palpable mass, 
(sub)obstruction, ascites and vaginal bleeding. Table 8.3 lists the indications and the 
corresponding response rates. Consistent with our first publication and literature (105, 107), a 
high overall response rate was achieved for all symptoms with ascites as least responding 
symptom. More specifically a complete clinical response in 69% of patients with malignant 
bowel obstruction (that ended treatment) was noted (table 8.2). The median symptom 
response duration (all symptoms grouped) was 16 weeks (range: 0–139). Patients with a 
Karnofsky Performance status (KPS) ≥ 70 had a significantly longer median response 
duration compared to those with KPS < 70: 22 (range: 0-139) vs 5 weeks (range: 2-8) 
(p<0,02).  
 
Table 8.3: Response rate per symptom (%) for all patients that completed treatment (n=30). 
Symptom n CR PR SD PD ORR 
Palpable Mass 7 43 43 1 0 100 
Pain 16 75 0 12,5 12,5 87 
(Sub)Obstruction 13 69 23 0 8 92 
Ascites 7 14 57 0 29 71 
Bleeding 2 100 0 0 0 100 
CR: Complete Response; PR: Partial Response; SD: Stable Disease; PD: Progressive Disease; ORR: 
Overall Response Rate. 
 
 
2.1.1.2. Overall Survival and abdominal progression free survival (aPFS). 
After multivariate analysis (Cox regression model with co-variates: age, KPS and CA125 at 
start WAPRT; Cisplatin sensitivity after the first cycle and FIGO stage at diagnosis) only KPS 
was significantly correlated with OS and aPFS. Median OS and aPFS for the intention to treat 
population was 4 months (range: 0-32) and 11 weeks (range: 0-142). Both were significantly 
longer for patients with KPS ≥ 70 compared with KPS < 70: 8 months (range: 1-32) vs 1 
month (range: 0-5), (p < 0,001) and 18 weeks (range: 0-142) vs 3 weeks (range: 1-21), (p < 
0,001) respectively. Median OS and aPFS for the patients that ended the treatment was 8 
months (range: 2-32) and 17 weeks (range: 4-142). Again, both were significantly longer for 
patients with KPS ≥ 70 compared with KPS < 70: 11 months (range: 2-32) vs 3 months (2-4), 
(p < 0,001) and 21 weeks (range: 4-142) vs 10 weeks (range: 8-14), (p < 0,001) respectively. 
Overall survival and aPFS rates are visualised in figure 8.3 
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Figure 8.3: Kaplan-Meier curves representing overall survival and abdominal progression free survival 
for all patients (intention to treat population; n=42) and the patients that ended treatment (n=30). Patients 
with a Karnofsky score (KPS) less than 70 are represented in red, with a KPS of 70 or more in green and 
the whole population in black. 
 
 
2.1.1.3. Tolerance of WAPRT 
Twelve patients did not end treatment, mostly due to disease progression before any palliation 
could be started (median fractions delivered: 6 (range: 2-13)). One patient died of cerebral 
bleeding (grade 5 trombopenia). Acute toxicity was assessed in 24 patients. As expected, 
grade ≥ 3 acute GI toxicity was most frequent. Details concerning acute toxicity are presented 
in table 8.4. Only in 2 patients diarrhoea persisted more than 3 months (both grade 2 late 
toxicity). 
 
Table 8.4: Acute toxicity in %. 
Acute toxicity 
    G 2 G 3 G 4 G 5 
Intestinal 46 29 4 0 
 Vomiting 33 8 4 0 
 Diarrhoea 50 25 0 0 
Urinary 0 0 0 0 
Hematological 4 4 8 4 
Fatigue 12 0 0 0 
G: Grade 
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2.1.2. The role of radiotherapy in the palliative setting. 
 
The role of RT in the palliative treatment of EOC has been studied before (105, 107-113). 
Despite the heterogeneity of patient populations and treatment schemes in these studies, 3 
global conclusions could be drawn.  
1. Excellent response rates for bleeding (71 -100%), pain (51-100%) and (GU or GI) 
obstruction (up to 75%), respectively are described. (105, 107-109, 111, 112). Other sites of 
metastasis that appear to benefit from palliative irradiation include brain metastasis, lymph 
nodes and bone (105, 112).  
2. Even heavily pre-treated women respond well 
3. Ascites and lymph oedema respond less (105, 107).  
Our data confirm all three above conclusions. Our study differs however from the earlier 
reports in target volume. Except for 24/109 in Tinger’s series (107) and 1 patient in 
Geldblum’s (111) all patients were treated locally. Malignant bowel obstruction is mostly 
present at multiple intestinal levels, precluding any surgical intent, in those mostly heavily 
pre-treated patients. By using WAPRT, patients with peritoneal carcinomatosis can be 
palliated. Our series is the first to show the ability of WAPRT to relieve intestinal obstruction 
caused by peritoneal carcinomatosis. Therefore, WAPRT should be considered as one of the 
possible treatments in those patients. Patient selection is, however, very important. Only 
patients with KPS > 70 benefit (update publication 5). 
 
2.2. The role of WAPRT in the adjuvant or salvage setting. 
 
The prognosis for patients with advanced EOC remains poor despite the use of aggressive 
surgical debulking and platinum-based multi-agent chemotherapy. The median time to 
recurrence is less than 2 years, with a 5-years OS rate of 20-25% (114). Recurrence of disease 
occurs mostly intra-peritoneal. Treatment of patients after debulking and chemotherapy is 
considered as the adjuvant setting; once the patient recurred she’s treated in a salvage setting. 
 
The use of WAPRT might sterilize small residual tumour deposits – mostly exclusive – in the 
peritoneal cavity. This approach is not new. Already in the 80’s postoperative WAPRT 
(adjuvant setting) has shown to be curative in certain subsets of patients with optimal disease 
(Table 8.4) (115). 
 
Table 8.4: “Optimal disease” in the adjuvant treatment for EOC as defined by Dembo et al. (115). 
Stage T rest S + C M + E S + C + U 
  G1 G: All >G1 
I  <2cm*       
II 0       
II  <2cm*       
III 0       
III  <2cm*       
Optimal disease = white cells. T rest: residual disease after debulking, largest diameter; * preferably. S: 
serous; C: clear cell; M: mucinous; E: endometroid; U: undifferentiated or unclassified. 
 
With the advent of chemotherapy, WAPRT has been increasingly abandoned. The relative 
effectiveness of surgery, chemotherapy and radiation (when given as monotherapy) enforced 
the hypothesis that combining those therapies could offer a treatment advantage. Many reports 
have appeared in literature since then, mostly single-arm (116). Three additional randomized 
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trials of consolidation WAPRT have been performed. Two trials were supportive of its use 
over chemotherapy or observation (117, 118), one trial found no difference between 
radiotherapy or chemotherapy (119). Sorbe et al. randomly assigned patients with a pCR after 
second-look laparatomy to treatment with WAPRT, chemotherapy or only observation. 
Patients with a complete clinical, but not pathologic response were randomly assigned to 
receive WAPRT or chemotherapy, without an observation protocol. Patients with 
macroscopic disease were excluded for randomization. For those with microscopic disease, 
the 5-years PFS and OS did not differ between WAPRT and chemotherapy. For the patients 
with a complete pathologic response, the 5-year PFS was 56% in the WAPRT cohort and 36% 
for both the chemotherapy and observation group (p = 0,03).(118). These observations made 
the authors conclude that WAPRT should be considered as consolidation therapy in advanced 
EOC patients who had a pCR after chemotherapy (120). The only (small) series of WAPRT 
for patients with clinical complete response after adjuvant chemotherapy 
(carboplatin/paclitaxel) supported this (121). 
However, when conventional RT is used as consolidation after combined surgery-
chemotherapy, complication rates are high. In the acute phase GI toxicity, which can be 
severe in 6% and present in around 70%, is the predominant toxicity. Hematologic toxicity, 
however, should not be underestimated Treatment interruptions or failures to finish WAPRT 
due to myelosuppression up to 36% are reported, with thrombocytopenia being the 
predominant reason (116, 121-123). Although several authors comment on increased 
incidence of bone marrow toxicity in patients who received chemotherapy prior to WAPRT, 
no objective correlation with bone marrow toxicity could be found (106). Also late toxicity 
constitutes mainly of GI toxicity, with small bowel obstruction (4 to 10 %) being the most 
important one (116, 122, 123). Bowel complication rates seems to be correlated with 
increasing number of prior laparotomies, higher radiation doses (>45Gy) to the pelvis (106) 
and the used radiation technique (122). Whole-abdominopelvic radiotherapy does not 
compromise the use of chemotherapy afterwards (121).  
Despite improved tumour response rates to newer chemotherapeutic regimens, the majority of 
patients with advanced EOC will recur with ultimately platinum resistant or refractory disease 
(salvage setting). The choice of second-line treatment depends on the recurrence-free period. 
For platinum sensitive relapsed patients, platinum based chemotherapy will be restarted with 
secondary debulking in selected cases. Response rates range from 27% to 72% and PFS rates 
from 8 to 12  months (114). In platinum resistant or refractory relapse, response rates and 
survival are poor, with median PFS rates ranging from 2 to 7 months (114). Several studies 
have evaluated the efficacy and toxicity of WAPRT in those patients with persistent disease. 
Again, OS rates were highly correlated with the amount of tumour prior to WAPRT. Overall, 
a response rate to salvage RT of 30 to 50% in patients with microscopic residual disease after 
chemotherapy versus a response rate of less than 10% for patients with evidence of gross 
disease are reported and a long-term OS of approximately 35% is described (124, 125). 
Results for patients with platinum-refractory/resistant disease are not different from the 
platinum-sensitive patients (126). 
 
Future direction: 
- Dose-response curves suggest that 30 to 40 Gy can eradicate 60 to 90% of subclinical (less 
than 1 cm) tumours (117, 127). However, using conventional techniques, renal and hepatic 
tolerance levels will lead to severe underdosage in some peritoneal regions (128) and 
especially hematologic toxicity often makes treatment interruptions or definitive treatment 
stop necessary, which is a predictor for worse outcome (116).We hypothesize that modern 
radiation such as IMAT-based WAPRT will reduce hematologic toxicity and consequently 
lower the rate of treatment interruptions or definitive treatment stops. Moreover, the 
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peritoneal cavity would be treated to higher and more homogeneous doses. A randomized trial 
using modern RT techniques should be initiated to reaffirm the role of consolidation WAPRT 
in the multimodality treatment of advanced ovarian cancer. 
- In salvage setting, the response rate after WAPRT is substantial and OS is more than 
satisfactory in patients with minimal disease. Especially in platinum refractory/resistant 
patients with disappointing response rates on second-line chemotherapy, this approach merits 
further investigation.  
- For patients with >2 cm persistent or recurrent disease, WAPRT didn’t show any results of 
importance thus far. This is not surprising since a radiation dose around 30 Gy is not able to 
eradicate macroscopic tumour (117, 127). Using IMAT for WAPRT, targeted dose escalation 
to macroscopic tumour areas is feasible. This possible chance of increased local control could 
open a new window of opportunities.  
 
 
3. Conclusion 
Capable of creating steep dose gradients, IMAT allows a challenging combination of reducing 
dose at the surrounding tissues while intensifying the radiation dose to the tumour at the same 
time. And so, introducing IMAT and its opportunities in the multimodality treatment of 
gynaecological tumours caused a chain of changes and a true paradigm shift. Performing 
IMAT with a SIB in locally advanced cervical cancer lead to low radiation related toxicity 
rates and allows a safe adjuvant hysterectomy. The resulting local, locoregional and OS rates 
are very promising. Low toxicities in the postoperative treatment of endometrial and early 
stage cervical cancer are achieved and open a new window for opportunities such as 
preventive radiation to the para-aortic nodes. Finally, in ovarian cancer, IMAT allowed a 
revival of WAPRT in the palliative setting with more than satisfactory symptom palliation 
and response rates that allow re-introducing WAPRT in more early stages of the treatment. 
A lot of work remains to be done. Multiple hypotheses described in this thesis are to be tested 
and should lead to further reduced toxicity and dose-intensification on radio-resistant foci 
within the tumour. The hardest challenge however, lies in convincing the radiotherapeutic 
community to embrace the opportunities created by new radiation techniques and to rethink 
the existing dogmas. 
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